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ABSTRACT 
Many phenotypes in humans and animals are resulted by the interaction between genes 
and environment. For example, animals from distinct breeds may have different nutritional 
requirements, and thus, may respond in a particular way for each diet. In a similar fashion, 
genetic variability in the human population is responsible for the difference in drug efficiency on 
the treatment of several diseases. The development of high-throughput genomic and 
transcriptomics technologies has been providing rapid access to DNA and RNA information in 
humans and cattle. The access to this genetic characterization is a cornerstone step in 
understanding the complexity of characteristics within populations of these organisms. 
In humans, much of the attention on gene by environment interaction is brought for the 
understanding of several diseases. Glioblastoma multiforme (GBM), a grade IV cancer, is a 
complex multifactorial disorder that has swift and devastating consequences. With the objective 
of identifying general and clinical-dependent biomarkers for biomarkers for GBM, the 
expression pattern of 22,277 probes from 320 individuals diagnosed with GBM was evaluated. 
Three GBM time-to-event variables were considered: lifetime, overall and progression-free 
GBM survival. A novel analytical strategy was developed to identify general associations 
between the biomarkers and GBM, and associations that depend on cohort groups. A novel 
approach consisted of a five-step analytical strategy was developed in order to identify 
biomarkers for GBM. Results were further investigated through gene network inference, cross-
validation and functional analyses. Through the novel analytical strategy, a total of 61, 47 and 60 
gene expression profiles were simultaneously significantly associated (P-value < 0.05) with 
lifetime, overall, and progression-free survival, respectively. Many of the gene biomarkers 
associated had been previously reported with GBM (35, 24, and 35 genes, respectively) or with 
other cancer (10, 19, and 15 genes, respectively), and new associations were uncovered. Sixteen, 
four, and ten novel genes were associated with lifetime, overall and progression-free GBM 
survival, respectively. In addition, several genes were overrepresented among the three GBM 
events: PIK3R1, E2F3, AKR1C3, CSF1, JAG2, PLCG1, RPL37A, SOD2, TOPORS, HRAS, 
MDM2, CAMK2G, FSTL1, IL13RA1, MTAP and TP53. Of the genes associated with GBM on a 
cohort-manner, C2, EGFR, PRKCB, IGF2BP3, and GDF10 had gender-dependent associations; 
SOX10, RPS20, RAB31, and VAV3 had race-dependent associations; CHI3L1, PRKCB, POLR2D, 
and APOOL had therapy-dependent associations. These associations are the basis for 
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individualized prognostic and gene-based therapies. The functional analyses identified many 
important biological processes and molecular functions associated with GBM, such as 
morphogenesis, cell cycle, aging, response to stimuli, and programmed cell death. In addition to 
the confirmation of biomarkers previously associated with GBM, novel general and cohort-
dependent gene profiles were uncovered. These findings support the development of more 
accurate and personalized prognostic tools to improve the survival and quality of life of 
individuals afflicted by glioblastoma multiforme. 
In cattle, the genomic information may be accessed through the use of dense single 
nucleotide polymorphisms (SNP) arrays that cover the bovine genome. One of the main goals is 
the identification of SNPs that show associations with economically important traits for the beef 
cattle industry. The largest variable cost in the beef cattle industry comes from feed and may 
represent from 62 to 84% of the total costs. In this manner, the relationship between feed intake 
and production needs to be assessed. The genomic potential for feed efficiency was evaluated in 
a feedlot beef cattle population in two distinct studies. For both studies, 1,321 steers from five 
different genetic compositions fed five diets were genotyped using a 50K SNP panel. The data 
was divided in two independent data sets, in order to identify (training) and to test (validation) 
the associations. In the first study, general, breed- and diet-dependent associations for feed 
efficiency were identified using SNPs and haplotypes. The traits evaluated were: the two-step 
feed efficiency indicators residual feed intake (RFI), residual average daily gain (RADG), and 
residual intake gain (RIG), and two complementary one-step indicators of feed efficiency, 
efficiency of intake (EI) and efficiency of gain (EG). These two novel indicators were developed 
to account for the total variation removed in the one-step indicators. In addition, a multi-SNP 
model was developed to assess the predictive power of several SNPs. Network and functional 
analyses of genes associated with feed efficiency aided in the interpretation of the results. Thirty-
one, 40, and 25 SNPs (P-value < 0.0001), and six, ten, and nine haplotypes (P-value < 0.001) 
were significantly associated with feed efficiency on a general, breed-dependent, and diet-
dependent manners, respectively. The associations of 17 SNPs and 7 haplotypes were confirmed 
(P-value < 0.05) on the validation data set. Overlapping of 20 SNPs and six haplotype 
associations between RFI and EI, and five SNPs and one haplotype associations between RADG 
and EG, confirmed the complementary value of the one and two-step indicators. A total of 89 
SNPs were included (P-value < 0.0001) in the multi-SNP models, and offered a precise 
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prediction of the five feed efficiency indicators. Thirteen molecular functions and six biological 
processes were identified (P-value < 0.001) in the functional analysis, including ion channel 
activity, nucleotide binding, and passive transmembrane transporter activity. These Gene 
Ontology categories were overrepresented among the genes harboring SNPs associated with feed 
efficiency. The breed- and diet-dependent associations between SNPs and feed efficiency 
suggest that further refinement of variant panels require the consideration of the breed and 
management practices. To conclude, the unique genomic variants associated with the one- and 
two-step indicators suggest that both types of indicators offer complementary description of feed 
efficiency. 
 In the second study, the feed efficiency components of average daily gain (ADG) and 
dry matter intake (DMI) adjusted for the maintenance requirements were used for SNP 
associations. Univariate and bivariate analyses were performed in order to assess feed efficiency 
in the training population. As in the first study, a multi-SNP model was developed, as well as 
functional and network analyses were performed. The bivariate model identified 11 significant 
associations (P-value < 0.0001), whereas the univariate analyses of ADG and DMI resulted in 
eight and nine associations, respectively. Of these, six SNPs were confirmed in the validation 
data set. The final multi-SNP model included seven, nine, and eight SNPs for the bivariate, and 
univariate ADG and DMI analyses, respectively. These models showed low drop in the model 
adequacy in the validation data set, amounting for 19.4, 11.68, and 7.21% compared to the 
training data set, respectively. Six Gene Ontology categories were (P-value < 0.001) identified 
for the SNPs associated (P-value < 0.001) in the bivariate model. These were all represented by 
molecular functions related to ion transport activity. The bivariate analysis of ADG and DMI 
helped in the identification of SNP that have beneficial associations with both components of 
feed efficiency and can be used for genome-enabled improvement of feed efficiency in feedlot 
beef cattle. 
These studies showed the importance of considering environmental factors, such as 
therapies and diets, interacting at transcriptomics and genomic levels in human and livestock 
research. These findings may have direct use in human health, through the development of gene-
based therapies in GBM, and in beef cattle production, and by the incorporation of specific SNP 
panels in different production systems.   
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“The further we go 
And older we grow 
The more we know 
The less we show” 
 
(Primary) 
 
Robert Smith, Simon Gallup and Laurence Tolhurst (The Cure, 1981) 
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CHAPTER 1: LITERATURE REVIEW 
1.1. General Considerations of Gene by Environment Interaction 
The variation in traits or phenotypes (from molecular phenotypes such as gene expression 
to organism-level phenotypes such as growth or presence of a disease) can be compartmentalized 
into genetic, environmental and gene by environment interaction. The variation of some 
phenotypes is mainly associated with variation at the genetic level (e.g. genetic polymorphisms, 
copy number variation), whereas the variation in other phenotypes is highly influenced by the 
environment or the particular synergistic or antagonistic interaction between genotype and 
environment. The inheritance laws postulated by Gregor Mendel (presented in 1865 as Versuche 
über Plflanzenhybriden
1
) constituted the first scientific attempt to explain the genetic variation 
underlying the phenotypic variation. Subsequently, the field of quantitative genetics, led by 
Fisher, Wright, Lush, Falconer and Hill, developed more advanced models that encompassed 
genetic and non-genetic components to describe the variation of complex phenotypes.  
Most complex phenotypes are influenced by innumerous genes that may act alone or 
together, independent of the environment or in response to some environmental stimuli. The non-
genetic factors range from natural effects such as temperature, humidity and others, to some type 
of artificial exposure as education, drugs, food etc. Some phenotypes depend on the activity of 
several genes, which may be regulated by other genes in a phenomenon known as epistasis. The 
model describing a phenotype is: 
            
(Eq. 1.1) 
where  ,  ,  , and     are the phenotype, and the genetic, environmental, and gene by 
environment effects, respectively. This model indicates that, for example, if two genetically 
identical subjects show difference on a particular phenotype, this variation is attributed to   and 
   . Conversely, if in the same environment two subject present distinct phenotypes, the 
difference is due to   and    . In the previous two cases, and assuming no     interaction, 
the magnitude of the environmental effects is the same across all genetic factors (Figure 1.1 a) 
                                                          
1
 Mendel, G. Experiments on plant hybridization. J. R. Hortic. Soc. 1901, 26:1–32. 
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or vice-versa. In situations when an environment factor has more influence in the phenotype for a 
given genetic factor than for others (Figure 1.1 b), there are evidences of interaction between 
genes and environment. 
 The presence of     may be detected and classified in different ways [1]. According to 
Haldane [2], the number of possible     is a function of the number of genes/genotypes and 
environments, and calculated as: 
             
      
    
 
(Eq. 1.2) 
where  and   are the number of genes/genotypes and environment, respectively. The gene by 
environment interaction may also be classified as linear and non-linear [3]. In this method, 
interactions are classified as linear when the genetic and environmental effects are additive, and 
non-liner when not. Other authors consider the occurrence of     only in cases of statistical 
significance [4]. Mather and Jones [5] suggested that     can be classified according the 
relative magnitude of each effect and the combination of the three factors result in six possible 
   . Pani et al. [6] also presented a method of classification, where four types of     are 
presented taking into consideration the statistical significance of     and modification of the 
genetic rankings. These examples are summarized in Figure 1.2. 
The partition of the phenotypic variation into its components is central in the 
identification of genes (and environments) influencing the phenotype: 
             
(Eq. 1.3) 
where   ,    and     are respectively the genetic, environmental, and genetic-by-environment 
interaction, respectively. This model is used to determine the fraction of the total variation that is 
explained by the genetic component (also known as heritability). Figure 1.2 depicts scenarios 
with different relative contributions of G, E and    . 
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1.1.1. Examples of G X E in Human and Livestock Phenotypes 
Many phenotypes in humans and animals may be affected by the interaction between 
genes and environment. For example, animals from distinct breeds may have different nutritional 
requirements, and thus, may respond in a particular way for each diet. In a similar fashion, 
genetic variability in the human population is responsible for the difference in drug efficiency on 
the treatment of several diseases. Although the goals on livestock animal experimentation differ 
substantially from those in human research, the interest on how genetically different 
experimental units, or groups, respond to changes in the environment is a common subject in 
many papers in the literature. 
In humans, much of the attention on gene by environment interaction is brought for the 
understanding of several diseases. One of the most well-known examples of different responses 
to an environment stimulus in genetically divergent individuals is regarding skin cancer, where 
the risk is higher in people with fair skin color [7]. The interest in studying the effects of    , 
in the context of medical genetics and epidemiology, has the objective to obtain better estimates 
of the population-attributable risk for genetic and environmental risk factors, to help dissecting 
disease mechanisms using information from genes and environmental factors relevant to a 
specific pathway, to determine environmental factors (e.g. diet or air pollution) that cause 
diseases, and to use information of molecular pathways to develop preventive and therapeutic 
strategies [8]. The genetic makeup in humans evolves very slowly [9], and thus, the ever 
changing environment component has an important role in     analysis. An easily 
understandable example is the increased prevalence of obesity and incidence of Type 2 diabetes 
within certain ethnic groups [10, 11]. In a time when some types of foods were not as abundant 
as nowadays, some groups developed genetic mechanisms to resist famines. Now, the 
evolutionary pressure to conserve these genes is an aggravating factor in groups with higher 
prevalence of obesity and Type 2 diabetes [11]. The effect of environment in human cancer is 
subject of study in several papers [12]. Reports [13-15] indicate that the environment is 
responsible from 1 to 19% of cancer etiology. For example, the chances of a lifetime smoker to 
develop lung cancer are 20 times higher than in non-smokers [16]. Regarding nutritional aspects, 
red and processed-meat intake are associated with higher risk of colorectal cancer [17]. Although 
the environment plays an important role in cancer, its effect may depend on the genetic 
background of a person or the population. 
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The consideration of      is important for understanding the variety in cancer 
progression in subjects with different genomic background, when treated with several methods. 
In glioblastoma multiforme (GBM), a type of brain cancer, patients treated with a particular 
agent (BCNU), present different response according to the methylation status of MGMT [18]. 
This gene encodes for a DNA repair enzyme that removes alkyl groups from guanine residues 
[19]. This type of treatment causes death of cells by alkylation; formation of cross-links between 
adjacent strands of DNA; and thus, the inactivity of this gene results in proper action of 
alkylating agents [18]. Another example of drug used in GBM treatment is the epidermal growth 
factor receptor (EGFR) tyrosine kinase domain inhibitor, gefitinib. This drug inhibits the activity 
of EGFR, and the responsiveness to gefitinib is higher in patients presenting coexpression of 
EGFRVIII and PTEN in tumors cells [20]. Studying the effects of radiation on GBM survival, 
Tata et al. [21] reported that patients with a mutant type of the tumor suppressor gene P53, 
presented better response to radiotherapy, with significantly longer survival. The efficiency of 
some methods of GBM treatment is dependent on the genetic content of the patient. In this 
manner, the knowledge on the patient genetic information must be taken into consideration to 
decide the most appropriate method for treating GBM. 
In livestock, the understanding of the     effects is important in several stages of the 
animal production system. From the selection of genetically superior animals for breeding to the 
management on the farm, consideration of     is required to yield the best results. The main 
breeding objective is to improve the performance of animals under specific environmental 
conditions [22]. In this manner, animals must be selected in an environment that permits the 
maximum expression of the phenotypes and that accurately represents the situation on which 
they will be raised in the future [22]. The problem is that, in many cases, the selection 
environment does not represent the production environment. This leads to two situations: (1) 
where the     is present, and thus, it is expected reordering in the ranking of the animals in a 
different environment; (2) selection is performed under a favorable environment, and thus, there 
is a correlation between the genetic and non-genetic effects, which results in Equation 1.4 [23]: 
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(Eq. 1.4) 
where       is the covariance between the genetic and environmental effects. The efficiency in 
selecting the superior animals in this situation is then decreased [22]. One way to deal with this, 
is to treat the same phenotype in different environments as distinct phenotypes, and therefore, 
use the correlation between these phenotypes to account for     [23].The problem is that 
many estimates in the literature indicate that selection of parents in one environment to optimize 
progeny performance in other, may not be an efficient method [24]. 
In beef cattle production, significant     (e.g. breed x E) has been reported in several 
papers. For example, although heifers (Brahman, Brahman x Friesian and Friesian) had lower 
feed intake at 38
o
C than in 17
o
C, the environmental effect was higher in Brahman animals, 
which presented the lower consumption among all combination of breed and temperature [25]. In 
order to identify risk factor for heat stress in heifers, Brown-Brandl et al. [26] tested the effects 
of breed, temperature, condition score, health and temperament. They verified that the panting 
score was dependent on the 3-way interaction between breed, temperature and finish, whereas 
the simple breed-temperature interaction was statistically associated with respiration rate. Fatty-
acid composition is an important nutritional component of beef [27], and it can be influenced by 
breed and nutritional background. Itoh et al. [28] studying Angus and Simmental treated with 
grain, and annual and perennial pasture, reported that five types of fatty acid were significant 
different according the interaction between breed and diet. The interaction between diets and 
genotypes show that different breeds have particular requirements. Considering four genotypes 
for Angus and Brahman (AA, AB, BA and BB) treated with two forages (bermudagrass and 
fescue), Sandelin et al. [29] reported higher adjusted means of estimated mature body weight in 
six of the eight possible combinations [bermudagrass x (AA, BA and BB) and fescue x (AA, AB 
and BA)]. Studying the effects of breed (Angus and Angus x Simmental) and diet (high and low 
starch) on gene expression in the longissimus lumborum muscle, Graugnard et al. [30] reported 
that the mRNA levels of genes related with transcriptional regulators of lipogenesis (SREBF1 
and THRSP), insulin signaling (INSR) and de novo fatty acid synthesis (FASN) were statistically 
associated with breed x diet interaction. Jones et al. [31] reported significant interaction between 
breed and diet. Analysis of one hundred twenty steers (½ Angus x ½ Hereford, BX; ½ Gelbvieh 
 6 
 
x ¼ Angus x ¼ Hereford, GX) fed with two diets, one with low (L) and the other with moderate 
(M) energy restriction (11% crude protein; 1.59 and 1.32 Mcal NEm/kg DM, respectively) 
showed significant interactions for dry matter intake and average daily gain, where the highest 
values where observed for GX receiving L in both traits. Including fatty acid composition, 
Warren et al. reported several phenotypes statistically affected by breed x diet interaction, where 
steers were slaughtered at three different ages [32]. Aberdeen Angus (AA) and Holstein-Friesian 
(HF) steers were fed with concentrate or silage. In animal performance and carcass classification 
traits, conformation, half carcass, final weight and live weight gain were statistically affected by 
breed-diet interaction, where in most of the phenotypes, the combinations AA + concentrate and 
HF + silage showed the highest means. Moreover, this interaction was associated with most of 
the fatty acid concentration in steers slaughtered at 19 months (7 of 12), whereas at the other 
ages, only one fatty acid was affected by the interaction (18:3n-3 at 24 months). 
The review of genetic-by-environment cases in humans and livestock indicates the 
importance of jointly considering genetic and non-genetic components when the goal is to 
understand the molecular basis of a phenotype. In humans, the development of personalized or 
individualized therapies to treat cancer is a valuable example that describes the importance of 
this interaction. For the genetic improvement of livestock animals, the consideration of     
increases the genetic gain with increased selection efficiency. 
1.2. Gene Expression 
Knowledge of the molecular and genetic mechanisms underlying the variability of gene 
expression is a cornerstone step in understanding the complexity of characteristics within a 
population [33]. The process of transcribing DNA into mRNA and of translating the latter into 
proteins, at specific levels of both products, is a result of the sum of many events [34]. Therefore, 
proper coordination of all factors influencing this dynamic mechanism defines the pattern of 
RNA and protein molecules, determining the phenotype of individual cells [35]. In this manner, 
information regarding the regulation of gene expression, and identification and quantification of 
mRNA products, are required to elucidate the variation observed in diverse traits among 
individuals. 
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The process of producing mRNA from a specific DNA sequence is dependent on the 
correct operation of several stages. Structural changes in the chromatin are required to initiate 
transcription and elongation, and the resulted primary transcript is processed and transported 
from the nucleus to the cytoplasm. In euchromatin, chromatin-remodeling complexes alter the 
contact between DNA and histones allowing the transcription machinery to bind the promoter 
region and initiate transcription [36]. Core promoter is the region containing specific binding 
sites that are recognized by transcription factors (TF). In eukaryotes, promoters are very diverse 
[37], but 10-20% of them are characterized by a consensus sequence of TATAA and called 
TATA box [38]. They are located ~25 bp upstream of the initiation point in high eukaryotes and 
are recognized by TATA binding proteins (TBP; [36]). Irrespective of the promoter sequence but 
specifically for RNA polymerase II (RNAPII; responsible for mRNA synthesis), TBPs are 
associated with TFs to form TFIID, which guide RNAPII to the startpoint [36]. After the first 
bound is synthesized, RNAPII is then released from the promoter to start transcript elongation 
[36]. The template strand (or non-coding strand) of the DNA is used by RNAPII to create a 
single strand RNA molecule. The enzyme RNAPII reads the DNA sequence from 3’→5’, 
transcribing a 5’→3’ RNA product identical to the coding DNA strand, except that uracils are 
placed instead of thymines. Elongation continues even after the stop codon of the open reading 
frame is transcribed at the 3’ end, and a poly(A) tail is synthesized to terminate the transcription 
and to protect the RNA to be degraded [36,39,40]. Other defensive mechanism is the addition of 
the 5’ cap during transcription. Shortly after initiation of transcription, a 5’ terminal guanine is 
added at the 5’ end of the nascent transcript [36]. Before the mature mRNA is transported 
through the nucleus pores to the cytoplasm, the primary transcript is processed, and non-coding 
sections are removed. The process which non-coding regions (introns) of the pre-mRNA are 
excised and the coding fragments (exons) are joined is called splicing. This event is a result of a 
series of reactions and catalyzed by a large particulate complex called spliceosome, although 
some introns can undergo self-splicing [36]. Moreover, in most of the cases, a single gene results 
in more than one mRNA sequence, a phenomenon called alternative splicing, increasing the 
diversity of structures and functions of a gene [36]. With a capped 5’ end, a poly(A) tail at the 3’ 
end and removed introns, the RNA is transported from the nucleus to the cytoplasm where is 
translated. In this manner, many steps are required to correctly synthesize mRNA from DNA 
sequences, and the complex process of gene expression may be regulated at all levels. 
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The levels of a specific mRNA in the cytoplasm depend on many factors, e.g., RNAi, but 
especially on the regulation of the steps of gene expression. The first stage of gene expression 
regulation is at chromatin level. The two main regulator events at this level are histone 
acetylation and DNA methylation [41]. Acetylation of histones is a reversible event that 
regulates transcription by modifying the chromatin structure and accessibility of transcription-
regulatory proteins to the DNA target [41]. When histones are acetylated, the affinity of these 
proteins for DNA is decreased, resulting in a relaxed form of the chromatin, which is favorable 
for the transcriptional machinery [42]. Much attention is brought to DNA methylation pattern 
owing to its role in cancer development [43]. An interesting feature is that DNA methylation is 
usually observed in regions rich in cytosines and guanines, known as CpG islands [41]. In this 
manner, transcription may be directly halted by methylation of CpG islands located in promoter 
regions [36]. With a suitable chromatin conformation and accessibility for the core promoter, 
transcription may be regulated by a range of mechanisms. Transcription of DNA by RNAPII 
requires the availability of TFs (TBP, TFIID and others TF-family enzymes) to recognize the 
core promoter and initiate RNA synthesis [36]. Moreover, these TFs can bind to short DNA 
sequence elements known as enhancers [36]. These short DNA sequences are located in different 
regions of the genome, down or upstream the promoter region, and even in different 
chromosomes [44]. Transcription factors can stimulate or repress gene expression, depending on 
the type and quantity of TFs that bind to enhancers. Thus, enhancer elements can act as 
activators or silencers of transcription [36]. An important class of post-transcriptional regulators 
is the RNA binding proteins (RBP). These proteins may regulate alternative splicing [45], RNA 
editing [46] and polyadenylation [47]. In addition, these events are executed by specific RNA-
binding activities and protein-protein interactions, indicating the complexity of post-
transcriptional regulation by RBP [47]. In this manner, transcription is regulated at many levels 
and several components are needed to properly generate a specific mRNA sequence in the 
cytoplasm. 
The knowledge of how gene expression is executed and regulated is a key aspect to 
understanding the phenotypic outcome in an organism. The dynamic flux of genetic information, 
where DNA, RNA and proteins share and transmit the genetic code, is a result of several 
molecular events inside the cell. All the levels of transcription are susceptive to different control 
mechanisms in which specific interactions between DNA, RNA and proteins are necessary for 
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the synthesis of mRNA. This product is then transported to the cytoplasm to be translated into 
proteins, resulting on the observed traits in a population. Hence, the correct quantification and 
identification of specific mRNAs are important stages to define and understand the phenotypic 
variability among individuals. 
1.2.1. Measurement of Gene Expression 
Quantification of the levels of gene expression in a given type of cell is a fundamental 
step to understand and explain the variation observed in populations under different 
circumstances. Gene products arise from cellular responses to environmental stimuli and may be 
quantified by a variety of techniques. Although many methods for gene expression measurement 
have been developed over the last 20 years, DNA microarray technology has been widely used 
since its first introduction in 1995 [39]. 
The genetic information flows from mRNA to proteins and the levels of these two 
molecules may be used to measure gene expression. Although a translated protein is the result of 
a specific mRNA sequence, both molecules undergo different regulation mechanisms, and thus, 
information regarding their levels may not always be explained by the variation on the levels of 
the other. Correlation between mRNA and protein levels vary substantially from low to high 
values, depending on the organism, sampling and RNA probe [48,49]. Levels of mRNA and, 
post-transcriptional and post-translational regulation may directly affect the protein content in 
the cell [48]. Due to this wide range of events, proteins levels may not be reliable responses of 
transcription. In addition, the available methods for quantification of mRNA and proteins are 
substantially different; they depend on the financial and temporal resource available, and 
specifically, the question being asked [50]. Moreover, the quantification of mRNA and proteins 
are not mutually exclusive events, and both methods provide valuable information regarding 
gene expression [50]. 
There are many methods to measure mRNA levels, such as Northern blot [51], real-time 
PCR [52], RNA-seq [53] and others [54,55]. Nevertheless, the high-throughput DNA microarray 
technology is a powerful tool to measure the expression of thousands of genes simultaneously, 
using information derived from mRNA. At fabrication, microarrays differ in two main 
technologies: robotic spotting and in-situ synthesis. The first microarrays were manufactured 
using robots to spot DNA probes, PCR products or oligonucleotides, onto the glass surface of the 
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array, resulting in the fabrication of spotted microarrays [56]. This method may be used to create 
in-house arrays to accommodate the research interest and cost limitations of an experiment, but 
results can be more variable than in-situ arrays [57]. In contrast, small DNA probes can be 
simultaneously built up base-by-base onto the array resulting in oligonucleotide microarrays. 
These platforms are manufactured by different companies, varying on oligo sizes and synthesis 
technology [56]. Arrays may contain short (25-30 bases) or long (50-80 bases) oligonucleotide 
probes [58,59] that can be synthesized using different technologies, as mask and maskless 
lithography, and inkjet printing [56]. 
In addition to these differences, the quantification of gene expression by microarrays can 
be performed using one or two-dye approaches [58]. In two-dye or channel experiments, two 
samples of the target gene (cDNA or cRNA) are labeled with different fluorophore dye, e.g., Cy3 
and Cy5 (that respectively fluoresce at red and green wavelengths), pooled and hybridized to a 
single array [60]. The relative expression levels of a specific target (spot in the array) are 
determined by comparing the measured intensity of the fluorescence emission at each 
wavelength in the array [60]. This method allows the direct comparison of two samples, and 
thus, the variability accounted for processing several arrays per analysis is reduced. In this 
manner, the accuracy and sensitivity of determining differences in the expression levels of 
sample pairs is theoretically increased [58]. On the other hand, only one dye is used to label the 
target gene in one-color in-situ microarrays. In this approach, two arrays with one sample each 
are needed to determine the expressional levels in each sample by measuring the fluorescence in 
both arrays [61]. The advantage on this method is that the comparisons between groups of 
samples and across microarrays is facilitated, owing to the simplicity and flexibility of the 
experimental designs [58]. However, the two-dye systems can have comparatively simple 
reference designs in which the same sample is used in all arrays and paired to each of the rest of 
the samples. 
Among all types of microarrays platforms, the Affymetrix GeneChips are widely used, 
representing the majority fraction on market [62]. The following review focuses on this in-situ 
platform. These chips are manufactured by photolithography and combinatorial chemistry [63, 
64]. Each GeneChip accounts for up to 1.3 million different oligonucleotides probes that are 
synthesized in-situ and each spot holds hundreds of thousands, and even millions, of copies of a 
given oligonucleotide [64]. The probe syntheses onto a glass substrate coated with linkers 
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containing photolabile protecting groups is performed using cycles of illumination. In each cycle 
a different mask is used to expose the selected portions of the probe arrays to ultraviolet light, 
whereas the illumination removes the photolabile protecting groups [64]. These cycles are 
repeated until the probes are synthesized in known locations [64]. Usually, the mRNA of interest 
is represented by a probe set of 11-20 25mer oligonucleotides probe pairs [65,66]. These pairs 
are characterized for having a perfect match (PM) probe and a mismatch (MM) probe, which has 
a modification on the 13
th
 base [66]. This information is used to identify and subtract nonspecific 
hybridization and background signals [67]. 
1.2.2. Data Processing and Normalization 
Quality control of the gene expression data involves the transformation of the image 
scanned from the arrays into reliable mRNA expression data. Hence, processes regarding the 
measurement of probe fluorescence in the array and data transformation are crucial steps that 
must be performed prior to statistical analyses in microarray experiments. This review of 
processing steps centers on the in-situ Affymetrix GeneChip platform. 
During hybridization, fluorescence signals are emitted from the GeneChips and images 
are scanned at the end of the process and stored as DAT files [68]. This raw data file contains 
details regarding the image size, technical information and the pixel intensities from the whole 
array [69]. The estimation of the intensity of each spot is stored in CEL files after the grid 
alignment, to localize each probe cell in the array, and the computation of the 75
th
 percentile of 
the intensity from the pixels in the corresponding cell or spot [69]. In this manner, the correct 
grid alignment is important to avoid errors when summarizing the information from DAT to CEL 
files [69]. In addition to this factor, other events can affect the overall quality of image 
acquisition, such as background variation and flagging [70]. Pixels in high-intensity parts tend to 
lose signals to surrounding areas. If these neighboring pixels have lower signals, they will record 
the intensity from different pixels resulting in blurry images [69]. Moreover, the intensity of a 
cell signal in the array is also represented by the non-specific hybridization of the MM probe, 
and thus, the background signal must be subtracted from the feature in order to have a better 
estimate of the cell hybridization [56]. Flagged features have image problems and must be 
removed from the analysis. Some cells can have a higher pixel standard deviation compared to 
the mean (bad feature), higher background than foreground signal (negative feature) or even 
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have a very low signal (dark feature). These estimates can be automatically removed from the 
data by software or manually by the user, but lost of valuable data must be avoided. Although 
laboring and time consuming, each flagged feature can be individually investigated in order to 
identify the problem and, if possible, obtain a reliable signal estimate [56]. Like in the other steps 
of gene expression analysis, image acquisition needs standardization of the procedures to yield 
high quality results. 
Prior to the statistical analyses, the probe intensity data must be normalized in order to 
remove systematic errors and bias originated from microarray experimentation [56]. The 
manufacturing process of the microarray, preparation of the biological samples and arrays, and 
measurement of the intensities can affect the data analysis, and thus, normalization attempts to 
remove these sources of variation allowing the realization of meaningful biological comparisons 
[71]. Several approaches have been proposed to normalize the expression measurements from 
one-dye in-situ Affymetrix GeneChips [72]. For example, the Affymetrix Microarray Suite 
MAS5.0 software [73] removes the overall background noise, using the intensity values of      
and    , of the i
th
 array and j
th
 probe pair, with i = 1, …, I and j = 1, …, J [72]. This method 
reduces the dependence of the variance on the mean [74], comparing with the previous method 
MAS4.0, using a log transformation [66]. The MAS5.0 algorithm uses Tukey’s biweight 
function (   ) to accommodate outliers, and the probe signal is estimated as: 
              {   (         )}  
(Eq. 1.5) 
where      is a correction to avoid negative values when      >      [66] (detailed in 
Affymetrix (2002)[73]), an event that may occur one third of the probe pairs [74]. The MAS5.0 
model is: 
   (         )              
(Eq. 1.6) 
where    represents the expression quantity on array i; and     is the error term of the i
th
 array 
and the j
th
 probe pair [66]. A normalization method developed to overcome MM problems is the 
Robust Multi-array Average (RMA) [74]. The modifications proposed in RMA were motivated 
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by the idea that information regarding MM probes were not biologically and mathematically 
appropriated and thus, should be ignored until used in a proper manner [66]. In this method, the 
background correction does not take the MM probes into account. The      intensities are then 
designated as  (    ) , where the values are transformed by background correction, 
normalization and applying logarithm [74]. A base 2 logarithm is applied  at the background-
corrected PM intensities and a quantile normalization is performed at probe level, where the 
probe intensities for each array in a set of arrays is distributed in the same way, using the mean 
quantile to substitute the original values [71]. Lastly, the RMA model is: 
 (    )            
(Eq. 1.7) 
where    is the log2 scale expression value of the i
th
 array,    represents the log2 scale affinity 
effects for probes j and is     the error associated with  (    ). The log scale expression values 
   are estimated through the median polish method [75]. The results from this method tend to 
provide more normally distributed gene expression estimates than the additive model in MAS5.0. 
A third widely used technique to normalized microarray data is the GCRMA. The GeneChip 
RMA (GCRMA) method, that was proposed by Wu et al. [76], takes into consideration the 
probes sequences and is similar to RMA, using quantile normalization and median polish to 
process the expression data, but uses a different background correction. Probes with different 
guanine and cytosine (GC) content show different log intensities, and thus, the probe sequence is 
used for intensity adjustment [76]. Whereas RMA ignores MM probes, GCRMA uses both PM 
(Eq. 1.8) and MM (Eq. 1.9) as:  
                  
(Eq. 1.8) 
              
(Eq. 1.9) 
where     is the optical noise of the i
th
 array and j
th
 probe set;    and    represent nonspecific 
binding; and log2      is the specific binding, the value of interest. Moreover, it is assumed that 
         
  , both log2       and log2       follow a bivariate-normal distribution with equal 
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variances   
  and correlation 0.7, and that O and N are independents [62,77]. In this method, the 
   values are adjusted by a correction factor, which includes the effect of the GC content and 
   probes, to estimate specific binding. After the background correction, the intensities are 
quantile normalized and summarized as in RMA [62,77]. Although these three methods have 
been extensively used in microarray analysis, GCRMA usually yield better results than MAS5.0 
and RMA, with GCRMA and RMA providing substantially more precise results than MAS5.0 
(small variation), and GCRMA being more accurate (uses    probes and GC content) than 
RMA [62,78-82].  
Data processing and normalization are critical steps to remove systematic errors and bias 
from the data and allow a more adequate subsequent modeling and testing of gene expression 
across conditions. In many microarray experiments, the ultimate goal is the identification of 
genes that are differentially expressed across conditions. In these cases, gene expression is the 
response variable and the explanatory variables are the condition (factors or covariates of 
interest). These models are analyzed using a one or multi-way ANOVA model or regression 
models and the results of these models include the ranking of the genes in terms of P-value and 
fold changes and identification of differentially expressed genes. In some microarray 
experiments, an additional objective is the identification of biomarker genes that can be used to 
accurately classify samples across conditions or predict phenotypes (e.g. survival, growth). In 
these cases, the condition is the response variable and the expression of one or multiple genes are 
the explanatory variables. The focus of the following review is on models that describe time-to-
event variables such as survival (i.e. time-to-death) or time-to-progression or recurrence of an 
event (such as disease). 
Microarray yields result of thousands of genes, but due the limitation on the number of 
experimental units, it is necessary to reduce the number of variables being study. Although there 
are available guidelines in the literature for variable reduction in gene expression analysis 
[83,84], these issues are usually experiment-depended and thus, need specific approaches. One 
way to reduce the number of variables is using model selection techniques as the forward and 
stepwise methods [85]. The variables can be selected adding the significant factors one by one 
according the p-values. In the forward method, the explanatory variable with the lowest p-value 
is added and then, with this factor fixed in the model, the next variable with the lowest p-value is 
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added into the model. This is repeated until no other variable reaches a specified significance 
threshold. The difference between forward and stepwise methods is that, in the latter, the 
variables fitted in the model must also have a p-value below a significance threshold. In other 
words, after a second variable is added, the first one will only stay in the model if is significant 
in the presence of the other. Therefore, is expected that the forward method select more variables 
than stepwise, and thus, both results should be combined for a third round of selection.  
1.3. DNA Technologies in Beef Cattle Production 
The development of sequencing and high-throughput genomic technologies has been 
providing rapid access to DNA information in several organisms. One of the most important 
results of this advance is the increasing identification of genomic variants known as single 
nucleotide polymorphisms (SNP). This genomic information in cattle may be accessed through 
the use of dense SNP arrays that cover the bovine genome [86], and it can be used in several 
different areas of animal production, including animal identiﬁcation, product traceback, 
paternity, marker-assisted selection (MAS), marker-assisted management (MAM), genome-wide 
association studies (GWAS), and whole genome selection (WGS) [87-89]. 
1.3.1. Genotyping 
A DNA microarray consists of features containing specific DNA sequence. These 
features are arrayed series of thousands of microscopic spots of DNA oligonucleotides, as the 
Illumina BeadArray Technology used for manufacturing of BeadChips [90]. These arrays have 
thousands of 50mer oligonucleotide grouped in unique bead types that are self-assembled in 
microwells etched into the surface of the BeadChip. Each bead type is represented, in average, 
over 30 times in the array, and the information can be used in gene expression measurements and 
genotyping [90].  
The collaborative efforts between Illumina, USDA-ARS, University of Missouri, and the 
University of Alberta resulted in the development the BovineSNP50 BeadChip [91]. The 
BovineSNP50 v2 BeadChip contains 54,609 highly informative SNPs, in which more than 
24,000 SNP probes target novel SNP derived from sequencing economically important cattle 
breeds using Illumina's Genome Analyzer. The remaining content includes SNPs obtained from 
public sources, whole-genome shotgun reads, Holstein BAC sequence data, and SNPs validated 
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by the Institute for Food and Agriculture Sciences Alberta and INRA [91]. This BeadChip 
includes SNPs presenting an average minor allele frequency (MAF) of 0.25 and an average 
probe spacing of 49.4 kb, providing substantial genomic characterization in beef and dairy cattle 
creeds. In addition, the BovineSNP50 v2 BeadChip offers call rates and reproducibility of over 
99% [91]. Due to these interesting and robust features, the BovineSNP50 v2 BeadChip have 
been widely used in GWAS in cattle [91]. 
1.3.2. Linkage Disequilibrium and Haplotypes 
The success of GWAS relies on the linkage disequilibrium (LD) between SNPs and the 
genomic regions affecting a given phenotype, known as quantitative trait loci (QTL). For 
example, considering a SNP with alleles A and C, and a QTL with favorable (Q) and unfavorable 
(q) phenotypes, in Figure 1.3 is presented two extreme scenarios for LD. A SNP is in linkage 
equilibrium (LE) with the QTL when a random association between the SNP alleles and QTL is 
observed (Figure 1.3 a). In this case, alleles A and C are linked to Q and q on random fashion, 
and thus, this SNP is not informative for this QTL. In contrast, when one of the two alleles is 
always associated with one of the two QTLs, this non-random association represents LD between 
the SNP and the QTL (Figure 1.3 b). In this situation, the SNP allele A is always associated with 
the favorable QTL Q. These two scenarios represent extreme situation in which a perfect LE and 
LD are observed, respectively. This non-random association may also be evaluated in groups of 
SNPs in order to identify and construct blocks called haplotype. The extent of LD between SNPs 
and QTLs, and also between pairs or groups of SNPs (haplotypes), can be measured though 
different ways. 
Measures of LD. Considering two SNPs on the same chromosome, SNP1 and SNP2, with 
polymorphisms A/G and C/T, respectively, the four possible haplotypes are: AC, AT, GC, and GT 
[92]. Assuming the same frequency of 0.5 for all alleles [f(A) = f(G) = f(C) = f(T) = 0.5], and 
haplotype frequencies of 0.1, 0.4, 0.4, and 0.1, for AC, AT, GC, and GT, respectively, LD may be 
measured using D [92,93], as: 
                          
(Eq. 1.10) 
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Using the D statistics, we obtain a LD of -0.15. Since this value is difference than zero, 
these two SNP may be in LD. The disadvantage of this LD measure is that it is very dependent of 
the haplotype frequencies, and thus, it is not useful for comparing the extent of LD among pairs 
of loci across the genome [92]. A LD measures less dependent on these frequencies is the r
2
 [94]: 
   
  
                   
 
(Eq. 1.11) 
In r
2
, values range from 0 to 1, which indicate perfect LE and LD, respectively. In this 
example, SNP1 and SNP2 are in moderate LD, with an estimated r
2
 of 0.36 [92]. The r
2
 statistics 
is a suitable measure of the extent of LD, since it can be interpreted as the proportion of variation 
of the QTL explained by the SNP [92]. 
Extent of LD in cattle. The knowledge of the extent of LD is a key element in the development 
of SNP array for GWAS and WGS, since this information can be used to determine the marker 
density required in fine mapping [95]. The extent of LD is function of complex events, and it 
varies according the number of generations, the different recombination rates across the genome, 
and among populations [89]. 
The exponential expansion of human populations and the selection pressure in cattle had 
resulted in different genomic structures, in which the average length of LD blocks is longer for 
cattle than for humans [96-98]. For instance, the large effective population sizes in humans had 
resulted in low levels of LD [95,99], and a dense marker map with resolution of less than 5 kb is 
required [95,100]. As for cattle, although the LD extent is population specific, the LD extends 
much larger regions that in humans, and recent reports indicate that strong LD (r
2
 > 0.8) may be 
observed within genomic regions of up to 720 kb [101]. Also, it has been proposed that 30K 
SNPs would have the potential to reproduce an average LD of r
2
 = 0.3 [96], although others had 
suggested a minimum of 50K [97]. 
Haplotypes. Haplotypes are evidences of chromosomal segments in which SNPs defining the 
ends of these regions are in very high LD [92]. In contrast, the LD surrounding these boundaries 
is in very, and these regions are defined as hot spots [102]. The rationales for considering the use 
of haplotype in GWAS are that haplotype blocks may capture epistatic interactions between 
SNPs [103-105] and can drastically reduce the number of tests (control of type I error). The 
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benefits of haplotype-based GWAS depend on the extent of LD between variants in the bock and 
thus the length of the haplotype block and distance between the variants [106]. 
A variety of computational and statistical methods are available for haplotype 
reconstruction [107]. Proposed by Gabriel et al. [108], the confidence intervals method focus on 
the LD statistics D' [92,109]. This measure uses the statistics D (Eq. 1.10), as: 
   
| |
    
 
(Eq. 1.11) 
where Dmax  is defined as: 
     {
                             
                             
 
In this haplotype inference method, blocks are defined as sets of consecutive sites with 
low or no recombination. The consecutive SNP information is used to create a confidence 
interval for each pair using the D’ measure. Pairs of SNPs can be classified in three categories 
depending on the values of D’: strong LD for D close to 1; weak LD for D' significantly <1; and 
intermediate/unknown, for pairs with wide confidence intervals [108,110]. 
1.3.3. GWAS in Beef Cattle 
The ability of genotyping tens or hundreds of thousands of SNPs in large populations 
provides the possibility to detect genomic regions in which show associations with economically 
important phenotypes in cattle. In this sense, genome-wide associations studies (GWAS) rely on 
the LD between the SNP and the QTL, or QTN (quantitative trait nucleotide), responsible for 
part of the observed phenotypic variation. One of the simplest ways to perform these associations 
is through single marker regression: 
               
(Eq. 1.12) 
where Yij is the phenotype, µ is the mean, SNPi is the fixed effect of SNP, and eij is the random 
error effect (normally and independently distributed [0,   
 ], where   
  is the error variance). In 
this model (Eq. 1.12), the SNP effect may include the additive and the dominance effects to be 
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estimated. In addition, this simplistic model considers only the fixed effects of the mean and the 
SNP, and assumes unrelated animals, a situation that may not well represent studies in cattle and 
other livestock animals. 
The power of detecting associations between SNPs and phenotypes depend on many 
factors [92]. First, as mentioned before, it depends on the LD between the SNP and QTL/QTN. 
Specifically, the power increases with the values of r
2
. Also, the sample size used to test the 
effect of the SNP must be increased by a factor of 1/r
2
 in order to detect associations with an 
ungenotyped QTL, compared to the sample size for testing the QTL itself [92,111]. Other factors 
affecting the power of detecting associations are: the proportion of the total phenotypic variation 
explained by the QTL (  
 ); the number of phenotypic records; the minor allele frequency 
(MAF); and the significant level used by the researcher [92]. 
The model described in Eq. 1.12 does not account for population structure, and it is very 
unlikely that animals from any beef cattle population are unrelated. In association studies, the 
failure in accounting for these relationships may lead to invalid (false positive) associations 
[92,112]. Although the transmission disequilibrium test (TDT) had been proposed to account for 
the population structure [113], this test requires genotypic information from both parents, an 
unusual procedure in animal breeding. An alternative and popular way to account for this is the 
traditional mixed model that includes the pedigree information: 
                     
(Eq. 1.13) 
where Yij, µ, SNPi, and eijk are defined as in Eq. 1.12, and      is the random polygenic effect 
[normaly distributed (0,     
 ), where A is the relationship matrix, and   
  is the polygenic 
variance]. In addition, this is a simplistic model (Eq. 1.13) including only the fixed effects of the 
mean and SNP, and the random polygenic effect, but other fixed and random effects could be 
included in the model. In cases where the pedigree information is not available, a genomic 
relationship matrix can be used [106]. Also, this same approach can be applied for associations 
between haplotypes and phenotypes. Considering the distinction between single SNPs and 
haplotypes regarding the motivation to their consideration in GWAS, the main difference in 
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using haplotypes in Eq. 1.13, is that the haplotype effect may have many more levels than the 
single SNP effect. 
 The BovineSNP50 BeadChip has been widely used in GWAS in several economically 
important traits in beef cattle. Using a population of beef cattle from several breeds, a GWAS 
was conducted for meat and carcass traits in Australian cattle [114]. The traits analyzed included 
intramuscular fat percentage (IMF), meat tenderness, and rump fat thickness. A total of 87, 64, 
and 63 were significantly (P < 0.001) associated with these traits, respectively. In addition, a 
bivariate analysis was performed with IMF and molecular breeding values, and a panel of 14 
SNP explained 5.6 and 15.6% of the phenotypic and genetic variance of IMF [114]. Using the 
same data set, associations between haplotypes and IMF had also been reported [115]. This study 
resulted in significant partial haplotype substitution effects for the genes ADIPOQ and CXCR4. 
Compared to the most significant SNPs located in these genes, the haplotypes for these genes 
explained 80% more the phenotypic variance. In an Angus population, other carcass and meat 
quality traits had been subject of study using the BovineSNP50 BeadChip. In this study, the set 
of selected markers explained 29.4, 45.1, and 28.1 % of the total variation of loin eye area, 
marbling score, and shear force, respectively [116]. 
Associations had been performed using this platform for carcass weight in Japanese 
Black cattle [117]. The model included a composed effect including age, slaughter year, and 
slaughterhouse, the effect of the minor allele and the genetic relatedness matrix. Significant 
associations were detected on bovine chromosomes (BTA) 6, 8, and 14. These three associations 
accounted for approximately one-third of the total heritability, indicating a possibility of 
efficiently increasing carcass weight using marker-assisted selection [117]. This platform had 
also been used for association analysis in tropically adapted beef cattle [118]. Using Brahman 
and Tropical Composite heifers, SNPs were tested for association with reproduction traits: age at 
puberty, postpartum anestrous interval, and occurrence of the first postpartum ovulation before 
weaning in the first rebreeding period. In Brahman, 41% of these significant markers mapped to 
a region on BTA14 whereas in Tropical Composites, 16% were located on BTA5. Some of these 
associations were located within genes, as for example, the high mobility group AT-hook 2 
(HMGA2) and pappalysin-2 (PAPPA2) genes [118]. 
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Associations for feed intake had also been report in Angus cattle. In a population 
including 689 steers, SNPs were tested for associations with average daily gain (ADG), average 
daily feed intake (AFI), and residual feed intake (RFI) [119]. The significant associations for 
each trait were further analyzed in a forward selection algorithm, resulted in a final model 
including 53, 66 and 68 SNPs explaining 54.12, 62.69, and 55.13% of the additive genetic 
variation in steer breeding values for AFI, RFI and ADG, respectively [119]. In another Angus 
population including steers and heifers, associations for ADG, dry matter intake (DMI), and RFI 
resulted in the identification of six, nine, and four significant haplotype associations, respectively 
[120]. In this study genomic regions previously associated with these traits [121,122] and new 
regions were found [120]. The results from studies using the BovineSNP50 BeadChip have been 
providing interesting findings that have important impact in beef cattle research and production. 
1.4. Functional Analysis 
Microarray technology provides data of thousands of genes, and the analysis of this data 
assist on the development of a list of genes according to the strength of their association with the 
conditions under consideration (e.g. time-to-event). Public databases compiling functional and 
genomic information and statistical tools to detect the enrichment of functional and genomic 
categories among the lists of genes are available [123]. Among the databases, popular 
repositories are the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology 
(GO) [124]. The KEGG database [125] is a public online resource [126] of systems, genomic 
and chemical information [127]. This bioinformatics tool consists of 19 main databases as 
described in Table 1.1. Systems information represents functional aspects of the biological 
systems, whereas genomic and chemical information represent the molecular building blocks of 
life in, respectively, the genomic and chemical spaces [127].  
Information regarding the molecular networks of several cellular processes can be 
accessed through the KEGG PATHWAY database. This graphic tool illustrates many 
reaction/interaction networks for metabolism, genetic and environmental information processing, 
chemical structure transformation network, and human diseases [127]. The pathway maps, 
representing a particular network, are described through nodes (genes, proteins etc.) and edges 
(reactions, interactions and relations) [127,128]. 
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The Gene Ontology Consortium (GOC) is a project established in 1998 with the objective 
of creating a dynamic and “controlled vocabulary that can be applied to all eukaryotes even as 
knowledge of gene and protein roles in cells is accumulating and changing” [129]. Although at 
the beginning there were only three model organism databases (mouse, yeast and fly), today the 
GOC includes the world’s major repositories for microbial, plant and animal genomes [130]. 
This public web tool annotates and organizes the biological properties of gene products, 
characterizing those according three ontologies: Molecular function, biological process and 
cellular component [131].  
Molecular function represents the biochemical activity of a gene product, irrespective of 
the time and place that event occurs. These functions can be general, as transporter, or more 
specific (adenylate cyclase); the biological process ontology is related with the biological 
objective of a gene or gene product. In other words, it refers to processes where occur chemical 
or physical transformations, such as cell growth and maintenance (general process) or 
translation (specific process); the latter category, cellular component, represents a physical 
location in the cell where multiple gene products would be found. This ontology encompasses 
broader, e.g. nuclear membrane, and specific (histone deacetylase complex) locations in the cell 
[129].  
The classification of genes and gene products in either category results in GO terms. 
These terms are uniquely identified, e.g. GO:0006915 (apoptosis), and for a given gene/gene 
product, many terms can be associated (general and specific terms) for any of the ontologies. 
Moreover, these terms are structurally organized within each of the three ontologies, and related 
to each other. This relation is characterized by three basic types: is a, part of and regulation. 
Such relations may be exemplified as: the molecular function (GO:0003674) p53 binding 
(GO:0002039) is a protein binding (GO:000551), the cellular component (GO:0005575) 
mitochondrion (GO:0005739) is part of cytoplasm (GO:0005737), and the biological process 
(GO:0008150) of cell cycle checkpoint (GO:0000075) regulates cell cycle (GO:0007049) [132]. 
The KEGG pathway and GO databases are comprehensive repositories that can be used to 
summarize the results from the analysis of high throughput microarray experiments.  
Among the tools to detect enrichment of functional categories, FatiGO is a web-based 
functional enrichment application [133] that extracts relevant GO terms, KEGG pathways, and 
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other information from several databases [134], testing a list of significant genes against a 
‘control’ list [133]. This test is performed using Fisher’s exact test [135] correcting for the 
multiple hypotheses tested (one for each GO term) [133]. The 2 x 2 contingency table of Fisher’s 
exact test is used to test if a group of genes of interest is significant for a GO term when 
compared with the ‘control’ list. The p-value generated from this test is adjusted based on three 
other tests. The step-down minP method of Westfall and Young (1993) [136] controls for Type I 
errors and two methods aim the control of false discovery rates (FDR); the FDR methods of 
Benjamini and Hochberg (1995) [137] and Benjamini and Yekutieli (2001) [138], which are 
performed, respectively, under independence and some type of dependence, and arbitrary 
dependence of the tests statistics [133]. FatiGO uses an inclusive analysis to define which GO 
terms are significant [133]. The GO analysis for a particular gene/gene product may results in 
several GO terms following a hierarchical pattern. In this manner, FatiGO considers the most 
general level of ontology among genes sharing similar terms, and thus, resulting in less terms 
with more genes. As an example, if the inclusive analysis is not used, eight genes may classified 
as the GO terms apoptosis (two genes), regulation of apoptosis (three), negative regulation of 
apoptosis (one) and induction of apoptosis (two). Conversely, if the inclusive analysis is 
considered, FatiGO assigned the eight genes for apoptosis and thus, increases the power of the 
test [133,139]. Enrichment analysis provides valuable information regarding gene ontologies and 
pathways for a set of significant genes. 
1.5. Survival Analysis 
The development of the microarray technology brought many expectations to the medical 
research community. High-throughput microarrays provide a comprehensive molecular portrait 
of diseases. This information is important to understand the molecular processes that define 
different pathologies and for the improvement of prognosis and treatment methods and to 
identify biomarkers of the disease [140]. The identification of molecular profiles associated with 
time-to-an-event such as survival is an area of active research. Survival measurements have 
particular characteristics and thus require the use of specific statistical methods.  
Survival analysis is a statistical methodology to model the probability of occurrence of an 
event at a specific time or hazard and the association of the explanatory with the hazard. The 
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time-to-event response variable can include censored records. Censoring takes place when there 
is incomplete information of an event. In this manner, if the event is not observed within a 
specified time frame, it means that the event could have occurred before, after or even during this 
period of time. These are respectively known as left, right and interval censoring. Death will be 
used as an example of the event to facilitate the description of the model. For this example, right 
censoring is applicable because not all subjects studied will be death by the end of the period 
considered, an example of this situation is presented in Figure 1.4. In a hypothetical situation, 
eight patients with cancer participate in a study and were observed for different time periods, but 
within the same time range (from January to December of the same year; Figure 1.4 a). In 
Figure 1.4 b, the beginning of the observation (diagnosis of cancer) for each patient was set as 
t=0 to show the length of the time period before the occurrence of the event (death) or not 
(censoring – individuals still living at the end of the observation period). In this manner, the 
consideration of censored data is an important characteristic of survival analysis, requiring the 
application of special methods that account for this binary variable.  
Survival data are generally described and modeled in terms of survival and hazard 
functions [141]. Given that   denotes the survival time, where    , and   is a specific value 
for  , the probability that a person survives longer than a specific time  , i.e.       ,  is 
defined as the survival function      [142]: 
            
(Eq. 1.14) 
In theory,   ranges from 0 up to infinity, with the survival function describing a smooth 
curve (Figure 1.5 a), whereas in practice, the study period is never infinite in length and the 
estimate survival function  ̂    describes step functions (Figure 1.5 b) [142]. In contrast to     , 
that represents the probability of non-occurrence of death at a particular time  , the hazard 
function      is the event (death) rate given that the individual survived up to time   and is 
expressed as [142]: 
        
    
          |    
  
 
(Eq. 1.15) 
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where    is a small time interval. In this manner, this equation gives the instant potential per unit 
of time for the event occur, since the conditional probability of death in a interval between   and 
    , given that   is greater than o equal to  , is divided by a particular time interval [142]. The 
hazard function is graphed with   ranging from 0 to , but, in contrast to the survival function, 
the plotted hazard function exhibits one of several profiles as described in Figure 1.6. The 
hazard function may have constant values, as in healthy individuals (Figure 1.6 a); it may 
increase, as in leukemia patients not responding to treatments (Figure 1.6 b); it may decrease, as 
in persons recovering from surgery (Figure 1.6 c); or even decrease after a prior increasing, such 
as in tuberculosis patients (Figure 1.6 d) [142].  
Three approaches are available for analyzing survival data. First, a parametric regression 
procedure is used to model the distribution of survival time, given explanatory variables. The 
Weibull model is a fully parametric method for survival analysis, which describes age-specific 
mortalities and failure rates [143,144], but it must be only used when the data follow a Weibull 
distribution [142], which is not always the case when several explanatory variables are being 
tested in the model. Second, a nonparametric procedure allows the estimation of a survivor 
function, comparison of the survival curves between explanatory variable levels, and testing the 
association between survival time and these variables. The Kaplan-Meier [145] estimator is a 
nonparametric approach that estimates the survival function between two or more groups by a 
log-rank test [146]. The groups are studied by comparing the curves of risk estimates in time. In 
this manner, the effects of the explanatory variables are not estimated. Lastly, a semiparametric 
procedure uses the Cox proportional hazards model to describe the hazard [147,148]: 
             [∑    
 
   
] 
(Eq. 1.16) 
where      is the hazard function on time  ;       is the baseline hazard function on time  ;     
is the exponential function;    is the vector of explanatory variables (e.g., gender, therapy, gene 
expression and others), with           and    is the vector of coefficients associated with   . 
In this manner, the Cox model accounts for two different portions. The first one is the 
nonparametric baseline hazard function      , which is time-dependent, and the second part is 
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the exponential expression of the time-independent explanatory variables  ∑     
 
   . The relation 
           occurs if              or if there are no explanatory variables (no    ) 
in the model. This property indicates that the Cox model is a semi-parametric method, although 
it yields results, approximating parametric models as the Weibull and exponential models [142]. 
In the Cox model, an unknown parameter is the hazard ratio      that compares the 
hazard function of two explanatory variable levels. The estimated hazard ratio (  ̂) of the ith 
explanatory variable is: 
   ̂     [  ̂   
     ] 
(Eq. 1.17) 
where   
  is the vector of the explanatory variable being tested against   ; and   ̂ is the vector of 
estimated coefficients associated with    
     . The hazard ratio estimates describe the 
association between the explanatory variable (e.g. gender – males against females) and the event 
hazard (death or disease diagnostic or disease progression). The values of   ̂ range from 0 to 
infinity (∞) because this estimate is the result of the exponentiation of a number ranging from –∞ 
to +∞. Estimates below 1 indicate that a particular factor level (e.g. radiation therapy), decreases 
the hazard of death, and thus increases the survival time when compared to the other level of the 
factor (e.g. absence of radiation therapy). Conversely, estimates higher than 1 indicate that the 
hazard associated with one factor level increased when contrasted to another factor.  
The Cox proportional hazard model assumes that the HR comparing any two explanatory 
variables levels is constant over time [148]. The hazard functions for the explanatory factor 
levels or groups are proportional and are parallel or maintain the same distance (i.e. group effect) 
across the time points [148]. Figure 1.7 illustrates examples of different hazard ratios values in 
two situations: when the proportional assumptions are met and when are not met. In Figures 1.7 
a and b, the assumption of proportionality is met; the survival curves for   
  and    are parallel 
across time, with      in Figure 1.7 a and      in Figure 1.7 b. For Figures 1.7 c and d, 
the proportional assumption is not met. In Figure 1.7 c, although     , the hazard ratio gets 
closer to 1 as time increases, whereas in Figure 1.7 d,    is lower than 1 until a given time    
but gets higher than 1 after   . The assumption of proportional hazard must be verified in order 
to use estimated hazard ratios to explain how some factors act on survival. 
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1.6. Multivariate Techniques in Genomic Studies 
The increasing development of omics technologies has been providing researchers with a 
large amount of information used for the identification and characterization biological processes. 
The amount of data resulted from these techniques presents a challenging aspect to researchers, 
making difficult the comprehensive and accurate interpretation of the data [149]. In addition, the 
biological events described through the use of these technologies are functions of many factors, 
and thus, the use statistical techniques that account for these relations may enhance the 
interpretation of the data. 
The group of statistical techniques used to simultaneously analyze multiple 
measurements, as either response (dependent) or explanatory (independent) variables, on 
individuals or objects under investigation is called multivariate analysis [150]. Multivariate 
techniques have been applied to facilitate the interpretation of high-throughput data in humans 
and livestock research, as in genomics [151], transcriptomics [152], proteomics [153], and 
metabolomics [154]. The selection of the appropriate multivariate technique for analysis depends 
on the research objective, the type of data (quantitative/metric or categorical /nonmetric), and the 
relationship between variables [150]. 
1.6.1. Types of Multivariate Techniques 
There are many multivariate techniques and these are used for different objectives. For 
example, they can be used in simpler analysis, in which two or more metric explanatory 
variables are used to predict a single metric depend variable (multiple regression), or in more 
complex models, in which the dependent and independent variables present multiple 
relationships (structural equation modeling; SEM). 
Multivariate techniques may be classified based on the dependency of the variables and 
on the data type [150]. When a set of variables (response variables) can be used to predict 
another set of variables (explanatory variables), the multivariate techniques are known as 
dependence techniques. In contrast, when this type of relationship is not present, and variables 
cannot be classified solely as response or explanatory, the multivariate techniques are known as 
interdependence techniques. In addition, these techniques can be further classified depending on 
type of data, where different techniques are used when the response and explanatory variables 
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are metric, nonmetric, or a combination of both. Following is a brief description of several 
multivariate techniques including one example of their use in omics studies. 
Principal component analysis. The objective of principal component analysis (PCA) is to reduce 
the number of variables (dimensions) of the data by creating a new set of orthogonal (i.e. 
independent) variables that contain the original information of the data. These new orthogonal 
variables are called principal components (PC). PCA relies on the fact that many of the variables 
studied in biological research show some degree of correlation/covariation, and thus, a smaller 
number of the new orthogonal variables (PCs) may explain great part of the variation of the data. 
On a cattle genetic diversity study using taurine (B. Taurus), zebu (B. indicus) and hybrid 
breeds (taurine-zebu hybrids), PCA was used to create PCs from SNP data (approximately 30K 
SNPs) in order to select a small subset of SNPs that correlate well with population structure 
[155]. 
Factor analysis. This technique is similar to PCA since it also aims to reduce the dimensionality 
of the data. The difference is that, while in PCA the total variation is fractioned in PCs, in factor 
analysis (FA), uncorrelated variables (called factors) are generated and retain a portion of the 
variance shared with all variables (common variance) and a fraction accounted by each of the 
factors (unique variance). This characteristic of FA implies that an observation is explained by a 
model which contains two variances, a common and a unique. Therefore, the decision on which 
multivariate method (FA x PCA) should be used to reduce dimensionality needs to take into 
consideration the interest of the researcher; if one wants to identify an underlying structure in the 
data (FA), or if wants to extract fractions of the total variance in the data (PCA). 
The use of FA had been proposed to reduce the dimensionality of SNP data 
(approximately 301 SNPs) for prediction of genomic breeding values (GEBV) [156]. The results 
of this study indicate that 32 factors showed higher correlation between GEBV and true breeding 
values than the consideration of all 301 SNPs. 
Multiple regression. Perhaps the most simple and used multivariate technique, in multiple 
regression the objective is the prediction of one single metric response variable using two or 
more metric explanatory variables. In many cases, the explanatory variables used for predictions 
are chosen based on methods developed for variable selection (as those described on section 
1.2.2 in this material). 
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One interesting application of multiple regression is on gene expression studies. It has 
been shown that the expression pattern of candidate genes can be used to predict intramuscular 
fat content in pigs from different breeds and crosses [157].  
Canonical correlation analysis. This technique can be viewed as a more complex version of 
multiple regression. While in multiple regression a set of metric explanatory variables are used to 
predict one single metric response variable, the objective in canonical correlation analysis (CCA) 
is to correlate two groups of metric variables simultaneously. In this case, there is not clear 
distinction between the response and explanatory variables. 
  The application of CCA in conjunction with Fisher's exact test has shown to provide 
additional information in gene set enrichment analysis. In a research using obese and diabetic 
mice, the selenoamino acid metabolism and steroid biosynthesis pathways were identified after 
the consideration of CCA using transcriptomics and plasma marker data [158]. 
Multiple discriminant analysis. In multiple discriminant analysis (MDA), a single nonmetric 
(categorical) response variable is predicted by two or more explanatory variables. The goal in 
MDA is to evaluate whether the set of explanatory variables is effective in predicting the 
different groups of the categorical response variable. This is accomplished by creating 
discriminant functions that maximizes the likelihood that an observation belongs to a particular 
group of response variable, based on the explanatory variables. 
A classical use on MDA in genomics studies is the allocation of individual animals to 
breeds using SNP data. It had been shown that three breed-specific SNPs had, on average, high 
efficiency (> 95%) and low misclassification probability (< 5%) to discriminate Holstein and 
Jersey bulls [159]. 
Cluster analysis. This popular multivariate technique is used to create two or more distinct 
groups containing individuals or objects with similar characteristics in each group. Differently 
from the MDA, in cluster analysis the groups in which the variables come from are not 
predefined. The groups (clusters) are created based on the degree of similarity of the 
observations, and subsequently, the variation within and between groups. 
Cluster analysis has been extensively used in gene expression studies. For example, the 
differential expression pattern of 62 genes in the liver of cows had been used for cluster analysis 
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[160]. The analysis resulted on eight clusters, and enhanced the identification physiological 
events in during the periparturient period. 
Correspondence analysis. Correspondence analysis can be viewed as a nonmetric (categorical) 
version of PCA. As in PCA, the variables have an interdependent relationship among them. 
Differently from most nonmetric techniques, in correspondence analysis the categorical variables 
may be transformed to a metric level and then subject for dimension reduction. 
Correspondence analysis can be used to determine the genetic relationships among 
animals from different breeds.  Microsatellite data from 18 local cattle breeds from Spain, 
Portugal, and France had been used for correspondence analysis [161]. The results from this 
analysis not only distinguished four breed groups but also confirmed results of previous studies. 
Structural equation modeling. In structural equation modeling (SEM), response and explanatory 
variables have multiple relationships, characterized by two basic components: (1) the structural 
model, and (2) the measurement model. In (1), as called the path model, the relationship between 
explanatory and response variables are defined by the researcher. In (2), these relationships are 
measured through (for example) regression. Due to this situation SEM may result in complex 
relationships in which variables may act as response and explanatory variables, depending on the 
relationship in the model. 
Phenotypes can be functions of complex gene networks, and thus, gene expression data 
may be suitable for the application of SEM. This technique had been applied to show how the 
expression pattern of genes may simultaneously act through a direct and/or indirect manner on 
the intramuscular fat content of pigs [162]. 
Multivariate analysis of variance. Lastly, the multivariate analysis of variance (MANOVA) is 
the extended version of the traditional univariate analysis of variance (ANOVA). As the name 
suggests, while only one response variable is tested using ANOVA, two or more response 
variables can be simultaneously tested through the same model in MANOVA. Like ANOVA, 
MANOVA is concerned with differences between the levels of the explanatory levels, but in this 
technique, the covariance between response variables is accounted. The assumptions, models, 
and examples for this technique are provided in the next section. For simplicity, Hotelling’s T2 
test will not be covered due to its limitation on the number of groups being tested.  
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1.6.2. MANOVA 
Assumptions. The assumptions for MANOVA are: (1) The data from variable i has common 
mean vector μi, (2) the data from all groups have common variance-covariance matrix Σ, (3) the 
experimental units are independently sampled, and (4) the errors are multivariate normally 
distributed.  
MANOVA model. The matrix notation of a mixed model MANOVA with two response variables 
is: 
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(Eq. 1.18) 
where Y1 and Y2 are the vectors of observations for variables 1 and 2, respectively; X1 and X2 are 
the incidence matrices for the fixed effects for variables 1 and 2, respectively; b1 and b2 are the 
vectors of solutions associated with X1 and X2, respectively; Z1 and Z2 are the incidence matrices 
for the random effects for variables 1 and 2, respectively; u1 and u2 are the vectors of solutions 
associated with Z1 and Z2; respectively, and e1 and e2 are the vectors of random errors associated 
with Y1 and Y2, respectively; assuming random effects distributed as multivariate normal having 
mean equal to zero and covariance equal to: 
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(Eq. 1.19) 
where    
 ,    
 ,    
 ,    
 , and       are the variance of the random effect Z for variable 1,  
variance of the random effect Z for variable 2, random error variance for variable 1, random error 
variance for variable 2, and random error covariance between variables 1 and 2, respectively. 
Hypothesis testing. Considering a one-way MANOVA with k levels of experimental units (k = 1 
to n), j levels of the explanatory variable (j = 1 to m) and i levels of response variables (i = 1 to 
p), the model (Eq. 1.20) and the null hypothesis of not effect (τ) of the k levels of the explanatory 
variable on the p response variables (Eq. 1.21) are: 
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(Eq. 1.20) 
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(Eq. 1.21) 
The total variation (T) from Eq. 1.20 can be partitioned in between (B) and within (W) 
variations, as presented in Table 1.2. This partition of the variations is used for the null 
hypothesis testing described in Eq. 1.21. Differently from ANOVA, several tests may be used to 
test the MANOVA null hypothesis, and all of these tests are made on A = W
-1
B. The most 
popular test statistics used to test the MANOVA hull hypothesis are based on the eigenvalues 
(λp) of the A matrix [163]. These tests are known as the Wilk’s lambda (Λ), Roy’s largest root 
(U), Pillai’s trace (V), and Hotelling-Lawley’s trace (T). The formulas for these tests are shown 
below in Eqs. 1.22, 1.23, 1.24, and 1.25, respectively: 
  
| |
|   |
 
(Eq. 1.22) 
          
(Eq. 1.23) 
                  
(Eq. 1.24) 
              
(Eq. 1.25) 
As the name suggests, Roy’s largest root uses the first discriminant function among 
response variables. This test is preferable when response variables have high correlation, and 
thus, most of the variation may be accounted by one dimension. Wilk’s lambda is also known as 
the multivariate F due to its popularity. Unlike Roy’s largest, Wilk’s lambda accounts for the 
total variation of the data; that is, it considers all discriminant functions in order to examine 
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differences among levels of the same explanatory variable. Similarly, Pillai’s trace and 
Hotelling-Lawley’s trace consider all discriminant functions in order to calculate the test 
statistics. In addition, these can be approximated by F statistics [150]. 
Advantages and disadvantages. As any other method in statistical analysis, MANOVA has 
advantages and disadvantages. The main advantages in using MANOVA in place of several 
ANOVAs is the reduction on the number of hypothesis being tested, and thus, reduction of the 
type I error. Also, many variables tested in biological studies are correlated, and these may be 
affected on the same manner by the explanatory variables. In this case, the joint consideration of 
these response variables in one single analysis may increase the power to reject the null 
hypothesis since the error covariances between response variables are accounted in MANOVA. 
Finally, MANOVA provides an opportunity to summarize several analyses into a single one. 
The main disadvantage in MANOVA is the interpretation of the results. In MANOVA, 
different discriminant functions may be responsible for each significant effect, and thus, the 
interpretation on how factors affect responsible variables may be ambiguous. Also, reduced 
power in detecting differences is expected as the correlation between response variables 
decreases. Therefore, MANOVA may not be used for all response variables. 
1.6.3. MANOVA and Association Analysis 
Multivariate approaches have been used to detect QTLs associated with production and 
health phenotypes in livestock [164-166].Multivariate approaches can augment the statistical 
precision to detect loci associated with multiple phenotypes through an increase in the signal 
(phenotype variation correlated by the loci) and  reduction in the noise or error 
[151,164,165,167-169]. Therefore, multivariate techniques, such as MANOVA, may be used for 
the identification of SNPs associated with phenotypes in livestock studies. 
Although promising, the number of studies reporting the use of MANOVA in GWAS is 
limited. In a study with 1887 Holstein–Friesian dairy cows, a bivariate model was used for the 
association of 37,590 SNPs with fertility traits [170]. A total of 15 bivariate models were 
analyzed, always including post-partum interval to the commencement of luteal activity (CLA) 
as one of the phenotypes, while using any of the other fertility traits as the second response 
variable. In this study, two regions of the genome were associated with CLA. Although the 
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univariate analysis showed a relatively high probability for these associations, the probability 
increased when the GWAS was undertaken in a bivariate analysis [170]. 
Multivariate analysis had also been reported for validation of SNPs [114]. A total of 940 
Australian beef cattle and 53,798 SNPs were used for SNP association and estimation of 
breeding values. After preliminary associations, a bivariate model including molecular breeding 
values (MBV) and intramuscular fat content (IMF) as phenotypes was used in a validation data 
set. The bivariate model included a panel of 14 SNPs that explained 5.6 and 15.6% of the 
phenotypic and genetic variance of IMF [114]. 
With the objective to understand the patterns of pleiotropic effects of genes, a bivariate 
analysis had been undertaken to detect SNPs associated with production traits [151]. Including 
data of 39,048 SNPs, and of 767 and 386 Holstein bulls, for training and validation, respectively, 
the Australian selection index (ASI) was also included as one of the two traits of the analysis. 
Compared to the univariate analysis of ASI, the bivariate analysis was responsible for the 
validation of 10 SNPs not confirmed previously [151]. These studies show that the identification 
of SNP associations may be improved by the joint consideration of complementary traits. 
1.7. Glioblastoma Multiforme Survival 
Commonly known as cancer, malignant neoplasm is a category of over 100 diseases 
characterized by abnormal cells featuring unsystematic proliferation and ability to grow into 
other tissues [171]. Irrespective of the site and biological behavior, neoplasms may be 
generically classified as tumors [172] and defined as a mass with distinct growth pattern from the 
adjacent normal tissues in the absence of stimuli [173]. These tumors can be classified in benign 
and malignant, depending on their capacity of invasion. Although benign tumors can be harmful, 
compressing healthy tissues and organs owing to their uncoordinated expansion, they can only be 
classified as malignant when they grow into other tissues [171]. In addition, this invasion may 
occur in adjacent tissues or in other parts of the organism by cells, malignant or not, via lymph or 
blood vessels in a process known as metastasis [174]. These events are results of several genetic 
modifications inside the cell [19]. 
Abnormal alterations in the genome, such as changes in the DNA sequence and 
methylation pattern, chromosomal organization and copy number variation are associated with 
 35 
 
malignant cells [19]. These genomic transformations modify the normal behavior of the cell; the 
expression pattern of genes changes, promoting the initiation and progression of cancer [19,175-
177]. In this manner, the genetic regulation of tumor inducing (oncogenes) and tumor suppressor 
(anti-oncogenes) agents is critical in tumorigenesis [178]. These two classes of genes, with 
antagonistic activities, regulate signaling pathways related to many cellular processes, including 
cell cycle, apoptosis, morphogenesis and others [179-181]. Despite the fact that these processes 
are not histology-specific and may occur in any malignancy, different types of cancer may have 
unique attributes, presenting different growth and proliferation rates, and response to therapies 
[171]. 
Considered one of the most abrasives and treatment-resistant types of primary 
malignancies [182], brain cancers can be classified according The World Health Organization 
(WHO) by group, histology and grading [183]. Cancers are designed as primary when are 
developed in the same site, without evidences of previous neoplasms, and secondary if originated 
from antecedent malignant cells [184]. The WHO grading system has four classes (I, II, III and 
IV), according the level of malignancy of brain neoplasm [183]. Grade I tumors have low 
proliferation rate and may be cured with surgical resection. With a similar growth pattern as 
WHO grade I tumors, WHO grade II neoplasms have increased capacity of recurrence, being 
able to develop to more aggressive types of cancer. Patients with tumors classified as grade III 
are usually treated by therapies in order to control the higher progression of the neoplasm, 
comparing to grade II tumors. Grade IV cancers are the most aggressive and fatal, reproducing 
rapidly and invading other tissues [183]. This grading system is applied to all types of primary 
malignant neoplasm of the central nervous system. Among the categories of brain neoplasms, 
astrocytomas constitute one of the largest groups and are derived from glial cells [185]. 
Astrocytomas, a subtype of glioma, account for over 20% of all primary brain and central 
nervous system tumors [186], and its most aggressive form is the WHO grade IV astrocytoma, 
known as glioblastoma multiforme (GBM). 
1.7.1. Importance of Glioblastoma Multiforme 
Glioblastoma multiforme accounts for 15%-20% of all intracranial tumors, 50% of brain 
malignancies [187] and has swift and devastating consequences. This malignant type of primary 
brain tumor is very aggressive and the median survival after diagnosis is one year [188,189]. In 
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this manner, many research groups have been focusing on the identification of the etiologic 
factors of GBM and its progression, in order to control the development of this disease 
[19,184,190-194]. The vast majority of GBM cases in adults are represented by primary tumors, 
while secondary GBMs are rare, having higher incidence in individuals below 45 years 
[184,190]. Moreover, the incidence of these subtypes of glioma varies with gender. Primary 
GBMs are more frequent in males and secondary GBM in females [190]. Although primary and 
secondary malignant gliomas develop through different pathways [190], the overall GBM 
survival is not affected by this classification [195]. 
Glioblastoma is classified as grade IV due to its impressive capacity to proliferate, invade 
and progress in brain. Even after surgery, malignant cells may spread through different areas of 
the brain, including vital regions [196]. The migration and invasion of glioma cells into normal 
tissue is a multifactorial process where different cellular mechanism and molecular pathways are 
regulated [192,197]. These events are controlled by many genomic alterations in the cell, and 
therefore, the understanding of the genetic basis of this malignance is important for the 
development of efficient therapies [19,184,198]. 
1.7.2. Molecular Genetics of Glioblastoma Multiforme 
Aberrant genetic function in glioma cells modifies core pathways in GBM. Deregulation 
of major molecular pathways by genetic phenomenon in GBM includes mutation, deletion and 
amplification of genes that inactivate the tumor protein 53 (p53) and retinoblastoma (RB) tumor 
suppressor pathways, and activate the phosphatidylinositol-3-OH kinase (PI3K) pathway 
[19,194]. 
The tumor suppressor proteins p53 and RB, encoded by respectively TP53 and RB1, are 
well-studied proteins acting on cell cycle processes. Gene TP53 is stimulated by a range of stress 
signals, e.g., DNA damage, acting of cell cycle progression and apoptosis, whereas RB1 
suppresses cell growth [194]. Part of the PTEN and PI3K pathways, TP53 may be inactivated by 
point mutations, loss of chromosome 17p and overexpression or amplification of MDM2 and 
MDM4 [184,191,194]. Malfunction of TP53 inhibits apoptosis of malignant cells and mutations 
on this gene are more frequent in secondary than primary GBM [190]. Transition from the G1 
phase to S phase in the cell cycle is possible by the activation of genes dependent on the E2F 
transcription factor family. Inactivation of RB1 by the CDK4/cyclin D1 complex induces the 
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release of these transcriptional factors [190]. In this manner, the cell progresses through the cell 
cycle when RB1 losses its function. Moreover, abnormal RB1 function may be due to loss of 13q, 
point mutations and overexpression of CDK4, CDK6 and P16 [184,190]. 
Although many of the genes described above have potential to be targets for therapies 
[199-202], genetic alterations on the O-6-methylguanine-DNA methyltransferase gene (MGMT) 
and DNA mismatch repair (MMR) genes are subject of many therapeutic cancer studies [203-
208]. During DNA replication MMR enzymes correct wrong nucleotide insertions and small 
loops [206]. The most common MMR genes with loss of protein products are MLH1, MSH2, 
MSH6 and PMS2 [208]. Patients under temozolomide therapy, present specifically loss of MSH6 
expression, resulting in tumor growth [205], although normal MMR function is required for the 
efficiency of this type of therapy [209]. As MMR, MGMT is a DNA repair enzyme and the 
success of temozolomide therapy also depends on the methylation status of MGMT [207]. 
Individuals presenting methylation of the MGMT promoter show increased survival when treated 
with temozolomide than patients with the active form of this gene [203]. These results indicate 
that the response to environmental factors, in this case therapy, is dependent on the genetic 
information of the patients with GBM in several situations. 
The initiation and progression of malignant tumors is a function of different abnormal 
genetic events. Deletions, mutations and amplifications of genes define the abrasive behavior of 
cancer. Many genes and pathways have been identified in GBM with roles related to cell cycle, 
motility and programming. The development of the tumor depends on the inhibition and 
expression of tumor suppressor and oncogenes. Moreover, the identification and understanding 
of the roles of these genes is vital for the development of targeted therapies. 
1.8. Feed Efficiency 
1.8.1. General Considerations 
The beef cattle industry represents the major portion of the American agriculture 
production and is the largest fed-cattle industry in the world [210]. In the U.S., the beef industry 
generated over US$ 70 billion in retail, resulted from a total beef production of 26.07 billion 
pounds in 2009 [211]. In contrast to the per capita consumption, the value of beef has increased 
over the years (Figure 1.8). The major reason for the increasing in beef price is due to efforts of 
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the industry in meeting the beef market requirements of higher value-added products, similar to 
what as occurs in pork and chicken [210]. This leads to the need of maximizing the beef cattle 
production system in order to increase the profitability. 
The largest variable cost in the beef cattle industry, apart from the cost of the animal 
itself, comes from feed, which represents from 62 to 84% of the total costs, depending on the 
stage of production [210]. Moreover, 70 to 75% of the total energy intake is used for 
maintenance in beef production [212]. Thus, reducing feed intake without decreasing animal 
production is desirable in order to reduce the costs of production. In this manner, the relationship 
between feed intake and production needs to be evaluated. Therefore, the development of 
mathematical tools that accurately estimate the efficiency of converting feed in beef products is 
of substantial interest in the beef cattle industry. 
1.8.2. Traits 
Feed efficiency is based on the relation between animal intake (input) and production 
(output). The efficiency of converting feed into animal products can be measured by several 
methods. The traditional ratios between feed and gain, feed efficiency index (
    
    
    ) and feed 
conversion ratio (
    
    
     ), offer an incomplete picture of feed efficiency and thus are not 
suitable to accurately evaluate and effectively improve animal efficiency. These ratios offer a 
gross estimate of efficiency that cannot distinguish between the consumption fraction used for 
maintenance and growth [213]. In addition, these ratios have a high genetic correlation with 
growth traits (revised by Crews [214]). Thus, improvement of this trait would result in animals 
that have higher mature size and maintenance requirement [214]. A third issue is that selection 
for ratio-computed traits can result in improvements due to either trait [214,215]. Ideally, the 
improvement of feed efficient traits should rely on traits and methods that accurately assess the 
efficiency of converting feed into animal product without the limitations cited above. 
A wide range of feed efficiency indicators have been proposed in livestock [216-221]. A 
popular method for measuring feed efficiency is the estimation of the residual feed intake (RFI). 
The first indicator of RIF (Eq. 1.26) was proposed by Koch et al. in 1963 [222], defined as the 
difference predicted and observed intake: 
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           ̂ 
   ̂    ̂    ̂      ̂    
(Eq. 1.26) 
where    ̂  is the predicted dry matter intake (DMI);   ̂ ,   ̂  and   ̂  are the intercept, and 
regression coefficients associated with average daily gain (ADG) and metabolic body weight 
(body weigth
0.73
; MBW), respectively. This equation assumes that all animals are under similar 
conditions [222]. This is an individual measurement, using information of production and body 
maintenance, with negative or lower RFI values denoting higher efficiency in converting feed 
into animal product than higher RFI values. This model was further modified by other authors. In 
sheep, François et al. [223] suggested the inclusion of body composition measures in the     
model (Eq. 1.27). The expanded     model takes into account the variation due to body traits, 
which can be important for explaining the feed intake [224]. 
   ̂    ̂    ̂      ̂            ̂     ̂   
(Eq. 1.27) 
where           is the live weight at mid-test;   ̂  and   ̂  are, respectively, the regression 
coefficients associated with back-fat (  ) and muscle depth (  ). Others had also suggested the 
inclusion of different covariates in the estimation of DMI [225,226]. These covariates may 
improve the estimation of DMI by further accounting for the variation due to the consumption 
fractions used for maintenance and growth. 
 Following the same principle, Crowley et al. [227] prosed using the estimation of the 
difference between observed and predicted body weight gain in order to evaluate feed efficiency. 
Although originally termed residual body weight gain (RG), this feed efficiency indicator may be 
view as an antagonistic of RFI, and thus, it can be renamed as residual average daily gain 
(RADG).  This measure of feed efficiency can be calculated using the parameters previously 
detailed in Eq. 1.26, as: 
            ̂ 
   ̂    ̂    ̂      ̂    
(Eq. 1.28) 
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As in RFI, the estimation of RADG may include other covariates, with biological 
meaning, that account for the variation in ADG. In addition, the American Angus Association 
and Angus Genetics Inc. had proposed the computation of RADG using genetic evaluation of 
several phenotypic traits and genomic data [228]. This measurement combines the Angus-
specific Igenity profile derived from a high-density whole-genome scan with 50,000 markers and 
genetic evaluation of traits, including calf weaning weight, postweaning gain, ultrasound 
subcutaneous fat thickness, individual calf dry-matter intake, and dry-matter intake. The 
prediction of the genetic feed intake value is obtained using the weight, gain, fat and genomic 
information. The results is then coupled the genetic ultrasound fat expected progeny difference 
(EPD) to predict the postweaning gain EPD. With this value,      is estimated. In contrast to 
RFI, positive values of RADG indicate more efficient animals [228].  
The feed efficiency indicators RFI and RADG are complementary measures that are used 
to assess the differences between the observed and predicted values of intake and production, 
respectively. With the objective of retaining the favorable characteristic of RFI and RADG, 
Berry and Crowley [229] suggested a new measure called residual intake and (body) gain (RIG). 
This feed efficiency indicator is calculated as the sum of −1 × RFI and RADG, both standardized 
to a variance of 1. The rationale in multiplying RFI by −1 is to account for a negative RFI being 
favorable compared with a positive RADG [229]. Therefore, as in RADG, positive values for 
RIG indicate favorable feed efficiency. Since RIG is a linear function of RFI and RADG, this 
indicator is a linear function of their predictors: DMI, ADG, and MBW. 
Although practical and informative, these three feed efficiency indicators (RFI, RADG, 
and RIG) are residual estimates. In other words, these are functions of point predictions that 
ignore the uncertainty (e.g. confidence intervals) associated with these predictions. For example, 
considering an animal with an observed and predicted DMI of, respectively, 9 and 10 kg/day, the 
point estimate for RFI would be -1 kg/d, which indicates that this is an efficient animal. But 
considering a standard error of prediction of 0.75 kg/d, the approximate 95% confidence interval 
for the predicted DMI would range from 8.5 to 11.5 kg/d. In this manner, the point estimate of 
RFI could have been any of the values ranging from -2.5 to 0.5 kg/d, and then, a conclusion on 
the efficiency of this animal could not be drawn. These feed efficiency indicators are very 
dependent on the estimation precision of the parameters. Therefore, they should be used with 
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caution in order to avoid misclassification of the animals regarding their potential in converting 
feed in animal product. 
1.8.3. Genetics of Feed Efficiency 
Several studies have investigated the magnitude of the genetic component of feed 
efficiency traits. Reviewed by Archer et al. [230], most of feed efficiency traits have moderate 
heritabilities (h
2
 = 0.20 to 0.40), and several are phenotypically and genetically correlated [214]. 
Selection for higher FCR results in increased growth and mature size [231], due to the high 
genetic correlation between FCR and growth traits [213,232,233]. Heritabilities and genetic 
correlations for RFI were reviewed by Crews [214]. Although RFI has moderate heritability (h
2
 
= 0.39 ± 0.09), the phenotypic variance of this trait is also high and the models used for 
estimation of RFI usually explain 30 to 45% of the total variation [214]. The high genetic 
correlation between RFI and feed intake (0.64 to 0.81), and its independence from body weight 
[231-234], indicate that improvement of RFI would result in a reduction of feed intake [214]. As 
for RADG and RIG, literature suggests similar genetic parameters. Reports indicate heritabilities 
for RADG varying from 0.28 to 0.30 [229,235], and genetic correlations with RFI and RIG of -
0.46 and 0.85, respectively [229]. In addition, it has been reported that RIG has moderate 
heritability (h
2
 = 0.36 ± 0.06), and has high negative genetic correlation (-0.85) with RFI [229]. 
The substantial genetic variation reported in feed efficiency traits has stimulated the 
search for genomic regions associated with feed efficiency indicators and their components. In 
Table 1.3 is summarized the number of chromosomal regions that had been associated with RFI, 
ADG and DMI, across BTAs. Whole-genome association studies have identified genomic 
regions associated with feed efficiency traits and components in beef cattle on most of the BTAs 
[121,122,236-247]. Many of these reports presented several quantitative trait loci (QTL) and 
single nucleotide polymorphism (SNP) for these traits. Although over 200 regions had been 
associated with these traits, the results are not consistent across studies. This may be due to the 
fact that many distinct breeds had been used in each study, as well as the consideration of 
different statistical methodologies for associations, and the type and density of the markers used 
for genotyping. Therefore, there are still great opportunities for the development of strategies 
that accurately assess the genetic basis of feed efficiency in beef cattle. 
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1.10. Figures 
 
 
  
 
 
 
 
 
 
Figure 1.1. Genetic-by-environment interaction 
G1 and G2 represent two different genetic content, whereas E1 and E2 are two distinct 
environments; a Non-significant interaction, the phenotypic value of G1 increases with the same 
magnitude as G2 when both change from E1 to E2; b Significant interaction, not only the 
magnitude is inverse from E1 to E2, but G1 and G2 have different phenotypic ranks when 
changing environments. 
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Haldane [2] Lerner [3] Weber and LeRoy [4] Mather and Jones [5] Pani et al. [6] 
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Figure 1.2. Types of genetic-by-environment interactions 
On the first column, each line (straight and semi-dashed) represent two different genetic content, 
whereas E1 and E2 are two distinct environments; On the third column, G, E and GE are the average 
effects of genes, environment and interaction, respectively. 
Source: Adapted from Mathur and Horst (1994) [248] 
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Figure 1.3. Linkage equilibrium and disequilibrium 
a Linkage equilibrium; SNP alleles (A/C) are QTL (Q/q) are independent. b Linkage disequilibrium; SNP allele A is linked to Q, 
wherea C is linked to q. 
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Figure 1.4. Illustration of censored data 
Experience of eight individual with staggered entry and follow-up until December. a Real time; 
b time, t, from entry into the study. 
Source: Adapted from Cox & Oakes (1984) [147] 
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Figure 1.5. Probability of survival across time t 
a Theoretical situation where probabilities are nonincreasing, with        when    , and 
       when       . b Practical situation where not all individual show occurrence of the 
event and, thus, the estimate survival function does not go to zero at the end of the study. 
Source: Adapted from Kleinbaum (1996) [142] 
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Figure 1.6. Hazard function across time 
For a specified value of t,      will always be nonnegative and without upper bound. Moreover, 
differently from the survival function,      does not have to start at 1 and go down to zero, but 
rather can start anywhere and go up or down in any direction over time. a Constant hazard 
(exponential model); b increasing Weibull model; c decreasing Weibull model; d lognormal 
survival model. 
Source: Adapted from Kleinbaum (1996) [142] 
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Figure 1.7. Hazard function across time for variables   
  and    
The discussion on the hazard ratios follows Equation 1.16, where   
  is tested against   . a 
Proportional assumption is met and     ; b Proportional assumption is met and     ; c 
Proportional assumption is not met and     ; d Proportional assumption is not met and 
     before     and      after   . 
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Figure 1.8. Changes in price and per capita consumption of beef in the U.S. from 1987 to 
2009
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1.11. Tables 
Table 1.1. KEGG databases 
Category Database Content 
Systems 
information 
 
KEGG PATHWAY Pathway maps for metabolism and other cellular processes, as well as human diseases; manually 
created from published materials 
KEGG BRITE Functional hierarchies (ontologies) representing our knowledge on various aspects of biological 
systems; manually created from published materials 
KEGG MODULE Tighter functional units for pathways and complexes; manually defined 
KEGG DISEASE List of disease genes and molecules; manually entered from published materials 
KEGG DRUG Chemical structures and associated information of approved drugs in Japan, USA, and Europe; 
manually entered from published materials 
KEGG EDRUG Chemical components and associated information of crude drugs and other natural products; 
manually entered from published materials 
Genomic 
information 
KEGG ORTHOLOGY KEGG Orthology (KO) groups based on PATHWAY and BRITE; manually defined 
KEGG GENOME Genome maps and organism information; generated from RefSeq and other public resources 
KEGG GENES Gene catalogs of complete genomes with manual annotation; generated from RefSeq and other 
public resources 
KEGG SSDB Sequence similarity scores and best-hit relations; computationally derived from GENES by 
pairwise genome comparisons of all protein-coding genes 
KEGG DGENES Gene catalogs of draft genomes with automatic annotation; generated from web resources 
KEGG EGENES Gene catalogs (consensus contigs) of EST data with automatic annotation; generated from 
dbEST 
KEGG MGENES Gene catalogs of metagenomes with automatic annotation; generated from NCBI resources 
Chemical 
information 
KEGG COMPOUND Chemical compounds; manually entered from published materials 
KEGG GLYCAN Glycans; manually entered from published materials 
KEGG REACTION Chemical reactions; manually defined from ENZYME and PATHWAY 
KEGG RPAIR Chemical structure transformation patterns; manually defined from REACTION 
KEGG RCLASS Reaction class defined by chemical structure transformation patterns of main reactant pairs; 
generated from RPAIR with annotation 
KEGG ENZYME Enzyme nomenclature; generated from ExplorEnz with annotation by KEGG 
Source: KEGG Overview [125]
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Table 1.2. One-way MANOVA table 
Source of Variation Degrees of Freedom Sum of Squares 
Between (Treatment; B)         ∑∑       ̅           ̅    
 
 
   
 
   
 
Within (Error; W)         ∑∑ ∑       ̅           ̅    
 
 
   
 
   
 
   
 
Total (T)      ∑∑ ∑       ̅           ̅    
 
 
   
 
   
 
   
 
N, total number of observations. 
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Table 1.3. Number of genomic regions previously reported
1
 for RFI, ADG, and DMI
2 
across BTAs 
 BTA 
Trait 1 2 3 4 5 6 7 8 9 10 
RFI 5 6 3 2 2 3 6 5 2 4 
ADG - 1 - 1 7 3 1 - 1 - 
DMI 2 1 2 1 4 1 5 5 1 1 
 BTA 
Trait 11 12 13 14 15 16 17 18 19 20 
RFI 6 5 3 4 1 2 6 5 6 5 
ADG 1 - - 5 1 2 3 1 2 2 
DMI 3 2 1 2 5 1 3 5 - 5 
 BTA 
Trait 21 22 23 24 25 26 27 28 29 X 
RFI 4 1 3 3 5 7 - 2 5 - 
ADG - 1 3 - - 4 - 1 - - 
DMI 2 - 3 1 1 1 - - - - 
1
 [121, 122, 236-247] 
2
 DMI and feed intake 
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CHAPTER 2: CELL CYCLE AND AGING, MORPHOGENESIS, AND RESPONSE TO 
STIMULI GENES ARE INDIVIDUALIZED BIOMARKERS OF GLIOBLASTOMA 
PROGRESSION AND SURVIVAL 
2.1. Abstract 
Glioblastoma is a complex multifactorial disorder that has swift and devastating consequences. 
Few genes have been consistently identified as prognostic biomarkers of glioblastoma survival. 
The goal of this study was to identify general and clinical-dependent biomarker genes and 
biological processes of three complementary events: lifetime, overall and progression-free 
glioblastoma survival. A novel analytical strategy was developed to identify general associations 
between the biomarkers and glioblastoma, and associations that depend on cohort groups, such 
as race, gender, and therapy. Gene network inference, cross-validation and functional analyses 
further supported the identified biomarkers. A total of 61, 47 and 60 gene expression profiles 
were significantly associated with lifetime, overall, and progression-free survival, respectively. 
The vast majority of these genes have been previously reported to be associated with 
glioblastoma (35, 24, and 35 genes, respectively) or with other cancers (10, 19, and 15 genes, 
respectively) and the rest (16, 4, and 10 genes, respectively) are novel associations. PIK3R1, 
E2F3, AKR1C3, CSF1, JAG2, PLCG1, RPL37A, SOD2, TOPORS, HRAS, MDM2, CAMK2G, 
FSTL1, IL13RA1, MTAP and TP53 were associated with multiple survival events. Most genes 
(from 90 to 96%) were associated with survival in a general or cohort-independent manner and 
thus the same trend is observed across all clinical levels studied. The most extreme associations 
between profiles and survival were observed for SYNE1, PDCD4, IGHG1, TGFA, PLA2G7, and 
PAICS. Several genes were found to have a cohort-dependent association with survival and these 
associations are the basis for individualized prognostic and gene-based therapies. C2, EGFR, 
PRKCB, IGF2BP3, and GDF10 had gender-dependent associations; SOX10, RPS20, RAB31, and 
VAV3 had race-dependent associations; CHI3L1, PRKCB, POLR2D, and APOOL had therapy-
dependent associations. Biological processes associated glioblastoma survival included 
morphogenesis, cell cycle, aging, response to stimuli, and programmed cell death. Known 
biomarkers of glioblastoma survival were confirmed, and new general and clinical-dependent 
gene profiles were uncovered. The comparison of biomarkers across glioblastoma phases and 
functional analyses offered insights into the role of genes. These findings support the 
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development of more accurate and personalized prognostic tools and gene-based therapies that 
improve the survival and quality of life of individuals afflicted by glioblastoma multiforme. 
2.2. Background 
Glioblastoma multiforme (glioblastoma, World Health Organization grade IV 
astrocytoma) accounts for 15%-20% of all intracranial tumors and 50% of all brain malignancies 
[1]. This aggressive malignant type of primary brain tumor has swift and devastating 
consequences resulting in a median survival after diagnosis of one year [2,3]. Primary 
glioblastoma has a higher incidence in Caucasian men than in other racial and gender groups [4] 
although these differences may be confounded with differences in access to health care or 
diagnostic practices [5]. Also, the variation in response to glioblastoma therapies and similar 
median survival across therapies has prevented the identification of a therapy or therapies 
directly associated with glioblastoma survival [6-9]. 
Numerous studies have proposed biomarker genes that can be used to accurately predict 
the clinical course of glioblastoma [10-16]. Although some genes have been associated with the 
presence of glioblastoma, few have been identified as prognostic biomarkers of glioblastoma 
survival and fewer have been confirmed in independent reports. The limited reproducibility of 
gene-glioblastoma associations may be, in part, due to limited or no consideration of the clinical 
characteristics of the individuals studied, such as gender and therapy subject [17-19]. Another 
reason for the lack of confirmation of biomarker genes of glioblastoma may be the consideration 
of the association between glioblastoma and individual genes independently, although multiple 
genes acting in unison are known to influence this disease. Statistical reasons for this lack of 
confirmation include the analysis of gene expression levels in glioblastoma versus non-
glioblastoma samples instead of analyzing survival, and the failure to correctly model the 
censored nature of the observations that may not exhibit the progression or death event by the 
end of the period considered. For example, The Cancer Genome Atlas Research Network 
(TCGA [20]) identified gene expression aberrations among the 206 glioblastoma cases 
considered but did not consider the age at glioblastoma death or progression, nor the clinical 
characteristics of the individuals studied. 
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The goal of this study was to identify general and clinical-dependent biomarker genes 
and biological processes of three complementary events: lifetime, overall and progression-free 
glioblastoma survival. A novel analytical strategy was developed to identify general and cohort-
dependent associations between the biomarkers and the three glioblastoma events. Cross-
validation and functional analysis further supported the identified biomarkers. The identification 
of gene biomarkers of glioblastoma survival supports the efficient follow-up studies using in 
vitro and in vivo experiments and augments the molecular toolbox that can be used to classify 
patients across and within cohort groups with respect to prognosis and the development of 
targeted treatments. 
2.3. Methods 
2.3.1. Data 
Clinical and gene expression information from 320 individuals diagnosed with 
glioblastoma was obtained from the TCGA repository (September 2009 data freeze [21]. 
Protocols for specimen preparation and gene expression measurements are described in detail in 
the report by The Cancer Genome Atlas Research Network [20]. Briefly, a retrospective search 
in glioblastoma sample banks identified newly diagnosed glioblastoma cases based on surgical 
pathology reports and clinical records. Only samples that had demographic, clinical and 
pathological information, a minimum of 80% tumor nuclei, and a maximum of 50% necrosis, 
qualified for gene expression analyses. 
The data included glioblastoma diagnostic and death records between the years 1989 and 
2009. Clinical factors used to classify individuals into cohort groups were Gender (Male or 
Female), Race (White Caucasian or Other), Therapy received (R = radiation alone; CRnoT = 
chemo, radiation and not targeted therapy plus other therapy if present; CRT = chemo plus 
radiation and targeted therapy only; Other = any other combination of radiation, chemo, targeted, 
immune and hormonal therapy; or None = no therapy), and detection of glioblastoma progression 
or recurrence (ProgRec - Yes/No). 
Three glioblastoma time-to-event variables were considered: lifetime survival 
(encompassing the period from birth to death), overall or post-diagnosis survival (encompassing 
the period from glioblastoma diagnosis to death) and post-diagnosis progression-free survival 
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(encompassing the period from glioblastoma diagnosis to progression of glioblastoma or to 
recurrence of glioblastoma). The distribution of the observations among the levels of the clinical 
or cohort variables is presented in Table 2.1. There were 287 individuals with sufficient survival 
information for analysis. Three individuals were excluded from the progression-free survival 
analysis because of inconsistency in the dates for diagnosis and progression or recurrence. 
Gene expression measurements were obtained using the Affymetrix HT HG-U133A 
platform, comprising 22,277 probe sets. The gene expression measurements were obtained in ten 
experimental batches, in which the percentage of individuals per batch ranged from 4.35% to 
21.25%. For samples with multiple gene expression measurements, the correlation between 
measurements across microarrays was higher than 0.98 and, thus, the average expression was 
used to represent the sample. Raw expression data was log2 transformed and normalized using 
quantile normalization and GC-RMA [22] approaches implemented in Beehive [23]. 
In addition to detecting genes in the microarray platform associated with the glioblastoma 
survival, particular attention was given to genes known to be associated with glioblastoma and 
the association detected in this study. A list, including 123 genes known to be associated with 
glioblastoma were identified from the literature [20,24-27] and 51 genes in the KEGG glioma 
pathway [28], was compiled (Table 2.2). 
2.3.2. Statistical Analysis 
A five-step approach was used to reduce the dimensionality of the data set caused by the 
large number of probes and few records of the individuals in this experiment. First, a Cox 
proportional hazards survival analysis [29] was undertaken for each non-control probe in the 
microarray platform. The model included all the clinical variables with the profile of only one 
probe. This step allowed the selection of probes associated with each of the three survival 
variables at P-value < 0.01. This mild threshold was used to minimize the chances of false 
negative associations and evaluate in subsequent steps probes with strong or moderate 
associations with glioblastoma per se.  
The number of probes identified for lifetime survival, overall, and progression-free 
survival was 963, 839, and 1048 respectively. Second, for each one of the three glioblastoma 
time-to-event variables, the clinical variables and all remaining probes identified in the first step 
were included simultaneously in a Cox survival model. In this manner, the clinical variables 
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were fixed component of the model and the probes associated with the survival variables were 
selected using a combination of forward and stepwise model selection methods. The forward 
selection method was used to add one probe at a time to the model containing the clinical 
variables using a significance level for entry of 30%. In the complementary stepwise selection 
method, the inclusion of probes followed the same rules as in the forward method but a probe 
only remained in the model if its P-value was lower than the significance levels for stay of 10%. 
Since these two selection methods could result in different models, a second stepwise selection 
was performed using the significant probes. This step allowed identifying broad or general 
associations between probe profiles and glioblastoma survival.  
Third, the interaction between the remaining probes and clinical variables was evaluated 
using the stepwise approach. This step permitted the detection of clinical or cohort-dependent 
associations between probe profiles and glioblastoma survival. The fourth stage of our approach 
aimed to select the significant probes from our list of 174 known genes associated with 
glioblastoma (see Additional file 1) fitting the probes and interaction with the clinical variables 
using the stepwise selection method. The consideration of the known probes alone aimed at 
minimizing the potential masking of associations by other probes in the model. Similarly to the 
previous step, in the final step the probes identified from both sets of analyses were combined 
and further streamlined using the stepwise method. This final step allowed the confirmation of 
prior probes associations reported in previous studies as well as the identification of novel 
associations. 
 With respect to P-value threshold selection at each stage, a lenient first-stage threshold 
was used to capture most true positive associations at the expense of some false positives. The 
more stringent threshold used in the subsequent steps and repeated selection process minimized 
the number of false positives remaining in the index. Thus, this approach would have the same 
effect than reducing the threshold in the first step with the added benefit of minimizing the loss 
of true positives. Likewise, extending the first-stage threshold would have resulted in more false 
positives being considered in the second stage and higher risks of overparameterization. 
In addition to a P-value, each probe had a hazard ratio (HR) estimate and associated 95% 
confidence interval limits. Hazard ratios below 1 indicate that the hazard under consideration 
decreases as the level of the gene increases. The proportional hazards assumption was assessed 
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for the final predictive models corresponding to each survival variable based on the residuals. 
There was no evidence of departure from the assumptions for all the models reported. The 
association between survival and clinical and probe expression profiles was visualized by 
plotting the probability of survival predicted by the Cox model against time. For depiction 
purposes, individuals were divided into low and high probe expression groups that corresponded 
to the 25
th
 and 75
th
 percentile respectively given the median expression for all other probes in the 
predictive model. The survival curves were computed based on the information used to identify 
the significant gene associations. Biomarker genes resulting from the multi-stage approach were 
compared to previous reports of genes associated with glioblastoma or other cancers. The protein 
interaction resource at the NCBI Gene data base [30] was used to check that biomarkers not 
previously associated with cancer were also not indirectly associated with cancer through 
intermediate genes. The genes identified by the five-step approach were compared to those 
resulting from a more conventional analysis using a one-step Cox survival analysis with a 
stringent cut-off (P-value < 0.0001). 
2.3.3. Function Analysis 
Identification of Gene Ontology (GO) categories (molecular function and biological 
process) and KEGG pathways represented among the significant genes associated with each 
glioblastoma survival variable was undertaken [31,32]. The representation of genes in the GO 
and KEGG pathway classes was evaluated using Fisher's exact (two-tailed) test and False 
Discovery Rate multiple test adjustment [33]. The relationships between the biomarker genes 
were further studied for the three glioblastoma survival variables and significant functional 
categories. The BisoGenet plug-in [34] from the Cytoscape software [35] was used to build and 
visualize the networks for each one of the three glioblastoma survival variables using the 
respective list of significant genes from the GO categories. All the available data sources in 
BisoGenet (including BIOGRID, DIP, BIND and others) were selected to generate the 
interactions. To facilitate the visualization of the networks, only interactions (edges) connecting 
two significant genes (nodes) directly or through an intermediate gene were depicted. 
2.3.4. Cross-validation 
The associations between gene profiles and survival detected in this study were 
confirmed using a three-fold approach. First, a leave-one-out cross-validation (LOOCV) 
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approach [36-38] is specially recommended in data sets of limited size, providing an almost 
unbiased estimator and identifying the same best classifiers as other X-fold training-test data 
partitions [38,39]. Validation of the predictive survival equation and biomarkers detected in a 
training data set on an independent test data set is desirable, followed by X-fold cross-validation 
on a particular data set. The representation of all cohort factors on both the training and test sets 
is necessary for unbiased evaluation of the biomarkers and to ensure that the detected biomarkers 
were not a spurious artifact of ignored cohort effects and for a fair evaluation of the training 
estimates. Consideration of race is particular critical for the validation of biomarkers detected in 
this study because lack of adjustment for this cohort factor could result in the identification of 
associations that are due to genetic background and not the particular gene expression profile. 
For the X-fold validation approach, the specification of suitable training and testing data 
sets would have required at least 200 patients in each data set (5 individuals × 2 races × 2 
genders × 5 therapies × 2 recurrence groups) and only 287individuals were available. The 
minimum of 5 individuals per group minimizes the risk of confounding between individual 
variation and cohort variation. Use of smaller data sets would have led to low power and biased 
findings because of the ill-representation of individuals across cohort groups. Thus, the X-fold 
cross-validation could not be implemented. Likewise, the test of the predictive hazard equations 
(that include cohort factors) on an independent data set could not be implemented due to the lack 
of dataset with comparable cohort information or adequate structure that would minimize the risk 
of confounding between factors. 
Accurate validation of associations between biomarkers and survival was attained using 
LOOCV discriminant analysis [40] that allows the assessment of the performance of biomarkers 
to classify individuals into high and low hazard (low and high survival, respectively). The same 
cohort information was used to obtain parameter estimates and to train the predictive hazard 
equations. For each survival variable, the median length of the period considered (age at death 
for lifetime survival; months from diagnosis to death for overall survival and; months from 
diagnosis to progression/recurrence for progression free survival) was calculated, and individuals 
were classified into either a high or low hazard group based on the median. The 20% of the 
individuals that had a length of period closest (higher or lower) to the median were not 
considered in order to minimize borderline cases that could affect the assessment of the model 
performance. Only non-censored records were used in the cross-validation analysis to favor 
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unbiased classification. All individuals except for one were used to develop a new hazard index 
using the biomarkers previously detected and the new index was used to classify the remaining 
individuals. This leave-one-individual-out analysis was repeated for all individuals and the 
observed and predicted affiliations of the individuals to the high and low groups for each hazard 
were compared in order to assess the correct assignment rate. 
Second, in addition to LOOCV, confirmation of the genes associated with the three 
glioblastoma hazards was investigated on the independent database REMBRANDT (REpository 
for Molecular BRAin Neoplasia DaTa) [41,42]. This database includes gene expression and 
survival information on 181 individuals diagnosed with glioblastoma. Third, a literature review 
was undertaken to identify independent studies that have reported associations between the genes 
associated with survival detected in this study and glioblastoma or other cancer types. 
2.4. Results 
2.4.1. Confirmed and Novel Biomarkers of Glioblastoma 
The median length of the periods associated with lifetime, overall, and progression-free 
survival across and within clinical or cohort group are presented in Table 2.1. The age of the 
individuals at death or at the end of the considered period ranged from 14 to 87 years with a 
median age of 60 years. The median survival length was 59 years, 13 months and 7 months for 
lifetime, overall, and progression-free survival, respectively. 
A total of 168 significant associations between expression profiles and glioblastoma 
survival (61, 47 and 60 associations for lifetime, overall, and progression-free survival, 
respectively) from 139 genes were identified. Among these, 10 associations are borderline 
significant (0.1 < P-value < 0.05) and are included in the tables in support of other more 
significant associations. 
The vast majority of the genes associated with glioblastoma survival have been 
previously reported to be associated with glioblastoma (35, 24, and 35 genes, respectively) or 
with another cancer (10, 19, and 15 genes, respectively) and the rest (16, 4, and 10 genes, 
respectively) exhibited novel associations with glioblastoma. Table 2.3 presents the distribution 
of genes and probes associated with more than one hazard. Cohort-independent and cohort-
dependent associations, respectively, were uncovered for lifetime (Tables 2.4 and 2.5), overall 
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(Tables 2.6 and 2.7), and progression-free (Tables 2.8 and 2.9) survival. Cohort-independent 
associations represented 90%, 96% and 92% of the significant gene associations for lifetime, 
overall, and progression-free survival, respectively. 
The five-step approach was consistently superior to a one-step Cox analysis with more 
stringent P-value < 0.001 on all three survival indicators. For the three variables studied; 
lifetime, overall, and progression-free survival, the simpler approach identified 60, 71 and 67 
probes of which 19, 17, and 23 respectively overlapped with the corresponding 61, 47, and 60 
probes identified in the five-step analyses of the three survival indicators. Of the 139 probes 
identified by the simpler approach and not identified by our approach, the vast majority (123 
probes across all three variables) has not been associated with glioblastoma and could not be 
confirmed. 
2.4.2. Genes Associated with Lifetime Death Hazard 
Sixty-one gene profiles, representing 55 genes, were associated with lifetime survival 
(Table 2.4). An increase in the level of expression of 31 genes was associated with a decrease in 
HR, with estimates ranging from 0.17 (SYNE1) to 0.87 (CHI3L1). The changes in survival across 
levels of gene expression and clinical variables for the population under consideration were 
visualized using survival plots. The decline on the probability of lifetime survival across age (in 
years) for individuals with high (75
th
 percentile) and low (25
th
 percentile) levels of Syne1 is 
depicted in Figure 2.1. Consistent with the hazard ratio estimate (HR = 0.17, P-value < 0.0001), 
the probability of survival of individuals with high levels of SYNE1 remains higher across age. 
Individuals with high and low levels of SYNE1 have a survival probability of 50% at 69 and 52 
years of age, respectively. The opposite trend was observed in the remaining 24 profiles that 
have hazard ratio estimates ranging from 1.16 (PPBP) to 4.7 (PDCD4). 
Among the genes exhibiting cohort-dependent associations with lifetime survival (Table 
2.5), the drop in the probability of lifetime survival across age (in years) for females and males 
with high (75
th
 percentile) and low (25
th
 percentile) levels of PRKCB 209685_s_at is portrayed in 
Figure 2.2. Consistent with the hazard ratio estimates for females (HR = 1.31) and males (HR = 
5.21), the probability of survival declines faster in males with high levels of PRKCB than 
females with low levels of this gene. 
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2.4.3. Genes Associated with Overall Survival 
A total of 45 genes were associated with overall survival (Tables 2.6 and 2.7). Among 
the cohort-independent associations, an increase in the levels of 20 genes was associated with a 
decrease in overall hazard with HR ranging from 0.12 (TGFA) to 0.83 (AKR1C3). On the other 
hand, an increase in the level of 25 genes was associated with an increase in overall hazard with 
HR ranging from 1.18 (THBS4) to 4.33 (IGHG1). Among the cohort-dependent associations, the 
hazard increased more in males (HR = 1.29) than in females (HR = 1.02) per unit increase in the 
levels of IGF2BP3. 
2.4.4. Genes Associated with Progression-free Survival 
Of the 60 probes (corresponding to 57 genes) associated with progression-free survival, 
55 had general associations and 5 had cohort-dependent associations (Tables 2.8 and 2.9). 
Among the genes that have cohort-independent associations, an increase in the level of 23 genes 
was associated with a decrease in HR, ranging from 0.11 (PLA2G7) to 0.85 (CD24). For the 
remaining 32 genes, an increase in the level of expression was associated with an increase in the 
progression-free HR ranging from 1.19 (CLEC2B) to 5.28 (PAICS). The decline in the 
progression-free survival probability across time (in months) for individuals with high (75
th
 
percentile) and low (25
th
 percentile) levels of neuroblastoma RAS viral (v-RAS) oncogene 
homolog (NRAS) is depicted in Figure 2.3. Consistent with the hazard ratio estimate (HR = 3.93, 
P-value < 0.0001), the progression-free survival probability falls faster in individuals with high 
expression levels of NRAS. With regard to the cohort-dependent association with progression-
free survival, an increase in the expression of GDF10 was associated with a higher decrease of 
the hazard ratio in males (HR = 0.37) than in females (HR = 0.80). 
2.4.5. Genes That Have Multiple Probes and Hazard Ratios 
When multiple probes of the same gene had opposite associations with the glioblastoma 
hazard (e.g. HR > 1 for probe 1 and HR < 1 for probe 2), the disagreements were resolved by 
assessing the dependability of each probe. Information on dissenting probes is briefly 
summarized here. Probe 214322_at, of CAM2KG, was obtained from an ovary EST and thus is 
less reliable in respect to brain cancer than probe 212757_s_at. Probe 208728_s_at, of CDC42, is 
expected to be more reliable than 208727_s_at because the former was obtained from an mRNA 
sequence that has double the length than the later. Probe 200729_s_at, of ACTR2, corresponds to 
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an mRNA and is more reliable than 200727_s_at, which corresponds to an EST from mixed 
tissues. Probe 210904_s_at, of IL13RA1, corresponds to a cluster of mRNA assigned to this gene 
in the NCBI-Gene database; meanwhile, probe 211612_s_at pertains to a single mRNA not 
assigned to the gene and is considered less reliable. Other probes include 201148_s_at of TIMP3, 
which corresponds to a pancreatic EST, 200727_s_at of ACTR2, which corresponds to a mixed 
tissue EST, and 209956_s_at of CAMK2B, which corresponds to a proline rich sequence. 
2.4.6. Functional and Gene Network Analyses 
The GO categories enriched (FDR adjusted P-value < 0.1, ≥ 3 genes/category) among the 
genes associated with each of the three glioblastoma survival variables are summarized in 
Tables 2.10, 2.11, and 2.12. The functional analysis revealed nine, two and ten biological 
processes enriched among the genes associated with lifetime, overall, and progression-free 
survival respectively, and three molecular functions enriched among the genes associated with 
progression-free survival. The biological processes of cell cycle (GO:0007049) and death 
(GO:0016265) were over-represented among the genes associated with the lifetime and 
progression-free survivals. The gene networks for the significant genes from the functional 
analyses associated with lifetime, overall, and progression-free survival are depicted in Figures 
2.4, 2.5 and 2.6, respectively. 
2.4.7. Cross-validation 
The performance of the gene sets as reliable prognosticators of the three glioblastoma 
survival variables was evaluated. The generalization capability of the biomarker index was tested 
in individuals other than those used to develop a hazard index using a leave-one-individual-out 
discriminant analysis. Individuals were predicted to pertain to the high or low glioblastoma 
hazard groups for each event using the predictive biomarker index, and the prediction was 
compared to the observed classification based on the length of the period corresponding to each 
event. For both, lifetime and overall hazard, the number of observed high and low individuals 
was 100, and the number of predicted high and low individuals was 97 and 103, respectively. For 
the progression-free hazard, the number of observed high and low individuals was 87 and 88, 
respectively, and the number of predicted high and low individuals was 83 and 92, respectively. 
Additional evaluation of the results was pursued by comparing the genes associated with 
the three glioblastoma hazards identified in this study and the target genes of microRNAs 
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associated with the glioblastoma hazard reported by Delfino et al. [43]. One third of the 
sequences identified in this study are putative targets of microRNAs associated with 
glioblastoma. A hypergeometric test confirmed that the overlap between the genes uncovered in 
this study and the target genes was significant (P-value ≤ 0.005). 
2.5. Discussion 
The data set analyzed offered a suitable representation of the general population of 
glioblastoma cases. The median overall survival was 13 months, and the probabilities of survival 
at 12, 24, 36, 48 and 60 months post-diagnosis were 0.59, 0.25, 0.15, 0.11 and 0.07 respectively, 
in this study. The median survival is similar to that reported by Krex et al. [14], and the 60 month 
survival probability is comparable to the 5-year survival rate of 0.13 estimated for grade IV brain 
cancer reported by the National Cancer Institute Surveillance Epidemiology and End Results 
[44]. The similarity between the survival rate in this study and that reported for primary 
glioblastoma suggests an insignificant fraction of secondary glioblastoma samples among the 
samples analyzed [20]. 
Comparing findings against a literature review confirmed that the Cox survival analysis 
of multiple gene expression profiles and clinical variables simultaneously was an effective tool 
to detect an integrated set of gene expression profiles exhibiting general and cohort-dependent 
associations with the three glioblastoma survival variables. The majority of the genes associated 
with lifetime, overall, and progression-free survival, in this study, have been previously reported 
to be associated with glioblastoma (35, 24, and 35 genes, respectively) or with another cancer 
(10, 19, and 15, respectively). In addition, the multi-factor analysis and data used in this study 
allowed the uncovering several novel associations between gene profiles and glioblastoma 
survival. Specifically, 16, 4, and 10 previously unreported genes were associated with lifetime, 
overall, and progression-free survival, respectively in the present work. The discussion of the 
findings from our study is divided into genes associated with multiple survival variables, genes 
associated with glioblastoma in a cohort-independent or cohort-dependent manner, and further 
investigation of complex associations. 
PIK3R1 and E2F3 were associated with all three glioblastoma survival variables (Tables 
2.3, 2.4, 2.6, and 2.8). The higher glioblastoma hazards associated with higher levels of PIK3R1 
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observed in this study are supported by previous work showing that over-expression of this gene 
plays a role in the activation of the PI3K/Akt pathway resulting in cell proliferation and tumor 
invasion [45]. Likewise, a link between E2F3 and glioblastoma has been reported [28,46]. 
Among the 15 genes associated with two glioblastoma events (Table 2.3), AKR1C3, CSF1, 
JAG2, PLCG1, RPL37A, SOD2, and TOPORS were associated with lifetime and overall survival 
(Tables 2.4 and 2.6). JAG2 has been associated with adenomas [47], pancreatic [48] and breast 
cancer [49], RPL37A with nasopharyngeal carcinoma cell lines [50], and the rest with 
glioblastoma [26,51-54]. The consistent findings across both glioblastoma survival events 
suggest that these genes may have specific roles in death. Likewise, the association between 
HRAS and overall and progression-free survival (Tables 2.3, 2.6, and 2.8), is consistent with 
previous glioblastoma studies [55] and suggests that this gene may have a role in aggressive 
glioblastoma growth. FSTL1, MTAP, TP53, CAMK2G 214322_at, and IL13RA1 probe 
210904_s_at, were associated with lifetime and progression-free survival (Tables 2.3, 2.4, and 
2.8) and these associations are supported by previous studies [20,24,25,28,56-58]. 
Most genes (lifetime survival, 55 out of 61 genes; overall survival, 45 out of 47 genes; 
and progression-free survival, 55 out of 60 genes) were associated with survival in a general or 
cohort-independent manner. The most extreme cohort-independent changes in lifetime survival 
were observed in SYNE1 (HR = 0.17) and PDCD4 (HR = 4.68), and the former profile has been 
found in lung [59], ovarian [60], colon, and breast cancers [61]; while, the second has been 
associated with glioma [62]. The most extreme cohort-independent changes in overall survival 
were observed in IGHG1 (HR = 4.33) and TGFA (HR = 0.12), and the former trend has been 
found in cancer cell lines [63]; meanwhile the latter is present in the KEGG glioma pathway 
[28]. Lastly, the genes that presented extreme hazard ratio values and general association with 
progression-free survival are PLA2G7 (HR = 0.11) and PAICS (HR = 5.28). The PLA2G7 and 
PAICS trends identified in this study are consistent with those reported for breast cancer in mice 
[64] and in non-glioma types of cancer [65,66], respectively. 
Several genes (lifetime survival, 6 out of 61 genes; overall survival, 2 out of 47 genes; 
and progression-free survival, 5 out of 60 genes) were associated with glioblastoma survival in a 
cohort-dependent manner. These findings indicate that effective use of these genes in prognostic 
indices or in therapy development must consider the personal characteristics of the individual. 
Higher levels of C2 and PRKCB (probe 209685_s_at) were associated with a higher lifetime 
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death hazard in males (HR = 1.93 and 5.22, respectively) than in females (HR = 1.30 and 1.31, 
respectively) and the profile of the latter gene has been observed in colon cancer cell lines [67]. 
The lifetime hazard estimate decreased with increased levels of SOX10 in Caucasian individuals 
(HR = 0.55) compared to non-Caucasian individuals, and this pattern is concordant with broad 
distribution of SOX10 in high grade gliomas [68]. Increases in the level of CHI3L1 were 
associated with significant increases in lifetime hazard estimates across all therapies with the 
highest hazard ratio observed in individuals receiving no therapy (None, HR = 2.42). This trend 
is consistent with reports that CHI3L1/YKL-40 was highly overexpressed in glioblastoma relative 
to nonneoplastic brain [69] and that YKL-40 is associated with poorer response to radiation and 
shorter lifetime survival in glioblastoma [70]. Males (HR = 0.36) and individuals receiving no 
therapy (HR = 0.38) have the lowest hazard ratio per increase in PRKCB (probe 207957_s_at). 
These trends are consistent with those reported for other cancer types [67] and with observations 
of protein kinase C activation in gamma-irradiated proliferating and confluent human lung 
fibroblast cells [71]. 
The cohort-dependent associations between overall survival and both POLR2D and 
IGF2BP3 have been observed in colorectal cancer [72] and glioblastoma [73], respectively. 
Three genes (RAB31, RPS20 and APOOL) exhibited a cohort-dependent association with overall 
survival that is consistent with previously reported trends [74-76]. Lastly, the gender-dependent 
association between GDF10 and progression-free survival is in agreement with reports of copy 
number loss of GDF10 in mesothelioma [77]. 
Further analyses of the association between individual genes (with or without clinical 
variables) and hazards were undertaken when the trend estimated from the multi-gene index was 
opposite to that previously reported. Nine genes and survival events were re-analyzed 
individually and compared to previous reports including: E2F3 and all three survival variables 
[28,46], EGFR and lifetime survival [78], CFS1 and lifetime survival, MDM2 with overall 
hazard [79], FSTL1 and lifetime and progression-free survival [25], MTAP and progression-free 
hazard [57], PDCD4 and lifetime survival [62], TGFA and overall survival [80], and race-
dependent VAV3 and overall survival [81]. In the first six cases, the consideration of the gene 
alone as predictor of glioblastoma survival as standard in previous reports resulted in non-
significant associations, in this study. These results indicate that the accurate identification of 
biomarkers and precise characterization of the trend requires the study of the genes in concert 
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with other genes in a systems biology framework, such as the approach implemented, in this 
study. Re-analysis of PDCD4 and VAV3 confirmed the significant trend detected in the multi-
gene analysis, suggesting that further studies are needed to precisely characterize the trend. 
The LOOCV confirmed the adequacy of the set of genes and clinical variables identified 
to predict the glioblastoma hazards. The minor differences between the observed and predicted 
numbers in each group may be due to the discretization of the survival length into high and low 
groups required by the discriminant analysis; whereas, the Cox survival analysis models 
continuous time to the glioblastoma event. The significant number of genes prognostic of 
glioblastoma survival identified in this study that are also targets of microRNAs associated with 
glioblastoma [43] further confirms our results. 
In addition to literature review and LOOCV, the gene-survival associations detected in 
this study were confirmed using the information from the REMBRANDT database. The 
associations between survival and the 10 gene probes with the most extreme hazard ratio 
estimate for each of the three survival variables studied that did not interact with cohort variables 
(Tables 2.4, 2.6, and 2.8) were investigated in REMBRANDT. The query was performed using 
the Kaplan-Meier survival plot for Gene Expression Data. Of these, eight genes had the same 
significant trend observed in our study (SYNE1, GIGYF2/TNRC15, SCN5A, HOXA10, PDCD4, 
TGFA, PLA2G7, and AGPAT1), two did not have information on the REMBRANDT database 
(IGHG1 and HNRNPD), FSTL1 had an opposite trend than the one observed in our study and in 
previous independent studies (Table 2.4) and most of the remaining genes, although non-
significant, had the same trend observed in our analysis. The latter results are consistent with the 
simpler analytical approach based on Kaplan-Meier curves available in REMBRANDT, when 
compared to the more flexible Cox survival analysis used in our study. The Kaplan-Meier 
approach relies on non-parametric rank-based test to compare the survival between individuals 
with high and low gene expression. These groups are obtained by setting up an arbitrary 
expression threshold. Non-parametric rank-based approaches tend to have lower power to detect 
significant variation than semi- and parametric approaches such as the Cox survival analysis. In 
addition, the Kaplan-Meier analysis only allows the consideration of one explanatory variable at 
a time, and this variable has to be discrete (thus, the reason for comparing high and low 
expression groups in REMBRANDT). This approach does not allow considering multiple 
continuous covariates (i.e. gene expression) and factors (e.g. race, gender, therapy and 
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progression) or interactions simultaneously. The Cox-survival analysis implemented in our study 
allows the simultaneous consideration of multiple factors (such as possible population 
stratification due to race), covariates (e.g. other gene expression profiles) and interactions, and it 
does not require the discretization of the gene expression values that could result in potential loss 
of information. Thus, the Cox approach used in our study is able to capture the association 
between continuous gene expression values and survival conditional on all other model terms 
and is able to detect associations that are likely not to reach statistical significance using the 
Kaplan-Meier comparison of survival between high and low gene expression groups. 
Among the GO categories, 19 biological processes and three molecular functions were 
over-represented (FDR adjusted P-value < 0.1, ≥ 3 genes per category) in the genes associated 
with the three glioblastoma events studied (Tables 2.10, 2.11, and 2.12). Two biological 
processes, cell cycle (GO:0007049) and death (GO:0016265), were over-represented in the 
lifetime and progression-free survival (Tables 2.10 and 2.12), and several biological processes 
have been previously associated with glioblastoma [17,62,68,70,79,82-86]. These processes 
included: aging, morphogenesis, cell cycle and proliferation, and death for lifetime survival; 
morphogenesis for overall survival; and cell cycle, death and recognition, death, response to 
biotic and abiotic stimuli, programmed cell death, and apoptosis for progression-free survival. 
The study of complementary glioblastoma survival variables allowed to confirm that the 
gene profiles associated with lifetime survival resulting in the enriched functional category of 
aging are clearly associated with cancer initiation and progression and are not a simply reflection 
of the natural aging process. Two results confirm that the biomarkers are not mere confounding 
with aging. First, the genes in the GO terms "aging (GO:0007568)" and "cell aging 
(GO:0007569)", PDCD4, CDKN2A, and TP53, have all been associated with GBM in previous 
independent studies (Table 2.4). In addition, TP53 was associated with progression-free survival 
(Table 2.8). Second, other functional terms enriched among the genes associated with lifetime 
glioblastoma survival were also identified on the other glioblastoma survival variables studied. 
The biological processes of cell death and cell cycle were enriched both for lifetime and 
progression-free survival. 
The biological processes, molecular functions and gene networks particular to a 
glioblastoma survival event offered insights into the processes particular to the initiation and 
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progression of this cancer. For instance, eight biological processes associated with lifetime 
survival were level 3, and one was level 4, indicating that the differentially expressed genes 
associated with lifetime survival participate on broad or general biological mechanisms. The 
interconnection between the genes pertaining to aging further confirms the significance of this 
gene network on lifetime survival (Figure 2.4). Although only two biological processes were 
associated with overall survival, these processes correspond to levels 4 and 6. This result 
indicates that the genes associated with overall survival correspond to more specific 
mechanisms. Moreover, both biological processes are related to generation and organization of 
anatomical structures, such as organs, and this finding may be associated to the dispersion and 
development of malignant cells after diagnosis and resection. The close relationship between 
biomarker genes in this network supports this finding (Figure 2.5). Albeit the study of 
progression-free survival encompassed a shorter period than lifetime and overall survival, the 
functional analysis showed several biological processes and molecular functions over-
represented among the genes associated with this survival. Four of the biological processes are 
from level 6 to 8, indicating that specific gene networks and roles are associated with 
progression-free survival. The biological processes associated with progression-free survival 
include regulation of progression through cell cycle, programmed cell death, and apoptosis. 
Extensive relationships between the biomarker genes in the cell cycle were identified further, 
supporting the major role of this network on glioblastoma progression (Figure 2.6). In addition, 
three molecular functions were enriched among the genes associated with progression-free 
survival. Therefore, many biological and molecular events occur in the period between the 
diagnosis of malignancy and progression or recurrence, probably due to response to numerous 
treatments, surgery, and cancer progression. Two genes were highly represented across the 
categories (Tables 2.10, 2.11, and 2.12). TP53 has an important role as a tumor repressor [83], 
and APP is highly expressed in individuals with short-term glioblastoma survival [24]. 
2.6. Conclusions 
An innovative approach to identify simultaneously multiple biomarkers of lifetime, 
overall and progression-free glioblastoma survival in a systems biology framework was 
presented. Furthermore, the inclusion of clinical information allowed the uncovering of general 
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and individualized associations between gene expression profiles and three complementary 
survival metrics. This study demonstrated the pre-eminence of developing multi-gene prognostic 
indices of glioblastoma survival through the integration of variable selection and survival models 
relative to the simple and yet simplistic single-gene analysis. Known biomarker gene profiles 
were confirmed, and new general and clinical-dependent gene profiles were uncovered. The 
present study looked at glioblastoma in general and complements work on the identification of 
genes associated with specific glioblastoma types [42,87,88]. Empirically confirmed findings 
will be the basis for improved prognostic tools and individualized treatments that improve the 
survival and quality of life of individuals suffering glioblastoma multiforme. 
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2.8. Figures 
 
Figure 2.1. Probability of lifetime glioblastoma survival across age for spectrin repeat 
containing, nuclear envelope 1 (SYNE1) 
Probability of glioblastoma survival across age for individuals with Low (25
th
 percentile) and 
High (75
th
 percentile) expression level of spectrin repeat containing, nuclear envelope 1 
(SYNE1). With a lower hazard estimate (HR = 0.17), the probability of survival of individuals 
with high levels of Syne1 remains higher across age 
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Figure 2.2. Probability of lifetime glioblastoma survival across age in females and males for 
protein kinase, C beta (PRKCB) 
Probability of glioblastoma survival across age for Females and Males with Low (25
th
 percentile) 
and High (75
th
 percentile) expression level of protein kinase, C beta (PRKCB). Consistent with 
the hazard ratio estimates for females (HR = 1.31) and males (HR = 5.21), the probability of 
survival in individuals with high levels of PRKCB declines before than in individuals with lower 
levels of PRKCB. Due to the significant interaction between the expression of PRKCB and 
gender, the probability of survival for females with high level of the gene declines faster than the 
probability of survival for males with low level of the gene. 
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Figure 2.3. Progression-free probability across post-diagnosis months for neuroblastoma 
RAS viral (v-RAS) oncogene homolog (NRAS) 
Progression-free probability across post-diagnosis months for individuals with Low (25
th
 
percentile) and High (75
th
 percentile) expression level of neuroblastoma RAS viral (v-RAS) 
oncogene homolog (NRAS). With a high hazard estimate (HR = 3.93), the progression-free 
probability falls faster in individuals with high expression levels of NRAS. 
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Figure 2.4. Gene network from the functional analysis of lifetime glioblastoma survival 
Interaction between the significant genes from the functional analysis of lifetime glioblastoma 
death. The gold edges represent protein interactions whereas the red edges represent interaction 
of the HNF4A protein with the DNA of the genes PDCD4, SOX10 and TIMM23. Of the 24 genes 
from Table 2.10, 18 (pink nodes) interact among each other in a direct way or through an 
intermediate gene (blue nodes). 
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Figure 2.5. Gene network from the functional analysis of overall glioblastoma survival 
Relationship between the significant genes from the functional analysis of overall survival. Of 
the nine genes from Table 2.11, four (pink nodes) interact among each other in a direct way or 
through an intermediate gene (blue nodes). 
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Figure 2.6. Gene network from the functional analysis of progression-free survival 
Relationship between the significant genes from the functional analysis of progression-free 
survival. Of the 19 genes from Table 2.12, 17 (pink nodes) interact among each other in a direct 
way or through an intermediate gene (blue nodes). 
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2.9. Tables 
Table 2.1. Median length of the period and relative frequency (in parenthesis) of the 
observations across clinical factors 
  
Overall survival 
(n = 287)
1
 
Post-diagnosis survival 
(n = 287)
2
 
Post-diagnosis 
progression 
(n = 284)
 2
 
Censored (0.12) (0.12) (0.23) 
Overall 59.2 13.1 6.5 
Gender       
 Male 58.8 (0.63) 13.6 (0.63) 6.6 (0.63) 
 Female 61.1 (0.37) 12.1 (0.37) 6.4 (0.37) 
Race       
 White 59.7 (0.77) 13.1 (0.77) 6.8 (0.77) 
 Other 57.7 (0.23) 12.6 (0.23) 5.3 (0.23) 
Therapy       
 CRnoT 57.7 (0.40) 15.7 (0.40) 8.0 (0.34) 
 R  60.7 (0.35) 12.3 (0.35) 5.3 (0.41) 
 CRT 53.4 (0.10) 15.4 (0.10) 6.8 (0.10) 
 Other 64.8 (0.08) 14.2 (0.08) 7.9 (0.08) 
 None 70.5 (0.07) 2.9 (0.07) 1.4 (0.07) 
ProgRec       
 Yes 57.6 (0.77) 15.1 (0.77) - (0.77) 
 No 64.8 (0.23) 5.9 (0.23) - (0.23) 
1
 expressed in years; 
2
 expressed in months. 
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Table 2.2. List of genes associated in glioblastoma from the literature 
References 
Number of 
Genes Genes 
Bredel et al. [26] 42
1,2,3,4
 ABCC4, ACTN4, AKR1C3, ANXA7, BAX, CASP3, CDC42, CDK6, CSF1, CUL1, CYCS, EGFR, 
EIF6, EP300, EWSR1, FGFR2, GBAS, IGF1R, MDM2, MFN2, MGAT3, MTAP, MXI1, MYBL2, 
MYC, PAK4, PCNA, PDCD4, PLCG1, POLD2, PPP1R15A, PTEN, PVR, RAF1, RALA, RANGAP1, 
SIRPA, SMARCB1, TIMP3, TOPORS, WDR11, and YME1L1 
TCGA [20] 21
1,3,5,6
 AKT3, CDKN2A, CDKN2B, EGFR, ERBB2, FGFR2, IRS2, MET, MLH1, MSH2, MSH6, NF1, 
PARK2, PDGFRA, PIK3CA, PIK3R1, PMS2, PTEN, PTPRD, RB1, and TP53 
KEGG Glioma 
Pathway [28] 
51
6
 AKT1, AKT2, AKT3, BRAF, CALM1, CALM2, CALM3, CALML3, CALML5, CAMK2A, CAMK2B, 
CAMK2G, CCND1, CDK4, CDKN1A, CDKN2A, E2F1, E2F2, E2F3, EGF, GRB2, HRAS, IGF1, 
KRAS, MAP2K1, MAP2K2, MAPK3, MTOR, NRAS, PDGFA, PDGFB, PDGRFA, PDGRFB, 
PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PRKCA, PRKCB, 
PRKCG, RB1, SHC1, SHC2, SHC3, SOS1, SOS2, and TGFA 
Marko et al. [24] 38
2,3,5
 ACTR2, ADAM2, ANK1, APP, ARAF, BMX, CAPN1, CD34, CPVL, EGFR, FSCN1, GBAS, GRM8, 
HSPA1B, IDH1, IGHG1, IL13RA1, IL17, IL22, ITGA6, JAG2, KCNQ2, KIFC3, LRP10, MMP14, 
NDRG1, NOS2, PADI3, PCDHA6, PFDN1, RPL10, RPL41, SERPING1, SHOX2, SOX4, TP53, 
UCP3, and WNT1 
Reddy et al. [25] 7
5
 AEBP1, CHI3L1, FSTL1, GADD45A, RHOC, SOD2, and TP53 
Zhang et al. [27] 23
4
 CCNA2, CCNB1, CCNB2, CDC45L, CDC6, CDC7, CDK2, CKS1B, DNMT1, GGH, IFNGR1, 
MCM6, PCNA, PTTG1, RAC2, RPA2, RPA3, RRM1, RRM2, TUBG1, TYMS, UNG, and WEE1 
1 
Genes FGFR2 and PTEN are represented by Bredel et al. and TCGA; 
2 
Gene GBAS is represented by Bredel et al. and Marko et al.; 
3 
Gene EGFR is represented by Bredel et al., TCGA, and Marko et al.; 
4 
Gene PCNA is represented by Bredel et al. and Zhang et al.; 
5 
Gene Tp53 is represented by TCGA, Marko et al., and Reddy et al.; 
6 
Genes AKT3 and CDKN2A are represented by the KEGG Glioma Pathway and TCGA. 
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Table 2.3. Genes and probes represented more than one time within or across the 
glioblastoma survival events 
Gene Overall survival Post-diagnosis survival Post-diagnosis progression 
ACTR2 - 200727_s_at - 
  200729_s_at  
AKR1C3 209160_at 209160_at - 
APP - - 211277_x_at 
   214953_s_at 
CAMK2B - - 211483_x_at 
   209956_s_at 
CAMK2G 212757_s_at - 214322_at 
 214322_at   
CDC42 208727_s_at - - 
 208728_s_at   
 214230_at   
CHI3L1 216546_s_at - - 
 209396_s_at   
CSF1 207082_at 209716_at - 
E2F3 203692_s_at 203693_s_at 203693_s_at 
EGFR 211551_at - - 
 211607_x_at   
FSTL1 208782_at - 208782_at 
HRAS - 212983_at 212983_at 
IGHG1 - 211908_x_at - 
  211693_at  
IL13RA1 210904_s_at - 211612_s_at 
JAG2 32137_at 209784_s_at - 
MDM2 - 217373_x_at 217373_x_at 
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Table 2.4. Genes that have a general association (P-value < 0.05) with the lifetime 
glioblastoma survival 
Gene Symbol Probe Identifier P-value Hazard Ratio
1
 
Relevant literature 
references 
SYNE1 209447_at <.0001 0.17 (0.10-0.32) [60]
O
 
E2F3 203692_s_at <.0001 0.26 (0.15-0.44) [28]
G
 
FSTL1 208782_at <.0001 0.31 (0.22-0.42) [25]
G
 
EP300 213579_s_at <.0001 0.34 (0.29-0.57) [26]
G
 
GIGYF2 212261_at <.0001 0.39 (0.26-0.58) n/a 
TOPORS 204071_s_at <.0001 0.41 (0.29-0.59) [26]
G
 
CHST4 220446_s_at 0.0989
2
 0.44 (0.17-1.16) [89]
O
 
SAR1A 201543_s_at <.0001 0.44 (0.29-0.66) n/a 
IL13RA1 210904_s_at <.0001 0.47 (0.36-0.60) [24]
G
 
SOD2 221477_s_at <.0001 0.47 (0.37-0.59) [25]
G
 
RAB15 221810_at <.0001 0.48 (0.34-0.69) n/a 
TIMM23 218118_s_at 0.0239 0.50 (0.27-0.91) n/a 
KCNJ4 208359_s_at <.0001 0.50 (0.38-0.66) n/a 
RPL37A 213459_at 0.0023 0.51 (0.33-0.79) [90]
G
 
CAMK2G 214322_at 0.0135 0.53 (0.32-0.88) [56]
G
 
PLCG1 216551_x_at 0.0068 0.55 (0.35-0.85) [26]
G
 
SLC43A3 213113_s_at 0.0004 0.56 (0.40-0.77) n/a 
CDC42 208727_s_at <.0001 0.57 (0.45-0.73) [26]
G
 
CSF1 207082_at 0.0092 0.58 (0.38-0.88) [26]
G
 
CCNB2 202705_at 0.0118 0.60 (0.40-0.89) [91]
G
 
TLK2 212997_s_at 0.0004 0.64 (0.49-0.82) n/a 
MTAP 204956_at 0.0091 0.67 (0.49-0.91) [26]
G
 
EGFR 211551_at 0.0743
2
 0.68 (0.45-1.04) [24]
G
 
AKT2 211453_s_at 0.0292 0.68 (0.48-0.96) [86]
G
 
AKR1C3 209160_at <.0001 0.70 (0.62-0.81) [26]
G
 
TP53 211300_s_at 0.0215 0.76 (0.60-0.96) [25]
G
 
IGF1 209541_at 0.0183 0.76 (0.61-0.95) [26]
G
 
RPL10 221989_at 0.0392 0.80 (0.64-0.99) [24]
G
 
ARHGEF4 205109_s_at 0.0647
2
 0.80 (0.64-1.01) n/a 
CDC42 214230_at 0.0554
2
 0.82 (0.67-1.00) [26]
G
 
CHI3L1 216546_s_at 0.061 0.87 (0.75-1.00) [70]
G
 
PPBP 214146_s_at 0.012 1.16 (1.03-1.30) n/a 
CDKN2A 209644_x_at 0.0003 1.18 (1.08-1.29) [92]
G
 
WDR67 214061_at 0.0237 1.30 (1.03-1.63) [93]
O
 
TSPYL5 213122_at 0.0003 1.34 (1.14-1.56) n/a 
USF2 215737_x_at <.0001 1.42 (1.19-1.69) [94]
O
 
CAMK2G 212757_s_at 0.0078 1.54 (1.12-2.13) [56]
G
 
PIK3R1 212240_s_at 0.0022 1.67 (1.20-2.32) [20]
G
 
AKT1 207163_s_at 0.0005 1.70 (1.26-2.30) [84]
O
 
RAC2 213603_s_at 0.0001 1.74 (1.31-2.31) [95]
G
 
SIX6 207250_at <.0001 1.82 (1.45-2.28) [96]
O
 
SPG21 217827_s_at 0.0387 1.91 (1.03-3.52) n/a 
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Table 2.4 (cont.) 
Gene Symbol Probe Identifier P-value Hazard Ratio
1
 
Relevant literature 
references 
WDYHV1 219060_at 0.0015 1.95 (1.29-2.94) n/a 
UROS 203031_s_at 0.0067 2.37 (1.27-4.42) n/a 
LIN7C 219399_at 0.0002 2.40 (1.51-3.80) [97]
O
 
ROS1 207569_at <.0001 2.58 (1.73-3.85) [98]
O
 
CDK2 204252_at <.0001 2.74 (1.78-4.21) [91]
G
 
JAG2 32137_at <.0001 2.78 (1.86-4.14) [24]
G
 
KIAA0090 212395_s_at <.0001 2.89 (1.87-4.47) n/a 
CCNB1 214710_s_at <.0001 3.16 (2.00-4.98) [91]
G
 
SCN5A 207413_s_at <.0001 3.21 (1.79-5.74) n/a 
COL14A1 212865_s_at <.0001 3.30 (1.93-5.63) [99]
O
 
HOXA10 213147_at <.0001 3.30 (1.93-5.65) [100]
O
 
CDC42 208728_s_at <.0001 3.94 (2.12-7.32) [26]
G
 
PDCD4 202731_at <.0001 4.68 (3.01-7.28) [26]
G
 
n/a, No association with any type of cancer found in literature; 
1 
Hazard ratio estimate (95% confidence interval); 
2 
Borderline significant (P-value < 0.1) included for completeness; 
G 
Gene confirmed in an independent glioblastoma multiforme study; the number between square 
brackets denotes the corresponding literature reference; 
O 
Gene confirmed in an independent study on any other type of cancer; the number between 
square brackets denotes the corresponding literature reference. 
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Table 2.5. Genes that have a cohort-dependent association (P-value < 0.05) with the lifetime 
glioblastoma survival 
Gene 
Symbol 
Probe 
Identifier 
Clinical 
Cohort P-value 
Level of 
Clinical 
Cohort Hazard Ratio
1 
Relevant 
literature 
references 
PRKCB2 207957_s_at Gender <.0001 Male 0.36 (0.24-0.55) [28]
G
 
    Female 1.27 (0.84-1.93)  
  Therapy 0.0006 None 0.38 (0.25-0.60)  
    CRnoT 0.51 (0.36-0.73)  
    R 0.64 (0.46-0.88)  
    CRT 0.71 (0.44-1.13)  
    Other 0.75 (0.43-1.32)  
SOX10 209843_s_at Race 0.0018 White 0.55 (0.44-0.68) [10]
G
 
    Other 1.08 (0.72-1.62)  
EGFR 211607_x_at Gender <.0001 Male 0.60 (0.50-0.72) [24]
G
 
    Female 0.88 (0.74-1.04)  
CHI3L1 209396_s_at Therapy 0.0006 CRT 1.27 (0.96-1.70) [70]
G
 
    R 1.28 (1.07-1.52)  
    Other 1.31 (1.04-1.66)  
    CRnoT 1.53 (1.31-1.79)  
    None 2.42 (1.56-3.75)  
C2 203052_at Gender 0.0033 Female 1.30 (1.03-1.65) n/a 
    Male 1.93 (1.56-2.39)  
PRKCB 209685_s_at Gender <.0001 Female 1.31 (0.79-2.14) [28]
G
 
    Male 5.21 (3.16-8.61)  
n/a, No association with any type of cancer found in literature; 
1 
Hazard ratio estimate (95% confidence interval); 
2 
Interaction with a single clinical cohort factor; 
G 
Gene confirmed in an independent glioblastoma multiforme study; the number between square 
brackets denotes the corresponding literature reference; 
O 
Gene confirmed in an independent study on any other type of cancer; the number between 
square brackets denotes the corresponding literature reference. 
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Table 2.6. Genes that have a general association (P-value < 0.05) with the overall 
glioblastoma survival 
Gene Symbol Probe Identifier P-value Hazard Ratio
1
 
Relevant literature 
references 
TGFA 205015_s_at 0.0002 0.12 (0.04-0.37) [28]
G
 
SIRPA 202895_s_at <.0001 0.24 (0.14-0.41) [26]
G
 
CTBP2 210835_s_at <.0001 0.28 (0.16-0.48) [101]
O
 
EEF1E1 213907_at <.0001 0.37 (0.23-0.61) [102]
O
 
MAPK3 212046_x_at 0.0041 0.43 (0.24-0.76) [103]
O
 
ACTR2 200727_s_at <.0001 0.43 (0.29-0.63) [24]
G
 
IGH@ 211637_x_at 0.0167 0.44 (0.23-0.86) n/a 
PLCG1 216551_x_at <.0001 0.46 (0.31-0.68) [26]
G
 
MGAT3 209764_at <.0001 0.51 (0.37-0.71) [26]
G
 
LRP10 201412_at 0.0041 0.60 (0.42-0.85) [24]
G
 
IDH1 201193_at 0.0051 0.60 (0.42-0.86) [24]
G
 
TMEM8B 207839_s_at <.0001 0.60 (0.46-0.77) n/a 
CCNA2 203418_at <.0001 0.60 (0.49-0.75) [104]
O
 
TOPORS 204071_s_at 0.0007 0.61 (0.46-0.81) [26]
G
 
RPL37A 213459_at 0.0164 0.66 (0.47-0.93) [90]
G
 
MDM2 217373_x_at <.0001 0.69 (0.61-0.78) [26]
G
 
E2F3 203693_s_at 0.0672
2
 0.75 (0.55-1.02) [28]
G
 
MDFIC 211675_s_at 0.0006 0.78 (0.68-0.90) [105]
O
 
SOD2 215078_at <.0001 0.80 (0.73-0.88) [25]
G
 
AKR1C3 209160_at 0.0014 0.83 (0.73-0.93) [26]
G
 
THBS4 204776_at 0.0007 1.18 (1.07-1.30) [106]
O
 
SHC3 206330_s_at 0.0031 1.32 (1.10-1.59) [28]
G
 
PIK3R1 212249_at 0.0145 1.34 (1.06-1.69) [20]
G
 
NKX2-5 206578_at 0.0027 1.38 (1.12-1.70) [107]
O
 
HRAS 212983_at 0.0187 1.42 (1.06-1.90) [85]
G
 
BHLHB9 213709_at 0.0192 1.42 (1.06-1.92) [108]
O
 
C9ORF95 219147_s_at 0.0004 1.43 (1.17-1.73) [109]
O
 
C17ORF101 219254_at 0.0085 1.46 (1.10-1.94) [110]
O
 
NOL3 59625_at <.0001 1.46 (1.21-1.76) [111]
O
 
RANGAP1 212125_at 0.0225 1.47 (1.06-2.05) [26]
G
 
FTSJ2 222130_s_at 0.017 1.48 (1.07-2.05) [112]
O
 
RRM1 201476_s_at 0.0006 1.49 (1.19-1.87) [27]
G
 
JAG2 209784_s_at 0.0351 1.63 (1.03-2.57) [24]
G
 
TNPO1 212635_at 0.0054 1.89 (1.20-2.96) n/a 
MYO7A 211103_at 0.0033 1.97 (1.25-3.10) [113]
O
 
ACTR2 200729_s_at 0.0001 2.18 (1.47-3.23) [24]
G
 
CSF1 209716_at <.0001 2.33 (1.65-3.27) [26]
G
 
ANK1 208352_x_at 0.0003 2.38 (1.49-3.82) [24]
G
 
B3GALNT1 211379_x_at <.0001 2.40 (1.76-3.28) [114]
O
 
KRAS 214352_s_at 0.002 2.44 (1.38-4.31) [85]
G
 
EWSR1 210012_s_at 0.0005 2.49 (1.49-4.15) [26]
G
 
SEC24C 202361_at <.0001 2.84 (1.76-4.60) n/a 
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Table 2.6 (cont.)
 
 
Gene Symbol Probe Identifier P-value Hazard Ratio
1
 
Relevant literature 
references 
RPL10L 217559_at <.0001 2.95 (1.83-4.74) [115]
O
 
IGHG1 211908_x_at 0.0007 3.41 (1.68-6.93) [116]
O
 
IGHG1 211693_at 0.0007 4.33 (1.86-10.04) [116]
O
 
n/a, No association with any type of cancer found in literature; 
1 
Hazard ratio estimate (95% confidence interval); 
2 
Borderline significant (P-value < 0.1) included for completeness; 
G 
Gene confirmed in an independent glioblastoma multiforme study; the number between square 
brackets denotes the corresponding literature reference; 
O 
Gene confirmed in an independent study on any other type of cancer; the number between 
square brackets denotes the corresponding literature reference. 
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Table 2.7. Genes that have a cohort-dependent association (P-value < 0.05) with the overall 
glioblastoma survival 
Gene 
Symbol 
Probe 
Identifier 
Clinical 
Cohort P-value 
Level of 
Clinical 
Cohort Hazard Ratio
1 
Relevant 
literature 
references 
POLR2D 214144_at Therapy 0.0044 Other 0.35 (0.18-0.70) [117]
O
 
    R 0.50 (0.31-0.81)  
    CRT 0.68 (0.38-1.21)  
    None 0.77 (0.43-1.39)  
    CRnoT 0.93 (0.58-1.5)  
IGF2BP3 203820_s_at Gender 0.0146 Female 1.02 (0.84-1.24) [118]
O
 
    Male 1.29 (1.12-1.49)  
n/a, No association with any type of cancer found in literature; 
1 
Hazard ratio estimate (95% confidence interval); 
G 
Gene confirmed in an independent glioblastoma multiforme study; the number between square 
brackets denotes the corresponding literature reference; 
O 
Gene confirmed in an independent study on any other type of cancer; the number between 
square brackets denotes the corresponding literature reference. 
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Table 2.8. Genes that have a general association (P-value < 0.05) with the progression-free 
glioblastoma survival 
Gene Symbol Probe Identifier P-value Hazard Ratio
1
 
Relevant literature 
references 
PLA2G7 206214_at <.0001 0.11 (0.05-0.23) [119]
O
 
PDGFB 216061_x_at <.0001 0.18 (0.09-0.35) [28]
G
 
CALM2 207243_s_at 0.0011 0.22 (0.09-0.54) [28]
G
 
TIMP3 201148_s_at <.0001 0.26 (0.16-0.41) [26]
G
 
AGPAT1 215535_s_at <.0001 0.27 (0.15-0.51) n/a 
IFNGR1 202727_s_at <.0001 0.32 (0.19-0.53) [27]
G
 
PVR 214444_s_at <.0001 0.32 (0.19-0.54) [26]
G
 
NDUFV1 208714_at 0.0002 0.33 (0.19-0.59) n/a 
FGFR2 211401_s_at <.0001 0.39 (0.26-0.57) [26]
G
 
E2F3 203693_s_at <.0001 0.42 (0.29-0.60) [28]
G
 
POLD2 201115_at 0.0007 0.43 (0.27-0.70) [26]
G
 
CALM3 200622_x_at 0.0001 0.43 (0.28-0.67) [28]
G
 
TP53 211300_s_at <.0001 0.43 (0.29-0.64) [25]
G
 
RAF1 201244_s_at 0.0141 0.46 (0.25-0.85) [26]
G
 
PKNOX2 219046_s_at <.0001 0.46 (0.33-0.62) [120]
O
 
APP 214953_s_at 0.0016 0.47 (0.30-0.75) [24]
G
 
FSTL1 208782_at <.0001 0.47 (0.35-0.62) [25]
G
 
CAMK2B 211483_x_at 0.0008 0.54 (0.38-0.77) [28]
G
 
PTEN 204053_x_at 0.0003 0.60 (0.46-0.79) [26]
G
 
MDM2 217373_x_at <.0001 0.66 (0.57-0.76) [26]
G
 
CCND1 208711_s_at 0.0273 0.80 (0.66-0.98) [28]
G
 
HSPA1A/HSPA1B 202581_at 0.0529 0.82 (0.67-1. 00) [24]
G
 
CD24 208650_s_at 0.0069 0.85 (0.75-0.95) [121]
O
 
CLEC2B 209732_at 0.0645
2
 1.19 (0.99-1.44) [122]
O
 
CAV2 203324_s_at 0.0024 1.25 (1.08-1.44) [123]
O
 
SNX10 218404_at <.0001 1.34 (1.16-1.57) [124]
O
 
WEE1 215711_s_at 0.0083 1.37 (1.08-1.74) [27]
G
 
HRAS 212983_at 0.0802
2
 1.49 (0.95-2.33) [85]
G
 
MNS1 219703_at 0.0053 1.51 (1.13-2.02) n/a 
PPP1R15A 37028_at 0.011 1.54 (1.10-2.15) n/a 
APP 211277_x_at 0.0811
2
 1.56 (0.95-2.56) [24]
G
 
FADD 202535_at 0.0934
2
 1.57 (0.93-2.65) [125]
O
 
PIK3R1 212239_at 0.018 1.60 (1.08-2.36) [20]
G
 
MMP14 217279_x_at 0.0182 1.66 (1.09-2.52) [24]
G
 
MTAP 204956_at 0.0016 1.66 (1.21-2.27) [26]
G
 
IL13RA1 211612_s_at 0.0003 1.72 (1.28-2.32) [24]
G
 
KCNJ13 210179_at 0.0235 1.74 (1.08-2.82) [126]
O
 
CLIP3 212358_at 0.0022 1.75 (1.22-2.50) n/a 
AANAT 207225_at 0.0114 1.78 (1.14-2.79) [127]
O
 
CAMK2G 214322_at 0.0024 1.86 (1.24-2.78) [56]
G
 
PRKCA 215195_at 0.0005 1.90 (1.32-2.73) [28]
G
 
KDM6B 41386_i_at 0.0003 2.03 (1.39-2.96) n/a 
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Table 2.8 (cont.) 
Gene Symbol Probe Identifier P-value Hazard Ratio
1
 
Relevant literature 
references 
ZFY 207246_at 0.0016 2.06 (1.31-3.22) [128]
O
 
SMARCB1 212167_s_at 0.0004 2.06 (1.38-3.07) [26]
G
 
UTP20 209725_at <.0001 2.08 (1.46-2.98) n/a 
IGL@ 211655_at 0.0209 2.22 (1.13-4.38) [129]
O
 
ATF5 204998_s_at <.0001 2.31 (1.72-3.11) [130]
G
 
SHOX 207570_at <.0001 2.66 (1.73-4.07) [24]
G
 
LOC283079 215929_at 0.0071 2.73 (1.31-5.69) n/a 
UNG 202330_s_at 0.0001 2.79 (1.66-4.68) [27]
G
 
HNRNPD 213359_at <.0001 2.94 (1.91-4.52) n/a 
CAMK2B 209956_s_at <.0001 3.02 (2.13-4.29) [28]
G
 
TIMP3 201150_s_at <.0001 3.10 (1.88-5.11) [26]
G
 
NRAS 202647_s_at <.0001 3.93 (2.60-5.95) [28]
G
 
PAICS 214664_at <.0001 5.28 (3.13-8.91) [66]
O
 
n/a, No association with any type of cancer found in literature; 
1 
Hazard ratio estimate (95% confidence interval); 
2 
Borderline significant (P-value < 0.1) included for completeness; 
G 
Gene confirmed in an independent glioblastoma multiforme study; the number between square 
brackets denotes the corresponding literature reference; 
O 
Gene confirmed in an independent study on any other type of cancer; the number between 
square brackets denotes the corresponding literature reference. 
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Table 2.9. Genes that have a cohort-dependent association (P-value < 0.05) with 
progression-free glioblastoma survival 
Gene 
Symbol 
Probe 
Identifier 
Clinical 
Cohort P-value 
Level of 
Clinical 
Cohort Hazard Ratio
1 
Relevant 
literature 
references 
GDF10 206159_at Gender 0.0317 Male 0.37 (0.23-0.60) n/a 
    Female 0.80 (0.45-1.42)  
VAV3 218807_at Race 0.008 Other 0.41 (0.29-0.59) [81]
G
 
    White 0.68 (0.55-0.85)  
RPS20 216246_at Race 0.0003 Other 0.75 (0.39-1.44) [75]
O
 
    White 1.83 (1.03-3.24)  
RAB31 217764_s_at Race <.0001 White 1.47 (0.93-2.30) [74]
O
 
    Other 7.72 (3.71-16.07)  
APOOL 213289_at Therapy 0.0026 R 1.64 (1.13-2.38) [131]
O
 
    None 1.93 (0.63-5.98)  
    CRnoT 2.23 (1.55-3.20)  
    Other 3.86 (1.83-8.13)  
    CRT 4.82 (2.69-8.63)  
n/a, No association with any type of cancer found in literature; 
1 
Hazard ratio estimate (95% confidence interval); 
G 
Gene confirmed in an independent glioblastoma multiforme study; the number between square 
brackets denotes the corresponding literature reference; 
O 
Gene confirmed in an independent study on any other type of cancer; the number between 
square brackets denotes the corresponding literature reference.
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Table 2.10. Gene Ontology categories enriched among the genes associated with lifetime glioblastoma survival
1
 
Gene 
Ontology Level Term P-value 
FDR 
Adjusted 
P-value 
Number 
of Genes Genes 
Biological 
process 
3 aging (GO:0007568) 2.13E-05 1.62E-03 3 PDCD4, CDKN2A, and TP53 
 regulation of biological process 
(GO:0050789) 
2.77E-04 1.50E-02 20 USF2, CDKN2A, CCNB2, AKT2, T
P53, CDC42, SIX6,JAG2, LIN7C, P
DCD4, CSF1, TOPORS, SPG21, A
KT1, EGFR, SOX10, C2, SCN5A, 
ARHGEF4, and CDK2 
 protein localization 
(GO:0008104) 
1.49E-03 3.77E-02 7 TOPORS, AKT1, SAR1A, EGFR, 
TIMM23, TP53, and LIN7C 
 cell division (GO:0051301) 2.04E-03 3.88E-02 3 CCNB2, CDC42, and CDK2 
 cell cycle (GO:0007049) 3.75E-03 5.14E-02 7 PDCD4, EGFR, CDK2, CDKN2A, 
CCNB2, TP53, and JAG2 
 nitrogen compound metabolic 
process (GO:0006807) 
4.06E-03 5.14E-02 4 CHST4, AKT1, EGFR, and CHI3L1 
 cell proliferation (GO:0008283) 8.32E-03 8.99E-02 6 CSF1, TOPORS, EGFR, CDK2, 
TP53, and JAG2 
 death (GO:0016265) 9.46E-03 8.99E-02 6 AKT1, CDKN2A, TP53, JAG2, 
PDCD4, and TOPORS 
4 cell aging (GO:0007569) 4.38E-06 9.42E-04 3 PDCD4, CDKN2A, and TP53 
1 
Only GO categories with False Discovery Rate (FDR) adjusted P-value < 0.1 and represented by three or more genes. 
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Table 2.11. Gene Ontology categories enriched among the genes associated with overall glioblastoma survival
1
 
Gene 
Ontology Level Term P-value 
FDR 
Adjusted 
P-value 
Number 
of Genes Genes 
Biological 
process 
4 anatomical structure morphogenesis 
(GO:0009653) 
5.39E-05 1.62E-02 9 NKX2-5, CSF1, MAPK3, TGFA, 
THBS4, JAG2, IGF2BP3, 
MYO7A, and HRAS 
6 organ morphogenesis 
(GO:0009887) 
3.83E-06 2.40E-03 7 NKX2-5, CSF1, MAPK3, TGFA, 
JAG2, MYO7A and, HRAS 
1 
Only GO categories with False Discovery Rate (FDR) adjusted P-value < 0.1 and represented by three or more genes. 
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Table 2.12. Gene Ontology categories enriched among the genes associated with progression-free survival
1
 
Gene 
Ontology Level Term P-value 
FDR 
Adjusted P-
value 
Number 
of 
Genes Genes 
Biological 
process 
3 cell cycle (GO:0007049) 3.89E-06 2.96E-04 11 HRAS, PPP1R15A, APP, CALM2, 
ATF5,PTEN, E2F3, WEE1, TP53, 
CCND1, and NRAS 
  death (GO:0016265) 3.18E-04 1.21E-02 9
2
 APP, RAF1, ATF5, PTEN, FADD,
HSPA1A/HSPA1B, TP53, 
and PPP1R15A 
  response to biotic stimulus 
(GO:0009607) 
4.11E-03 5.13E-02 6
2
 FADD, HSPA1A/HSPA1B, CLEC2
B,CCND1, and IFNGR1 
  response to abiotic stimulus 
(GO:0009628) 
8.17E-03 6.90E-02 6
2
 FADD, HSPA1A/HSPA1B, CLEC2
B,CCND1, and IFNGR1 
 4 cell cycle process (GO:0022402) 4.26E-06 9.16E-04 10 APP, ATF5, PTEN, E2F3, WEE1, 
TP53,CCND1, NRAS, HRAS, and 
PPP1R15A 
 5 regulation of cell cycle 
(GO:0051726) 
2.90E-07 1.22E-04 10 WEE1, TP53, CCND1, APP, NRA
S,HRAS, PPP1R15A, ATF5, PTEN
, and E2F3 
 6 regulation of progression through 
cell cycle (GO:0000074) 
1.47E-07 9.24E-05 10 TP53, CCND1, NRAS, HRAS, PPP
1R15A,APP, ATF5, PTEN, E2F3, 
and WEE1 
  cell death (GO:0008219) 2.13E-04 6.18E-02 9
2
 PPP1R15A, APP, RAF1, ATF5, P
TEN,FADD, HSPA1A/HSPA1B, 
and TP53 
 7 programmed cell death 
(GO:0012501) 
1.19E-04 2.23E-02 9
2
 PPP1R15A, APP, RAF1, ATF5, P
TEN,FADD, HSPA1A/HSPA1B, 
and TP53 
  apoptosis (GO:0006915) 1.41E-04 5.21E-02 9
2
 PPP1R15A, APP, RAF1, ATF5, P
TEN,FADD, HSPA1A/HSPA1B, 
and TP53 
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Table 2.12 (cont.) 
Gene 
Ontology Level Term P-value 
FDR 
Adjusted P-
value 
Number 
of 
Genes Genes 
Molecular 
function 
3 pattern binding (GO:0001871) 3.26E-04 3.55E-02 3 FSTL1, APP, and FGFR2 
  carbohydrate binding 
(GO:0030246) 
1.26E-03 6.89E-02 4 FSTL1, APP, FGFR2, 
and CLEC2B 
 4 polysaccharide binding 
(GO:0030247) 
3.01E-04 8.70E-02 3 FSTL1, APP, and FGFR2 
1 
Only GO categories with False Discovery Rate (FDR) adjusted P-value < 0.1 and represented by three or more genes; 
2 
Although HSPA1A/HSPA1B are represented by the same probe (202581_at), these isoforms are counted as two units. 
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CHAPTER 3: SINGLE NUCLEOTIDE POLYMORPHISMS AND HAPLOTYPES 
ASSOCIATED WITH FEED EFFICIENCY IN BEEF CATTLE  
3.1. Abstract 
General, breed- and diet-dependent associations between feed efficiency in beef cattle and single 
nucleotide polymorphisms (SNPs) or haplotypes were identified on a population of 1321 steers 
using a 50K SNP panel. Genomic associations with traditional two-step indicators of feed 
efficiency – residual feed intake (RFI), residual average daily gain (RADG), and residual intake 
gain (RIG) – were compared to associations with two complementary one-step indicators of feed 
efficiency: efficiency of intake (EI) and efficiency of gain (EG). Associations uncovered in a 
training data set were evaluated on independent validation data set. A multi-SNP model was 
developed to predict feed efficiency. Functional analysis of genes harboring SNPs significantly 
associated with feed efficiency and network visualization aided in the interpretation of the 
results. For the five feed efficiency indicators, the total number of general, breed-dependent, and 
diet-dependent associations for SNPs was 31, 40, and 25, and for haplotypes was six, ten, and 
nine, respectively. Of these, 20 SNP and six haplotype associations overlapped between RFI and 
EI, and five SNP and one haplotype associations overlapped between RADG and EG. This result 
confirms the complementary value of the one and two-step indicators. The multi-SNP models 
included 89 SNPs and offered a precise prediction of the five feed efficiency indicators. The 
associations of 17 SNPs and 7 haplotypes were confirmed on the validation data set. Among the 
Gene Ontology categories, 13 molecular functions and six biological processes including ion 
channel activity, nucleotide binding, and passive transmembrane transporter activity were 
overrepresented among the genes harboring the SNPs associated with feed efficiency. The 
general SNP associations suggest that a single panel of genomic variants can be used across 
breed and diet. The breed- and diet-dependent associations between SNPs and feed efficiency 
suggest that further refinement of variant panels require the consideration of the breed and 
management practices. The unique genomic variants associated with the one- and two-step 
indicators suggest that both types of indicators offer complementary description of feed 
efficiency that can be exploited for genome-enabled selection purposes. 
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3.2. Background 
Feed efficiency is based on the relation between animal intake (input) and production 
(output). Several indicators that address in different ways the complexities of feed efficiency 
have been proposed [1-6]. Feed-to-gain ratio (F:G) and two-step indicators of feed efficiency, 
including residual feed intake (RFI) and residual average daily gain (RADG) [1], are commonly 
reported. These indicators have distinct characteristics, such as correlation (overlap) with growth 
traits [7], absence of partition between the energy used for maintenance and production [1], use 
of ratios between variables with different variances [8], and failure to consider the level of 
uncertainty of estimates in two-step approaches [1]. 
Several genome-wide association studies (GWAS) have identified single nucleotide 
polymorphisms (SNP) associated with feed efficiency in beef cattle [9-15]. The outbreeding 
nature of beef cattle populations lead to differences in linkage disequilibrium (LD) between the 
alleles at SNP and at the loci controlling the trait, between breeds and between families within 
breeds. Thus, the association between SNPs and phenotypes may vary across breeds [9, 12-15]. 
Similarly to breed-dependent associations, environment-dependent associations between SNPs 
and phenotypes, such as diet-by-SNP interactions, must be considered in GWAS studies [16, 17]. 
In addition to individual SNP, the study of haplotype associations in GWAS has benefits. 
Haplotype blocks may capture epistatic interactions between SNPs [18-20], and drastically 
reduce the number of tests (control of type I error). The benefits of haplotype-based GWAS 
depend on the extent of LD between variants in the bock and thus the length of the haplotype 
block and distance between the variants [21]. Few studies have reported associations between 
haplotypes and feed efficiency in beef cattle [22]. The study of haplotypes, rather than single 
SNP associations, has been proposed. The rationale are that haplotype provide more information 
to estimate whether two alleles are identical by descent, reduce the number of tests and hence the 
type I error rate, allow informed testing between clades of haplotype alleles by capturing 
information from evolutionary history, and provide more power than single SNPs when an allelic 
series exists at a locus [20]. However, these arguments have caveats [20]. The information 
content of haplotypes is dependent on the particular mutational and recombinational history of 
the loci and nearby SNPs. Also, the distribution of loci and SNP variants are not parallel across 
the genome, and thus haplotype information could capture associations that would elude single 
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SNPs [20]. Following recommendations, both single SNP and haplotypes are investigated to take 
advantage of the full information content of the genotype data. 
The objectives of this study were: 1) to identify general, breed- and diet-dependent 
associations between feed efficiency in beef cattle and SNPs or haplotypes and, 2) to compare 
the genomic associations with traditional two-step indicators of feed efficiency – RFI, RADG 
and residual intake gain (RIG) – relative to two complementary one-step models of feed 
efficiency: efficiency of intake (EI) and efficiency of gain (EG). Associations uncovered in a 
training data set were evaluated on a validation data set. A multi-SNP model was developed to 
predict feed efficiency. Functional analysis and network visualization aided in the interpretation 
of the results. 
3.3. Methods 
3.3.1. Animals and Data Description 
Animals used in this trial were managed according to the guidelines recommended in the 
Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching [23]. 
Experimental protocols were submitted to and approved by the University of Illinois Institutional 
Animal Care and Use Committee [24]. 
A beef cattle population encompassing various breed compositions and receiving various 
diets was used to uncover general and breed- or diet-specific genomic variants associated with 
feed efficiency. A total of 1,321 feedlot steers obtained from five ranches in Montana 
representing calving years between 2005 and 2008 were studied. Animals were harvested in 
different groups and the combination of these groups, ranches, and years was used to create 
contemporary groups (CG, 27 levels). The pedigree and breed information of steers were 
accessed from the American Simmental Association Herdbook Service [25]. The pedigree 
included a total of 3,331 animals. After individual verification, steers pertaining to one of five 
breed compositions: purebred Angus (AN), 3/4 Angus (3/4AN), crossbred Angus and Simmental 
(ANSM), 3/4 Simmental (3/4SM) and purebred Simmental (SM). The steers received one of 12 
diets in which many showed similar composition and nutritional value. Thus, the diets were 
further grouped into five levels according to the main ingredient, total net energy, and non-
degradable fiber as shown in Table 3.1. 
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Prior to the beginning of the trial, initial weight (IW, kg) of each animal was recorded 
and steers were measured for average daily gain (ADG, kg), dry matter intake (DMI, kg/day), rib 
eye area (REA, cm
2
), and back fat thickness (BF, cm). Adjusted final weight was obtained as hot 
carcass weight divided by the average dressing percentage of the slaughter group, and used to 
calculate ADG. Individual feed intake records were collected using the GrowSafe automated 
feeding system (GrowSafe Systems Ltd., Airdrie, Alberta, Canada). Chromatography paper was 
used to take an image of the longissimus dorsi for REA measures, and recorded using a 
planometer. Measures of BF were taken in a transverse orientation between the 12th and 13th 
ribs, at approximately 10 cm distal from the midline. The average (±standard deviation) of IW, 
ADG, DMI, REA, and BF were 310.10±40.08 kg, 1.61±0.24 kg, 10.48±1.42 kg/day, 
90.18±10.19 cm
2
, and 1.26±0.36 cm, respectively. A more detailed description of the diets, 
measurements of the traits, and slaughter procedures may be found elsewhere [24]. 
3.3.2. Feed Efficiency Indicators 
Established and new indicators of feed efficiency were evaluated. Among the known 
indicators, RFI was calculated as the difference between the observed and predicted DMI [1]. 
The DMI values were predicted using a linear model including ADG, mid-test metabolic body 
weight (MBW; mid-test BW
0.73
), REA, and BF. In a similar fashion, RADG (also known as 
residual body weight gain; RG [5]) was calculated subtracting the observed ADG by its 
prediction. The ADG values were predicted using a linear model including DMI, MBW, REA, 
and BF. Residual intake and gain (RIG) was calculated as the sum of RADG and -1*RFI, and 
both are standardized to unit variance [6]. Positive values for RADG and RIG, and negative 
values for RFI, are indicators of higher feed efficiency. Predictions of DMI and ADG, as well as 
computation of RFI, RADG, and RIG, were performed using the MIXED procedure is SAS 9.2 
(Statistical Analysis System Institute, Inc., Cary, NC, USA). 
Both RADG and RFI are the result of a two-step approach. The first step consists of the 
estimation of ADG (or DMI) once the covariation due to MBW, DMI (or ADG), REA, and BF 
have been removed. The second step consists on the identification of SNPs or haplotypes 
associated with the resulting point residuals of ADG (or DMI). These residuals are a function of 
point predictions that ignore the uncertainty (e.g. confidence intervals) associated with these 
predictions. The purpose of the two-step calculation of RFI, RADG, and RIG indicators is to 
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achieve some independence from body weight [6]. A one-step approach can achieve comparable 
independence while accommodating the uncertainty of the predictions. 
Two complementary indicators of feed efficiency obtained from a one-step model are 
proposed. In the one-step model, the association between SNPs or haplotypes and feed efficiency 
is described in one model that includes the covariates used in the first step of the computation of 
RFI and RADG. The complementary one-step model overcomes the limitation of RFI and 
RADG by accommodating parameter estimate uncertainty. The one-step indicators used as 
complements for RFI and RADG are termed efficiency of intake (EI) and efficiency of gain 
(EG), respectively. 
3.3.3. Genotyping and Quality Control 
Genotypes were obtained using the Illumina® BovineSNP50 BeadChips v1 and v2 
platforms (Illumina Inc., San Diego, CA) that include 54,001 and 54,609 SNPs, respectively. The 
52,340 SNPs presented in both versions of the platform were analyzed. Quality control was 
performed in two steps. First, SNPs not assigned to chromosomes, according to the 
Bos_taurus_UMD_3.1 assembly (519 SNPs) [26], and with GenCall scores below 0.2 (16 SNPs) 
were excluded from further analyses. GenCall scores below 0.2 generally indicate failed 
genotypes [27]. In the second step, quality control was implemented using PLINK [28]. 
Observations were removed when not meeting the following thresholds: steer missingness per 
SNP (< 20%; --geno 0.2) [29], Hardy-Weinberg equilibrium test (P-value > 0.00001; --hwe 
0.00001) [30], SNP missingness per steer (< 10%; --mind 0.1) [31], and minor allele frequency 
(MAF > 5%; --maf 0.05) [31]. Respectively, 264 SNPs, 1,202 SNPs, 9 steers, and 9,811 SNPs 
were not considered for further analysis. The final data set included 1,312 steers and 40,528 
SNPs, with a total genotyping rate of 99.55%. 
3.3.4. Haplotype Reconstruction 
Using the genotypic data after quality control, haplotype blocks were estimated (--blocks) 
and phased (--hap-phase) using PLINK. Blocks were estimated within a 200 kb window [32] 
using the confidence interval method [33], resulting in 1,129 non-overlapping haplotype blocks. 
The size of the window offers a compromise between encompassing SNPs in LD while 
controlling for the number of alleles. A large number of alleles could jeopardize the 
representation of alleles across breeds and diets and could result in spurious significant contrasts 
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between pairs of alleles. In cattle, linkage disequilibrium does not extend substantially beyond 
500 kb (r
2
 < 0.08) and is low at 100 kb (r
2
 < 0.18) [32, 34]. A window of 200 kb was selected to 
generate block that will encompass most LD and the average number of alleles was 3.88. 
The association between feed efficiency and non-overlapping blocks was tested. The 
lower number of non-overlapping blocks, relative to sliding window overlapping blocks, resulted 
in a substantial reduction in the number of tests and thus in less stringent multiple-test 
adjustment of the significance P-values. A potential drawback of the non-overlapping approach 
is that all SNPs in LD with the loci could be assigned to different blocks, thus resulting in loss of 
power. This situation may also arise for the sliding window approach when a limited number of 
window widths are applied [35]. In this case, the single SNP analysis in the present study will 
detect numerous nearby SNPs associated in various degrees with feed efficiency. 
Haplotype alleles with posterior phasing probability below 1 were excluded to increase 
the reliability of the haplotype alleles. The second quality control step in the haplotype data used 
the same thresholds from the individual SNP analysis, and no blocks or steers were removed. 
The extent of LD between SNPs within haplotype blocks was computed in PLINK (--r2) using 
the pairwise average r
2
 statistics [36] in order to assess the recombination potential in these 
genomic regions. 
3.3.5. Training and Validation Data Sets 
Two data sets were obtained from the records that passed the quality control. The training 
data set consisted of 976 steers (75%) and was used to identify SNPs and haplotypes associated 
with feed efficiency. The validation data set consisted of 336 steers (25%) and was used to 
validate the findings. Steers from each sire were assigned to one of the two data sets to minimize 
the dependencies between data sets and attain a less biased validation [14, 37]. The number and 
proportion of steers on each data set, by the levels of diet and breed, are presented in Table 3.2. 
Only 23% of the grandsires were represented by steers in both data sets. 
3.3.6. Statistical Analyses 
Whole-genome SNP and haplotype association analysis. The general model used to identify 
associations between SNPs and the two-step feed efficiency indicators RFI, RADG, and RIG 
was: 
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                                                         ̅̅ ̅̅  
               
(Eq. 3.1) 
where Yijklm is the value of RFI, RADG, or RIG, µ is the overall mean, SNPi is the fixed effect of 
the SNP genotype, Bj is the fixed effect of breed (5 levels), Dk is the fixed effect of diet (5 
levels), CGl is the random effect of contemporary group (27 levels, [0,    
 ]), b1 is the fixed 
effect regression coefficient for the covariate IW, aijklmn is the random animal effect (0,    
 ; 
where A is the additive relationship matrix), and eijklmn is the random error (0,   
 ) associated with 
Yijklm. The analysis included the covariate IW due to its correlation with DMI and ADG [4]. 
For the complementary one-step models, Eq. 3.1 was extended to include the adjustments 
previously detailed for RFI and RADG, resulting in the following models for, respectively, EI 
(Eq. 3.2) and EG (Eq. 3.3): 
                               ̅̅ ̅̅ ̅̅                  ̅̅ ̅̅ ̅̅ ̅̅                ̅̅ ̅̅  
                ̅̅ ̅̅ ̅̅   
(Eq. 3.2) 
                               ̅̅ ̅̅ ̅̅                  ̅̅ ̅̅ ̅̅ ̅̅                ̅̅ ̅̅  
                ̅̅ ̅̅ ̅̅   
(Eq. 3.3) 
where b2, b3, b4, and b5 are the fixed effect regression coefficients for the covariates ADG, MBW, 
BF, and REA, respectively, for the EI model, and b6, b7, b8, and b9 are the fixed effect regression 
coefficients for the covariates DMI, MBW, BF, and REA, respectively, for the EG model. The 
additive and dominance effects of the SNPs were tested jointly and SNPs were considered 
significant at P-value < 0.0001 [15]. 
Similar models were used to test the individual association between the 1,129 haplotype 
blocks and the five indicators by substituting SNP for haplotype in the models. The additive 
effect of haplotype was tested and considered significant at P-value < 0.001 to account for the 
lower number of haplotype hypotheses tested (1,129 haplotypes) compared to SNP hypotheses 
tested (40,528 SNPs). 
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Additive and dominance estimates are presented relative to the less frequent or minor 
allele. The additive effect was tested for SNPs located on BTA X, when testing the interactions 
with breed and with diet, and for the haplotype analyses. The additive estimates for SNPs 
interacting with breed or diet are the contrasts between each breed level relative to SM steers for 
breed-by-SNP associations, and each diet level relative to diet E, for diet-by-SNP associations. 
Before association analyses, the normality and homoscedastic of the residual estimates from each 
model without the SNP effect was confirmed assessing the Shapiro-Wilk’s using the 
UNIVARIATE procedure in SAS. All association analyses were performed using Qxpak v.5.05 
[38]. 
Multi-SNP model selection. A SNP-based indicator of feed efficiency was developed by 
simultaneously considering significant SNPs and their ability to predict each of the five feed 
efficiency indicators evaluated using a stepwise selection approach. All other explanatory 
variables in Eqs. 3.1, 3.2, and 3.3 were kept in the model, and only the SNPs underwent variable 
selection. For each feed efficiency indicator, the set of SNPs that were significantly associated at 
P-value < 0.001 in the whole-genome SNP association analysis were assessed for entering and 
staying in the model at P-value < 0.0001. 
SNP and haplotype validation. The significant SNPs and haplotypes identified in the genome-
wide analyses were evaluated in the validation data set using the same models. Both, the 
significance level and trend (sign of the estimates) of the SNP and haplotype were compared 
between the two independent data sets. Each SNP and haplotype was individually tested and 
considered validated at P-value < 0.05 [13]. For the multi-SNP models, the goodness of fit was 
assessed by comparing the estimated root mean square errors (RMSE) between the training and 
the validation data sets. 
Genetic parameter. Heritability estimates were obtained using single trait analyses, whereas the 
genetic and phenotypic correlations were obtained using bivariate analyses. The five feed 
efficiency indicators were analyzed using the models described for whole-genome analysis, 
excluding SNP or haplotype and the interactions with other model factors. The software package 
WOMBAT was used to estimate the variance components of the indicators [39]. 
Functional and gene network analyses. The Gene Ontology (GO) categories that are 
overrepresented among the genes harboring the SNPs associated with feed efficiency were 
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identified. This analysis and gene network visualization offered insights into molecular functions 
and biological processes that could be potentially associated with feed efficiency in beef cattle. 
Gene Ontology [40] categories and KEGG pathways [41] that were enriched among the genes 
harboring SNPs and intergenic SNPs (SNPs within 2 kb 5' or 0.5 kb 3' to a gene [27]) associated 
with feed efficiency at P-value < 0.01 were identified using DAVID [42]. Genes farther upstream 
and downstream from the detected SNPs were not included in the functional analysis because the 
number of spurious genes added to the functional analysis would have overwhelmed the fewer 
potential true loci, thus biasing the results. Enrichment of FAT categories that include molecular 
function and biological process was investigated. Gene ontology FAT categories are a subset of 
the broadest GO terms, in which are filtered so that they do not overshadow the more specific 
terms. Enrichment was identified in three gene lists: general SNP associations, breed-by-SNP 
associations, and diet-by-SNP associations that resulted from the combination of all five feed 
efficiency indicators. Functional annotation charts were generated using Bos taurus as the 
genome background, and considered significant at P-value < 0.001. 
Gene networks associated with feed efficiency were inferred based on the lists of genes 
corresponding to the significant GO terms. Networks were visualized using the BisoGenet plug-
in [43] from the Cytoscape software [44]. All the available data sources in BisoGenet (including 
BIOGRID, DIP, BIND and others) were selected to generate the interactions, in which are 
represented by the edges between two genes (nodes). The final pathway included genes separated 
by at most one intermediate gene to highlight the interactions between the target genes. Target 
genes are represented by pink nodes, while intermediate genes are by blue nodes. The size of the 
network nodes from the target genes is a function of the P-values from the association analyses, 
in which larger nodes indicate more significant P-values, while the size of the nodes of 
intermediate genes are constant. The node size of genes with more than one SNP associated was 
represented as the average P-values of the SNPs. Nodes with self-edges represent genes 
presenting self-regulation function. 
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3.4. Results and Discussion 
3.4.1. General Results 
A summary of the total number of unique significant SNPs (P-value < 0.0001) and 
haplotypes (P-value < 0.001) are presented in Tables 3.3 and 3.4, respectively. In the SNP and 
haplotype analyses, RIG showed the highest number of unique associations, followed by the 
intake-based indicators RFI and EI, and lastly the gain-based indicators RADG and EG. The 
traditional indicators RFI and RADG had a similar number of associations than the respective 
complementary indicators EI and EG in both the analyses. Of the 21 SNPs associated with RFI 
and any other indicator, 18 were also associated with EI, and in all cases the same type of 
association (general or breed/diet-dependent) was significant. Similarly, of the 7 SNPs associated 
with RADG and any other indicator, 5 were also associated with EG, always with the same type 
of association. The overlap between the RFI and RADG associations and the EI and EG 
associations, suggests that the latter indicators may have the potential to be used in lieu of the 
former ones, respectively. 
3.4.2. Genetic Parameters of Feed Efficiency 
The estimated heritabilities for RFI, RADG, RIG, EI, and EG were, respectively, 0.40 
(±0.10), 0.17 (±0.07), 0.40 (±0.10), 0.40 (±0.10), 0.16 (±0.07). Consistent with SNP and 
haplotype results, the heritability for RFI and RADG are similar to EI and EG, respectively. The 
RFI heritability estimate is consistent with those previously reported [3, 6, 7]. The RADG 
heritability estimate is slightly smaller than that (0.28) reported in another study [5]. Similarly, 
our results are comparable to the heritability estimate for RIG in beef cattle (0.36) previously 
reported [6]. 
All absolute genetic and phenotypic correlation estimates, were above 0.9 with the 
exception of RADG with RFI and RIG. The high correlations are expected considering the 
similarity between indicators. The genetic and phenotypic correlation estimates between RADG 
and RFI were, 0.43 (±0.09) and -0.34 (±0.03), respectively, and are in accordance with previous 
reports [5]. The genetic and phenotypic correlation estimates between RADG and RIG were 
0.55±0.08 and 0.48±0.03, respectively, and agree in sign with previous studies (0.83 and 0.85, 
respectively) [6]. The similarity of the genetic parameter estimates between the two-step 
indicators RFI and RADG, and the one-step indicators EI and EG, respectively, further support 
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the proposition that the complementary indicators can be used as proxy for the traditional 
counterparts. 
3.4.3. Whole-genome SNP Association Analysis 
The SNPs significantly associated (P-value < 0.0001) with each indicator per se or 
interacting with breed or diet that were mapped to gene regions are presented in Tables 3.5, 3.6, 
and 3.7, respectively. The complete list including SNPs not mapped to genes is provided in the 
Tables A.1, A.2, and A.3, for the respective associations (see Appendix A). 
Significant associations between feed efficiency and SNP-by-breed or SNP-by-diet 
interactions uncover breed- and diet-dependent SNP associations. The identification of breed-
dependent SNPs associated with feed efficiency has two uses. First, beef cattle crossbreeding 
systems can exploit the higher feed efficiency for SNPs with dominant mode of action. Second, 
use of SNP information for breeding and selection must be done at a within-breed level. The 
identification of diet-dependent SNPs associated with feed efficiency supports breeding and 
selection strategies optimized for specific feeding managements. In the absence of significant 
interactions, significant SNP association uncover general genetic variants that are associated with 
feed efficiency regardless of breed or diet and that are useful across beef cattle breeding systems. 
A total of 137 significant genomic associations with feed efficiency indicators, 
representing 93 SNPs, were detected. Associations were identified on all chromosomes with the 
exception of BTAs 21, 26, and 27. Ten or more associations were observed on BTAs 6, 8, 12, 
15, and 17 (approximately 42% of the significant associations). Although the later chromosome 
had the highest number of associations (15), only three SNPs were located in gene regions. 
Noteworthy associations are described. 
There was a significant breed-dependent association between RFI, EI and RIG, with 
rs29024448 (BTA 17) and breed that indicates that this SNP has a breed-dependent mode of 
action (Table 3.6). This SNP is located within 2 kb of the replication factor C (activator 1) 5, 
36.5kDa gene (RFC5). The additive estimate of the minor allele G was consistent across the 
three indicators, with purebred SM being more efficient than 3/4AN steers. This SNP is located 
within a QTL region for RFI previously reported [45]. There was a significant breed-dependent 
association of rs110280556 with RADG and RIG (Table 3.6). Purebred SM steers carrying the 
UNC5C G>A allele on BTA 6 had higher feed efficiency than 3/4AN and AN. On BTA 12, 
 129 
 
rs109291606 and rs41611457, that map to ecto-NOX disulfide-thiol exchanger 1 (ENOX1), had a 
significant association with EG in a general and diet-dependent, respectively (Table 3.5 and 3.7, 
respectively). All diets with the exception of Diet E (lower total net energy) had higher feed 
efficiency in steers carrying the variant G. This gene acts on intracellular redox homeostasis, 
exhibiting cyclic NADH oxidase activity [46]. On BTA 12, two SNPs that map to the dachshund 
homolog 1 gene (DACH1) showed breed-dependent associations: rs41625438 with RIG, and 
rs42456314 with RFI, EI, and RIG. On BTA 15, rs41620774, rs108964818, and rs109709275 
corresponding to ELMO/CED-12 domain containing 1 (ELMOD1), Lys-Asp-Glu-Leu containing 
1-like gene (KDELC2), and GRAM domain containing 1B (GRAMD1B), respectively, had 
significant general associations with feed efficiency (Table 3.5). For KDELC2, the allele C>T 
had dominant mode of action and increased feed efficiency. Consistent across RADG, EG, and 
RIG, the minor allele C in ELMOD1 had higher RADG and EG, whereas the minor allele G in 
GRAMB1B had higher RFI.  
From the SNP analysis, 29 genes located on 18 BTAs were associated with feed 
efficiency indicators. In particular, the significant SNPs for ciliary neurotrophic factor receptor 
(CNTFR), CUB and Sushi multiple domains 2 (CSMD2), ELMO/CED-12 domain containing 1 
(ELMOD1), glypican 5 (GPC5), Lys-Asp-Glu-Leu containing 1-like (KDELC2), replication 
factor C (activator 1) 5, 36.5kDa (RFC5), transmembrane protein 40 (TMEM40), and unc-5 
homolog C (UNC5C) genes were associated with two or more indicators (Table 3.8). Located on 
BTA 22, TMEM40 had the highest number of associations (seven) across indicators. The same 
SNP in this gene (rs108942504) exhibited significant diet-by-SNP association with RIG (Table 
3.7), and significant breed-by-SNP (Table 3.6) and diet-by-SNP (Table 3.7) associations with 
both EI and RFI, with the minor allele G showing lower efficiency. For the breed interaction, 
purebred SM animals had higher feed efficiency than composite SM. For the diet interaction, 
feedlot steers fed Diet E had higher feed efficiency than those fed any diet. All seven 
associations were consistent, showing that the allele G is associated with lower feed efficiency. 
Located on BTA 8, rs109500421 on CNTFR was associated with RFI and EI. This gene is known 
to regulate cell activity, participating in cytokine-cytokine receptor interaction, and in the Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) pathway [41]. The 
relationship between TMEM40 and CNTFR and feed efficiency may be related to the role of 
these genes in the transport of substances that regulates energy expenditure inside the cell. 
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For rs41634631 and rs111010038, similar trends were observed for both RFI and EI 
(Table A.1). Genotypes CT and TT in rs41634631 and genotype AA in rs111010038 were 
associated with higher feed efficiency. Located on BTA 16, rs41634631 is within 200 kb 
downstream the H2.0-like homeobox (HLX) and molybdenum cofactor sulphurase C-terminal 
domain containing 1 (MOSC1) genes. For RADG and EG, rs109945988 (Table A.1) presented 
similar trends for both indicators, where feedlot steer with genotype TT had lower efficiency 
than genotypes GT and GG. This SNP is located on BTA 11, 60 kb upstream the latent 
transforming growth factor beta binding protein 1 gene (LTBP1). For SNPs not mapped to genes 
interacting with diet, two polymorphisms showed high divergence between diets (Table A.3). 
For instance, the minor allele A for rs41619246 was associated with higher feed efficiency in 
steers fed diet C for both RIG and EI, when compared to the other diets. This SNP (BTA 11) is 
located with 200 kb of the genes p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1), aquaporin 
11 (AQP11), chloride channel, nucleotide-sensitive, 1A (CLNS1A), and remodeling and spacing 
factor 1 (RSF1). In contrast, for steers fed the same diet C, the minor allele C for rs41256074 is 
associated with lower feed efficiency by increasing both RFI and EI. This SNP is located 
approximately 100 kb upstream the B-cell CLL/lymphoma 11A (zinc finger protein) gene 
(BCL11A) on BTA 11.Steers with genotypes AA and TT, for rs41619246 and rs41256074, 
respectively, showed higher feed efficiency in feedlot beef production systems that use dry-
rolled corn and corn gluten feed diets. 
Genomic regions harboring QTL associated with RFI have been reported on all bovine 
chromosomes except BTAs 27 and X [9-13, 45]. Significant associations with RFI were 
identified for 26 SNPs on 16 BTAs (Tables A.1, A.2, and A.3), with a higher concentration on 
BTAs 5, 6 and 17, with three, three, and four SNPs, respectively. The three SNPs on BTA 5 were 
associated with RFI in a breed-dependent manner. These SNPs are located between within two 
QTL regions for RFI that have been reported [13]. Of the three SNPs, rs110425294 (Table 3.6) 
is located approximately 675 kb upstream a region previously reported for DMI [47], and falls in 
the intronic region of the advillin gene (AVIL). The protein encoded by this gene acts as a 
positive regulator of neuron projection development [48]. Among feedlot steers carrying the 
A>G allele, 3/4SM steers had higher feed efficiency compared to ANSM. Among the SNPs on 
BTA 6, rs41663978 (Table A.3) had significant diet-dependent association. This SNP is located 
8 Mb from the QTL peak location previously associated with DMI [11]. Feedlot steers that carry 
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the C>A substitution and fed Diet E had higher RFI relative to Diet C. Of the four SNPs 
associated with RFI on BTA 17, rs111010038 had significant general association (Table A.1), 
rs41854727 and rs29024448 had breed-dependent associations (Table A.2), and rs41856111 had 
a diet-dependent association (Table A.3). rs29024448 is located within 2 kb of the 5’UTR of the 
RFC5 gene, within two regions previously associated with RFI [10, 45]. For the association 
between rs111010038 and RFI, steers homozygous for the minor allele A have higher efficiency 
than steers AC and CC. In addition to these SNPs, many of the other SNPs associated with RFI 
in our study are located on or close (within 6 Mb) to regions previously reported, including 
rs109500421 on BTA 8 [45], rs41256074 on BTA 11 [10], rs109198879 on BTA 13 [11], 
rs41660789 on BTA 15 [12], rs41856111 on BTA 18 [45], rs43238631 on BTA 20 [45], and 
rs29018901 [45], and rs109863480 [12] on BTA 24. 
Considering only the general association results (Table A.1), the minor allele had a 
favorable additive deviation for many SNPs (negative for RFI and EI, and positive for RADG, 
EG, and RIG). For instance, of the 47 significant associations across the indicators studied, 
almost half (21 associations) had the minor allele associated with higher feed efficiency. The 
association of these SNPs was consistent across indicators. The minor alleles of rs109500421, 
rs41620774, rs108964818, rs110522962, and rs111010038 had positive associations with feed 
efficiency. This result indicates that the alleles associated with higher feed efficiency are not well 
represented in the population. This may have been the result of decades of selection for body 
weight or ADG. 
3.4.4. Haplotype Association Analysis 
The complete list of haplotypes associated with feed efficiency indicators at P-value < 
0.001 is presented in Table A.4 (see Appendix A). The haplotypes associated with feed 
efficiency at P-value < 0.0001 and the contrast between the alleles with most extreme additive 
estimates for each haplotype across indicators are presented in Table 3.9. 
Of the 1,129 haplotypes studied, 32 significant associations with feed efficiency 
indicators were detected, representing 20 unique haplotypes and 81 SNPs. Of these, 36 SNPs are 
located in 22 different gene regions. Haplotype associations were identified on BTAs 1, 2, 5, 6, 
7, 10, 11, 12, 15, 16, 17, 20, and 25, and BTAs 1, 10, 11, 12, and 15 had multiple haplotype 
blocks associated with feed efficiency. 
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The haplotype block 2 (H02, Table A.4), located on BTA 1, included SNPs from three 
different genes, and had a significant general association with RFI. The haplotype is depicted in 
Figure 3.1 and SNPs in this block are in moderate LD ( ̅  = 0.43). The distance between the first 
(rs41635180) and the last (rs41603780) SNPs is of approximately 130 kb, and rs41578805 and 
rs41603780, located approximately 80 kb apart, are in perfect LD (r
2
 = 1). The three genes in this 
block were: microtubule-associated protein 6 domain containing 1 (MAP6D1), presenilin 
associated, rhomboid-like (PARL), and YNL107w, ENL, AF-9, and TFIIF small subunit 
(YEATS) domain containing 2 (YEATS2). This block had two SNPs located upstream of the 
genes, two located within 2 kb 5’ to the genes MAP6D1 and PARL, and one in an intronic region 
of YEATS2 (Figure 3.1). These genes participate on biological processes including histone H3 
acetylation (YEATS2), negative regulation of microtubule depolymerization (MAP6D1), and 
negative regulation of release of cytochrome c from mitochondria (PARL) [48]. The heme 
protein cytochrome c has an essential role in the mitochondrial electron transport chain, 
transferring electrons between Complex III and cytochrome c oxidase [49]. The efficiency of 
mitochondrial respiration may be affected by the availability of cytochrome c in the organelle. 
These results are consistent with previous reports. Low expression of the cytochrome c oxidase 
gene has been linked to more efficient beef cattle [50], and protein abundance is higher in 
efficient steers [51]. 
Among the haplotypes with significant association at P-value < 0.0001 (Table 3.9), H03 
and H011 had diet-dependent associations, H09 and H18 had breed-dependent associations, and 
H16 had a general association with feed efficiency indicators. The latter block was significantly 
associated with EI, and consisted of four SNPs (BTA 15) with an average r
2
 of 0.29. Comparing 
the two alleles with the most extreme additive estimates, higher efficiency is expected for feedlot 
beef cattle carrying the haplotype allele GCCG in place of GTCT. Block H03 located on BTA 2 
had an average r
2
 of 0.66 and was associated with RFI, EI, and RIG. The SNPs in this block are 
located in the intronic region of the F-box protein 42 gene (FBXO42). This gene encodes for F-
box proteins, which interact with other products to act as protein-ubiquitin ligases [52]. In all 
three feed efficiency indicators, feedlot steers carrying the TT haplotype allele and fed diet A had 
higher efficiency than steers carrying the CT allele fed diet C. Block H11 was associated with 
RFI and EI, and is located on BTA 11 approximately 2 Mb to a QTL for RFI [10]. The highest 
and lowest EI were found in feedlot steers receiving diet C carrying the GACTT and GAGTC 
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alleles, for respectively RFI and EI. Also, steers carrying the allele GGGTC and fed diet C had 
lower RFI compared to diet D. The SNPs in this block are in moderate LD ( ̅  = 0.45), and the 
first SNP is located in the region of the sprouty-related, EVH1 domain containing 2 (SPRED2). 
This gene encodes for a protein of the Sprouty/SPRED family of proteins regulates the activation 
of the MAP kinase cascade [53], and SPRED2 participates in the Jak-STAT signalling pathway, 
a signalling mechanism for a variety of cytokines and growth factors in mammals [41]. 
Four of the seven SNPs in H09 located on BTA 10 are in intronic regions of the nidogen-
2 gene (NID2) and one in the intronic region of the DNA helicase homolog PIF1 gene (PIF1). 
This haplotype was in moderate-high LD ( ̅  = 0.62) and had a breed-dependent association with 
RIG. In this block, 3/4AN steers carrying the haplotype allele GCAATGA had higher efficiency 
than purebred SM steers carrying GAAATGA. This haplotype is 131 kb to a QTL peak location 
for RFI previously reported [11]. Located on BTA 17, H18 was associated with RADG and RIG 
in a breed-dependent manner. Four SNPs are presented in this haplotype (Table A.4), with an 
average r
2
 of 0.61, and encompass two genes: Sin3 histone deacetylase corepressor complex 
component SUD3 (SUD3), and serine/threonine-protein kinase TAO3 (TAOK3). The 
serine/threonine-protein kinase TAO3 participates in the MAPK signalling pathway and the JNK 
cascade [41, 48]. For RIG, higher efficiency was observed in purebred AN steers compared to 
3/4SM for the same allele ACTC. For RADG, crossbred ANSM steers carrying the favorable 
allele ACTC had higher feed efficiency than 3/4AN carrying the haplotype allele GTTT. 
3.4.5. Multi-SNP model 
Feed efficiency is costly to measure on an animal basis. Genomic information can be 
used to develop a low-cost steer-side predictor of feed efficiency. Information on SNPs 
significantly associated with feed efficiency indicators was used to develop a predictor of feed 
efficiency in the training data set. The precision of the predictor was assessed on the validation 
data set.  
All SNPs significantly associated at P-value < 0.001 (data not shown) were evaluated in 
the stepwise selection in order to consider SNPs that may have weaker associations when 
considered alone, and stronger associations when considered simultaneously with other SNPs. 
The selected SNPs included in the final models as general or breed/diet-dependent associations 
for each feed efficiency indicator is presented in Table 3.10. The final models for RFI, RADG, 
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RIG, EI, and EG included 20, 19, 13, 17, and 18 SNPs, respectively. A total of 89 SNPs (P-value 
< 0.0001) were fitted across all indicators. Of these, 42 SNPs were previously uncovered in the 
single SNP analysis and the remaining (47 SNPs) represent new associations. These new 
associations represent ten new genes not previously associated in the single SNP analysis. The 
feed efficiency indicators and additional genes are: for RFI, CD3e molecule, epsilon (CD3-TCR 
complex) (CD3E), and CCR4-NOT transcription complex, subunit 6-like (CNOT6L); for RADG, 
ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), and family with sequence 
similarity 135, member B (FAM135B); for RIG, fer-1-like 5 (FER1L5), GTPase activating 
protein (SH3 domain) binding protein 2 (G3BP2), and spectrin, beta, non-erythrocytic 2 
(SPTBN2); for EG, ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 (AGAP1), 
cyclin M2 (CNNM2), glypican 5 (GPC5), glycerol-3-phosphate dehydrogenase 1 (soluble) 
(GPD1), and WDFY family member 4 (WDFY4). 
The SNPs in the multi-SNP model mapped to several genes with known functions that 
could be potentially associated with efficiency. On BTA 8, rs41590616 is located on the intronic 
region of the ATP-binding cassette, sub-family A (ABC1), member 1 gene (ABCA1) and was 
associated with RADG in a breed-dependent manner (Table 3.10). This gene encodes a 
transporter protein in the ABC family. This large family of proteins couple ATP hydrolysis and 
activate the transport of several components, such as sugars, lipids, proteins, and others. In 
addition, this protein plays an important role in fat digestion and absorption, transporting 
phospholipids and cholesterol from small intestinal epithelial cells to the intracellular space, in 
where these substances join apolipoprotein A1, resulting in serum high-density lipoproteins 
(HDL[41]). In addition, rs41568366 (BTA 15) located in the intronic region of the CD3e 
molecule, epsilon (CD3-TCR complex) gene (CD3E), a gene that encodes for a protein that acts 
in immune-response related biological processes, including regulation alpha-beta T cell 
proliferation, interleukin-2 biosynthetic process, and interleukin-4 production[48]. This SNP was 
associated with RFI, and is also part of the H15 that was associated with RFI and RIG. On BTA 
5, rs109880264 is located on the intronic region of the glycerol-3-phosphate dehydrogenase 1 
(soluble) gene (GPD1). This gene has NAD binding molecular function [48] and plays a critical 
role in the glycerophospholipid metabolism pathway [41]. The protein encoded by this gene 
catalyzes the reduction of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P), 
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and simultaneously coverts reduced nicotine adenine dinucleotide (NADH) to nicotinamide 
adenine dinucleotide (NAD
+
[54]). 
3.4.6. SNP and Haplotype Validation 
The SNPs and haplotypes significantly (P-value < 0.0001) associated with feed efficiency 
indicators on the training data set were evaluated in the validation data set. Individual SNP and 
haplotype associations were confirmed in the validation data set at P-value < 0.05. The less 
stringent P-value threshold reflects the limited number of tests that are validated, the stringent 
threshold used in the training data set, and the expected lower false positive rate of validation 
tests. For the multi-SNP models, validation was assessed by the goodness-of-fit of the selected 
SNPs from the training on the validation data set. 
For the single-SNP analysis, the results for the validated SNPs are summarized in Tables 
A.1, A.2, and A.3, for SNPs with general, breed-dependent, and diet-dependent associations, 
respectively. A total of 17 SNPs were validated in the single-SNP analysis, with RFI, RADG, 
RIG, EI, and EG having, respectively, four, one, five, six, and one SNPs validated. These 17 
associations represent 11 unique SNPs and four unique genes. The modest number of steers in 
the validation data set hindered the statistical power to confirm more SNPs. 
The associations of rs109452133 and rs41856111 with feed efficiency were validated. On 
BTA 6, rs109452133 was associated with RFI and EI, and is located within 200 kb of several 
genes, such as the spondin 2, extracellular matrix protein (SPON2), C-terminal binding protein 1 
(CTBP1), macrophage erythroblast attacher (MAEA), KIAA1530 ortholog (KIAA1530), stem-
loop binding protein (SLBP), transmembrane protein 129 (TMEM129), and transforming, acidic 
coiled-coil containing protein 3 (TACC3) genes. On BTA 18, rs41856111 was associated with 
RFI and RIG. This SNP is located 70 kb downstream the v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog (avian) gene (MAF) and approximately 1.5 Mb to a genome 
region previously associated with RFI [45]. Of the other five validated SNPs not mapped to 
genes, four were associated with RIG. Three SNPs had breed-dependent associations 
(rs109195623, rs41662450, and rs109137042), and rs42530614 had diet-dependent association. 
This SNP is located on BTA 1, 99 kb downstream the predicted craniofacial development protein 
2 gene (CFDP1), and steers carrying C alleles had higher efficiency when fed diet C compared 
to diet E. For the other three SNPs that had breed-dependent association with RIG, rs109195623 
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(BTA 3) is located 242 kb upstream the nuclear factor I/A gene (NFIA), rs41662450 (BTA 9) is 
within an uncharacterized loci 8 kb downstream the erythrocyte membrane protein band 4.1-like 
2 gene (EPB41L2), and rs109137042 (BTA 10) is within 200 kb of the secretory carrier 
membrane protein 1 (SCAMP1), lipoma HMGIC fusion partner-like 2 (LHFPL2), and 
arylsulfatase B (ARSB) genes. The association between EG and rs110522962 was also validated. 
This SNP is located on BTA 17, approximately 100 kb upstream the predicted histone chaperone 
anti-silencing function-1 homolog B gene (ASF1B), and feedlot steers carrying the C>T 
substitution had higher EG and thus higher efficiency.  
The SNP that maps to TMEM40 (rs108942504) was validated in five analyses, having a 
general association with RFI and RADG, a breed-dependent association with RFI and EI, and a 
diet-dependent association with EI. The other three gene-mapped validated SNPs were 
rs109053103, rs108964818, and rs42072585 and are harbored in genes bridging integrator 2 
(BIN2), KDELC2, and ceroid-lipofuscinosis, neuronal 3 (CLN3), respectively. These SNPs had 
validated breed-dependent association with EI, general association with RADG, and diet-
dependent association with EI, respectively. Although the SNPs in KDELC2 and CLN3 are 
located in introns, rs109053103 is within 2 kb 5’ of BIN2. CLN3 is located on BTA 25 and 
encodes for a minor lysosomal membrane protein. Steers carrying allele G and receiving diet E 
had lower EI and thus higher efficiency. 
The results of the haplotype analysis validation are provided in Table A.4. A total of 
seven haplotype blocks were validated, with RFI, RADG, RIG, and EI having two, one, three, 
and one blocks confirmed, respectively. These seven haplotype associations encompass 29 
unique SNPs and six unique genes. Two of the seven confirmed haplotypes include SNPs not 
mapped to genes. These are block H06, that has a general association with RADG, and H20, that 
has a diet-dependent association with RIG.  
Validated haplotypes H07 and H09 were associated with multiple indicators. Block H07 had a 
breed-dependent association with RFI and EI and included four SNPs that are in moderate to low 
LD ( ̅  = 0.21), in which three of them map to the intronic region of the myosin IXA gene 
(MYO9A) located on BTA 10. This promising haplotype is also located in a region previously 
associated with RFI [12]. Supporting the previous discussion about these haplotypes, H02 and 
H09 were validated and showed general association with RFI, and breed-dependent association 
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with RADG and RIG, respectively. Six SNPs located in the intronic regions of the protein 
phosphatase 1, regulatory subunit 12A gene (PPP1R12A), and one not mapped to any gene, 
formed H04 located on BTA 5. This gene encodes for a protein that acts in biological processes 
related to motility, such as vascular smooth muscle contraction, focal adhesion, and regulation of 
actin cytoskeleton [48]. This haplotype showed a breed-dependent association with RIG. 
The validation of the multi-SNPs models was assessed by comparing the model fit 
between the training and the validation data sets. The model adequacy indicator used was RMSE. 
Low differences between the RMSE of both models, relative to the largest RMSE (corresponding 
to the validation data set) indicated comparable multi-SNP model adequacy across data sets. The 
relative differences in multi-SNP model prediction are presented in Table 3.10. The set of SNPs 
selected using the training data set fitted and predicted well in the training data set. For RFI, the 
loss in prediction when the training multi-SNP model was applied to the validation data set was 
3.45%. This result indicates that RFI may be well predicted using the set of SNPs presented in 
Table 3.10. Likewise, there was limited loss in prediction accuracy for RADG, RIG, and EI 
amounting to 14.35%, 17.24%, and 17.89%, respectively. The higher loss in model fit for EG 
suggests that other factors not included in the model play an important role in predicting this feed 
efficiency indicator. 
3.4.7. Functional and Gene Network Analyses 
A summary of the results from the functional enrichment analysis is presented in Table 
3.11. Additional details, including the genes enriched for each term, are presented in Table A.5 
(see Appendix A). Overall, 13 molecular functions and six biological processes were enriched 
among the known genes corresponding to the SNPs with significant associations to feed 
efficiency. 
Of the 13 molecular functions, five were overrepresented for the general and breed-by-
SNP associations: channel activity, ion channel activity, nucleotide binding, passive 
transmembrane transporter activity, and substrate specific channel activity. These findings are 
consistent with the characterization of the function considering that the majority of the terms are 
associated with the catalysis of diffusion of substances through the cell membrane [48], a process 
required for the digestion and absorption of nutrients. The three biological processes enriched 
among the SNPs that have breed-dependent associations encompassed general cellular events, 
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and secretion plays an essential role in digestion and absorption of nutrients. Other promising 
molecular functions identified include metalloendopeptidase activity, protein kinase activity, and 
protein serine/threonine kinase activity. 
The network of genes that have protein serine/threonine kinase activity (P-value = 5.2E-
5, FDR-adjusted P-value = 0.074) were further investigated. A comprehensive network was 
generated and is depicted in Figure 3.2. The pink nodes represent the target genes, whereas the 
blue nodes are the intermediate genes generated in the pathway analysis. In addition, the size of 
the nodes of the target genes is inversely proportion to their P-values. The gene with the greatest 
number of edges was the glycogen synthase kinase 3 beta gene (GSK3B). This gene is located on 
BTA 1, and encodes for a serine-threonine kinase protein involved in several metabolic and 
disease- related pathways [41]. Although known for acting on regulation of cell proliferation, 
serine/threonine kinases may also work as regulator of nutrient storage in white adipose tissue 
and skeletal muscle tissue [55]. Consistent with feed efficiency processes, genes encoding for 
proteins with serine/threonine kinase activity regulate rates of glucose uptake, fatty acid synthase 
transcription, and glycogen synthesis [55]. In addition to these molecular functions of the genes 
with diet-by-SNP association, the biological processes of phosphate metabolic process, 
phosphorus metabolic process, and protein amino acid phosphorylation. The functional and 
network analyses were able to provide general roles of the genes acting on feed efficiency. 
Furthermore, these results show that many factors, as result of complex interactions between 
genes, act together in order to define feed efficiency. 
3.4.8. Overall Performance of EI and EG 
The two complementary one-step indicators to assess feed efficiency, EI and EG, were 
responsible for the discovery of 49 unique SNPs (Tables A.1, A.2, and A.3). Many of these 
SNPs were also uncovered by the traditional two-step indicators RFI and RADG. 
The combined number of significant associations (P-value < 0.0001) for EI and RFI was 
63, and for EG and RADG was 37. For EI and RFI, 42 SNPs were simultaneously uncovered in 
these two indicators, whereas the number of overlapped associations between EG and RADG 
was ten. The trend (direction of the estimate) and type of association (general or breed/diet 
dependent) of each of these associations were similar when comparing the results of the one-step 
indicators with their two-step counterparts (EI with RFI, and EG with RADG). In addition, the 
 139 
 
comparable genetic parameters estimated for the pairs EI/RFI and EG/RADG indicate that the 
one-step indicators of feed efficiency account for the same portion of phenotypic and genetic 
variation accounted for the two-step indicators. The benefit in using EI/EG in place of 
RFI/RADG may be better observed comparing the RMSE of the multi-SNP (Table 3.10) and 
null (without SNPs; data not shown) models for these indicators using the training data set. The 
estimated RMSE of the null models for RFI, RADG, EI, and EG, were 0.5820, 0.2492, 0.4731, 
and 0.2420, respectively. In all cases, the RMSE values of the one-step indicators were smaller 
than those for the two-step indicators. Although similar values were observed between EG and 
RADG, the RMSE values of the null and multi-SNP models for RFI were 23% and 38% higher 
than those for EI, respectively. Therefore, the high number of overlapping significant 
associations, the similar genetic parameter estimates, and the comparable (for EG and RADG) 
and favorable RMSE values (for EI over RFI) indicate that the one-step indicators (EI and EG) 
may at least mimic the performance of the two-step indicators (RFI and RADG) in association 
studies for feed efficiency in feedlot beef cattle. 
3.5. Conclusions 
Genomic SNPs and haplotypes associated with feed efficiency indicators in feedlot beef 
steers were identified. General, breed-dependent and diet-dependent associations were 
characterized and validated. These findings support both general and targeted selection 
decisions. Single SNPs and haplotypes showed significant association with all the five feed 
efficiency measures considered. Although many SNPs were associated in a general manner, 
other showed significant associations dependent on the breed of the animals or on the diet 
provided. A multi-SNP panel that can be used to predict feed efficiency was developed. The 
complementary one-step indicators of feed efficiency (EI and EG) had comparable genetic 
variance than traditional two-step indicators (RFI and RADG). The unique and overrepresented 
SNPs, haplotypes, and genes identified for each group of indicators suggest that the one-step 
indicators offer complementary description of feed efficiency that can be exploited for genome-
enabled selection purposes. Functional and network analysis uncovered molecular functions and 
biological processes enriched among the genes associated with feed efficiency. In addition, the 
diet- and breed-dependent genomic associations can be exploited in different production systems.  
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3.7. Figures 
 
Figure 3.1. Graphical representation of haplotype block H02 located on BTA 1 
The allelic variants of H02 are presented as the combination of the five SNPs that form this haplotype. The nitrogenous bases in red 
represent the possible alleles for each SNP whereas those in black are the conserved sequence flanking the SNP. The five alleles for 
H02 are: CCCCG, CCCTG, CTCCG, CTACA, and TCCCG. The position of the SNPs, and the number and length of exons and 
introns within genes were obtained in NCBI according to the Bos_taurus_UMD_3.1 assembly. 
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Figure 3.2. Network of genes associated with feed efficiency that have protein 
serine/threonine kinase activity 
Interaction between the significant genes from the functional analysis of feed efficiency (P-value 
< 0.001). Genes significantly associated with feed efficiency (target genes; P-value < 0.01) are 
represented by pink nodes, whereas those in blue represent intermediate genes. The size of the 
network nodes from the target genes is a function of the P-values from the association analyses, 
in which larger nodes indicate more significant P-values. Target genes with self-edges indicate 
genes with self-regulation activity 
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3.8. Tables 
Table 3.1. Description of the diets 
 Dietary Treatments 
Item A B C D E 
TNE, Mcal/lb 1.40 1.15 1.15 1.15 1.09 
NDF, %  18.5 39.2 41.5 40.1 45.1 
DM, % 66.7 63 65 54 49 
CP, % 13.9 18.8 14.4 17.7 21.4 
ADF, % 7.8 21.9 23.6 22.8 25.6 
TDN, % 75.7 67.5 68 68 66 
Main 
ingredients 
Dry-rolled 
corn and 
stored wet 
distiller grain 
Distiller 
grains with 
solubles and 
fresh wet 
corn gluten 
feed 
Dry-rolled 
corn and corn 
gluten feed 
Fresh wet 
distiller 
grains and 
wet corn 
gluten feed 
Stored wet 
distiller 
grains and 
hay 
TNE, Total net energy; NDF, Non-degradable fiber; DM, Dry matter; CP, Crude protein; ADF, 
Acid detergent fiber; TDN, Total digestible nutrient. 
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Table 3.2. Number (proportion) of steers by breed and diet within data sets 
Training (n = 976)  Validation (n = 336) 
Breed Diet  Breed Diet 
AN 102 (0.10) A 232 (0.24)  AN 35 (0.10) A 83 (0.25) 
3/4AN 115 (0.12) B 300 (0.31)  3/4AN 67 (0.20) B 88 (0.26) 
ANSM 640 (0.66) C 111 (0.11)  ANSM 190 (0.57) C 48 (0.14) 
3/4SM 39 (0.04) D 257 (0.26)  3/4SM 19 (0.06) D 105 (0.31) 
SM 80 (0.08) E 76 (0.08)  SM 25 (0.07) E 25 (0.07) 
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Table 3.3. Number of haplotypes significantly associated
1
 with feed efficiency and genes harboring SNPs by association and 
indicator 
 Type of haplotype association  
Indicator 
General  Breed-dependent  Diet-dependent  Total
2
 
SNPs Genes  SNPs Genes  SNPs Genes  SNPs Genes 
RFI 7 2  10 4  12 2  26 9 
RADG 9 3  9 5  1 1  19 6 
RIG 8 1  20 6  9 2  37 9 
EI 10 3  8 5  16 4  31 10 
EG 13 8  4 2  1 1  18 8 
Total
2
 31 11  40 15  25 6  93 29 
1 
P-value < 0.001; 
2 
Total number of unique SNPs and genes. 
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Table 3.4. Number of haplotypes significantly associated
1
 with feed efficiency and genes harboring SNPs by association and 
indicator 
 Type of haplotype association  
Indicator 
General  Breed-dependent  Diet-dependent  Total
2
 
Haplotypes Genes  Haplotypes Genes  Haplotypes Genes  Haplotypes Genes 
RFI 4 6  2 2  2 2  8 10 
RADG 1 0  4 6  1 0  6 6 
RIG 1 1  6 8  4 4  11 13 
EI 2 2  2 2  3 2  7 6 
EG 0 -  0 -  1 0  1 0 
Total
2
 6 6  10 12  9 4  20 22 
1 
P-value < 0.001; 
2 
Total number of unique haplotypes and genes. 
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Table 3.5. Additive
1
 and dominance estimates of SNPs harboring genes that have general association
2
 with feed efficiency 
Indicator SNP BTA Allele 
Gene 
Symbol Gene Name Additive
3
 Dominance
3
 P-Value 
RFI rs109500421 8 C/T
*
 CNTFR Ciliary neurotrophic factor receptor -0.01±0.05 0.24±0.06 4.54E-05 
 rs108942504 22 A/G
*
 TMEM40 Transmembrane protein 40 0.36±0.10 -0.09±0.11 9.04E-06 
RADG rs108964818 15 C/T
*
 KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 1-
like 
0.35±0.06 0.34±0.06 3.44E-08 
 rs41620774 15 A/C
*
 ELMOD1 ELMO/CED-12 domain containing 1 0.12±0.03 0.13±0.03 5.58E-05 
 rs42342964 23 G
*
/T PAK1IP1 PAK1 interacting protein 1 0.01±0.01 0.05±0.01 9.16E-06 
RIG rs108964818 15 C/T
*
 KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 1-
like 
2.96±0.56 2.83±0.57 7.43E-07 
EI rs109500421 8 C/T
*
 CNTFR Ciliary neurotrophic factor receptor -0.02±0.05 0.23±0.06 5.03E-05 
 rs109709275 15 A/G
*
 GRAMD1B GRAM domain containing 1B 0.05±0.05 -0.18±0.05 6.29E-05 
 rs108942504 22 A/G
*
 TMEM40 Transmembrane protein 40 0.32±0.10 -0.05±0.11 2.29E-05 
EG rs110340232 1 G
*
/T RAB6B RAB6B, member RAS oncogene family 0.01±0.01 0.04±0.01 5.07E-05 
 rs110787048 4 A
*
/G DPP6 Dipeptidyl-peptidase 6 -0.03±0.01 -0.04±0.01 9.32E-05 
 rs110051312 8 A
*
/C PTPN3 Protein tyrosine phosphatase, non-
receptor type 3 
0.04±0.03 0.09±0.03 5.46E-05 
 rs110196238 8 C
*
/T PTPN3 Protein tyrosine phosphatase, non-
receptor type 3 
0.04±0.03 0.09±0.03 5.09E-05 
 rs41611457 12 A/G
*
 ENOX1 Ecto-NOX disulfide-thiol exchanger 1 -0.04±0.01 0.03±0.01 6.70E-05 
 rs108964818 15 C/T
*
 KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 1-
like 
0.37±0.07 0.37±0.07 4.42E-07 
 rs41620774 15 A/C
*
 ELMOD1 ELMO/CED-12 domain containing 1 0.12±0.03 0.15±0.03 2.94E-05 
 rs109889052 19 C/T
*
 PIK3R6 Phosphoinositide-3-kinase, regulatory 
subunit 6 
-0.27±0.07 0.29±0.07 7.79E-05 
1 
Additive estimate relative to the minor allele; 
2 
P-value < 0.0001; 
3 
Estimate±standard error; 
* 
Minor allele. 
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Table 3.6. Additive
1
 estimates of SNPs harboring genes that have breed-dependent association
2
 with feed efficiency 
Indicator SNP BTA Allele 
Gene 
Symbol Gene Name 
Breed
3
 
P-Value AN 3/4 AN AN/SM 3/4 SM 
RFI rs110425294 5 A/G
*
 AVIL Advillin -0.09±0.06 0.09±0.06 0.13±0.05 -0.23±0.08 5.71E-05 
 rs42456314 12 A/G
*
 GPC5 Glypican 5 -0.08±0.07 -0.27±0.07 -0.20±0.06 -0.57±0.08 2.69E-05 
 rs29024448 17 G/T
*
 RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
0.14±0.06 0.31±0.06 0.05±0.05 0.20±0.07 8.32E-06 
 rs108942504 22 A/G
*
 TMEM40 Transmembrane protein 40 0.05±0.13 0.15±0.12 0.17±0.10 0.53±0.13 3.07E-06 
RADG rs109808044 3 A
*
/G SNED1 Sushi, nidogen and EGF-like domains 
1 
-0.04±0.01 -0.08±0.01 -0.01±0.01 -0.03±0.01 2.44E-05 
 rs110742206 3 C/T
*
 CSMD2 CUB and Sushi multiple domains 2 0.11±0.03 0.11±0.03 0.08±0.02 0.23±0.04 1.98E-05 
 rs110690110 5 C
*
/G ERC1 ELKS/RAB6-interacting/CAST family 
member 1 
-0.03±0.01 -0.05±0.01 -0.02±0.01 -0.07±0.01 2.49E-05 
 rs110280556 6 A
*
/G UNC5C Unc-5 homolog C (C. elegans) -0.02±0.01 -0.03±0.01 0.00±0.01 0.05±0.01 6.65E-06 
 rs41583989 24 C
*
/T DTNA Dystrobrevin, alpha -0.07±0.02 0.04±0.02 -0.02±0.01 -0.04±0.02 9.20E-05 
RIG rs110131536 2 A
*
/G IGFBP5 Insulin-like growth factor binding 
protein 5 
0.33±0.14 0.40±0.13 0.47±0.12 -0.69±0.20 2.30E-05 
 rs110280556 6 A
*
/G UNC5C Unc-5 homolog C (C. elegans) -0.13±0.08 -0.11±0.08 0.06±0.06 0.62±0.11 3.88E-05 
 rs41625438 12 C/T
*
 DACH1 Dachshund homolog 1 (Drosophila) 0.06±0.15 0.03±0.15 0.05±0.13 1.08±0.21 8.82E-05 
 rs42456314 12 A/G
*
 GPC5 Glypican 5 0.22±0.10 0.41±0.10 0.36±0.08 0.90±0.12 2.35E-06 
 rs41623603 16 A
*
/C CNST Consortin, connexin sorting protein 0.08±0.10 0.10±0.11 0.19±0.09 -0.36±0.13 5.13E-05 
 rs29024448 17 G
*
/T RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
-0.15±0.09 -0.48±0.09 -0.09±0.07 -0.32±0.11 1.71E-05 
EI rs109053103 5 A
*
/G BIN2 Bridging integrator 2-like 0.28±0.08 0.28±0.08 -0.01±0.06 0.36±0.10 8.57E-05 
 rs42456314 12 A/G
*
 GPC5 Glypican 5 -0.10±0.07 -0.26±0.07 -0.21±0.06 -0.55±0.08 3.13E-05 
 rs29024448 17 G
*
/T RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
0.11±0.06 0.30±0.06 0.07±0.05 0.19±0.07 3.23E-05 
 rs108942504 22 A/G
*
 TMEM40 Transmembrane protein 40 0.05±0.12 0.09±0.11 0.16±0.10 0.48±0.13 8.72E-06 
 rs110206384 X A/G
*
 F8 Coagulation factor VIII, procoagulant 
component 
0.17±0.05 -0.07±0.05 -0.02±0.04 0.01±0.07 5.48E-05 
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Table 3.6 (cont.) 
Indicator SNP BTA Allele 
Gene 
Symbol Gene Name 
Breed
3
 
P-Value AN 3/4 AN AN/SM 3/4 SM 
EG rs110742206 3 C/T
*
 CSMD2 CUB and Sushi multiple domains 2 0.54±0.13 0.46±0.12 0.35±0.11 1.08±0.17 7.31E-05 
 rs42250803 17 A
*
/G SLC7A11 Solute carrier family 7 (anionic amino 
acid transporter light chain, xc- 
system), member 11 
0.06±0.06 -0.06±0.05 0.02±0.04 -0.31±0.06 2.23E-05 
1
 Contrast of the additive estimate between each level of breed and breed SM, relative to the minor allele;  
2 
P-value < 0.0001; 
3 
Estimate±standard error;  
* 
Minor allele. 
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Table 3.7. Additive
1
 estimates of SNPs harboring genes that have diet-dependent association
2
 with feed efficiency 
Indicator SNP BTA Allele 
Gene 
Symbol Gene Name 
Diet
3
 
P-Value A B C D 
RFI rs108942504 22 A/G
*
 TMEM40 transmembrane protein 40 0.27±0.08 0.28±0.08 0.29±0.09 0.22±0.08 1.66E-05 
RADG rs43474365 7 A/G
*
 SLC12A2 solute carrier family 12 
(sodium/potassium/chloride 
transporters), member 2 
0.00±0.01 -0.03±0.01 0.01±0.01 -0.03±0.01 4.11E-05 
RIG rs108942504 22 A/G
*
 TMEM40 transmembrane protein 40 -0.51±0.12 -0.40±0.11 -0.46±0.14 -0.32±0.12 5.80E-05 
EI rs41593945 4 A
*
/C CNPY1 canopy 1 homolog -0.04±0.07 -0.16±0.07 0.22±0.07 -0.02±0.07 4.80E-05 
 rs108942504 22 A/G
*
 TMEM40 transmembrane protein 40 0.21±0.08 0.23±0.07 0.24±0.09 0.18±0.08 8.28E-05 
 rs42072585 25 A/G
*
 CLN3 ceroid-lipofuscinosis, 
neuronal 3 
0.18±0.06 0.21±0.06 0.36±0.06 0.27±0.06 7.02E-05 
EG rs109291606 12 G/T
*
 ENOX1 ecto-NOX disulfide-thiol 
exchanger 1 
0.04±0.01 0.04±0.01 0.04±0.01 0.02±0.01 8.93E-05 
1
 Contrast of the additive estimate between each level of diet and diet E, relative to the minor allele;  
2 
P-value < 0.0001; 
3 
Estimate±standard error;  
* 
Minor allele. 
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Table 3.8. SNPs that have associations with multiple feed efficiency indicators 
SNP BTA Gene Indicator (type of association
1
) 
rs42320097 2 - RFI (d), EI (d) and RIG (d) 
rs110742206 3 CSMD2 RADG (b) and EG (b) 
rs41654149 4 - RFI (g), EI (g) and RIG (g) 
rs109158476 5 - RFI (b) and EI (b) 
rs109452133 6 - RFI (d) and EI (d) 
rs110280556 6 UNC5C RADG (b) and RIG (b) 
rs41663978 6 - RFI (g, d) and EI (g, d) 
rs43453950 6 - RFI (d) and EI (d) 
rs109500421 8 CNTFR RFI (g) and EI (g) 
rs110922588 8 - RFI (g), EI (g) and RIG (g) 
rs42378531 9 - RFI (d) and EI (d) 
rs109945988 11 - RADG (g) and EG (g) 
rs41256074 11 - RFI (d) and EI (d) 
rs42456314 12 GPC5 RFI (b), EI (b) and RIG (b) 
rs110732787 13 - RADG (g) and EG (g) 
rs108964818 15 KDELC2 RADG (g), EG (g) and RIG (g) 
rs41620774 15 ELMOD1 RADG (g) and EG (g) 
rs41660789 15 - RFI (d) and EI (d) 
rs41634631 16 - RFI (g) and EI (g) 
rs110479395 17 - RFI (d) and EI (d) 
rs110522962 17 - EG (g) and RIG (g) 
rs111010038 17 - RFI (g), EI (g) and RIG (g) 
rs29024448 17 RFC5 RFI (b), EI (b) and RIG (b) 
rs41854727 17 - RFI (b), RADG (b) and RIG (b) 
rs41856111 18 - RFI (d) and RIG (d) 
rs43238631 20 - RFI (d) and EI (d) 
rs108942504 22 TMEM40 RFI (g, b, d), EI (g, b, d) and RIG (d)  
rs109863480 24 - RFI (b) and RIG (b) 
rs41619246 29 - EI (d) and RIG (d) 
1
 g, general SNP association; b, breed-by-SNP association; d, diet-by-SNP association. 
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Table 3.9. Contrast between alleles with the minimum and maximum additive estimates of haplotypes associated
1
 with feed 
efficiency 
   Allele
2
   
Indicator Haplotype Association Minimum Maximum Contrast
3
 P-value 
RFI H03 Diet-dependent TT - Diet B CT - Diet C 1.25 (0.25) 2.95E-5 
 H11 Diet-dependent GGGTC - Diet C GGGTC - Diet D 2.76 (1.11) 1.11E-5 
RADG H18 Breed-dependent GTTT - 3/4AN ACTC - ANSM 0.48 (0.15) 6.01E-5 
RIG H03 Diet-dependent CT - Diet C TT - Diet B 1.68 (0.37) 2.24E-5 
 H09 Breed-dependent GAAATGA - SM GCAATGA - 3/4AN 2.97 (1.08) 9.94E-5 
 H18 Breed-dependent ACTC - 3/4SM ACTC - AN 1.51 (0.39) 8.14E-5 
EI H03 Diet-dependent TT - Diet A CT - Diet C 1.53 (0.32) 4.09E-6 
 H11 Diet-dependent GACTT - Diet C GAGTC - Diet C 1.41 (0.52) 5.56E-6 
 H16 General GCCG GTCT 0.45 (0.14) 5.10E-5 
1 
P-value < 0.0001; 
2 
Alleles with extreme additive estimates; 
3 
Contrast of additive estimates between alleles with maximum and minimum estimates (standard error). 
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Table 3.10. SNPs [harboring genes] selected
1
 for the multi-SNP models and goodness-of-fit by indicator 
 SNPs  RMSE
2
 Goodness-of-
fit
3
 Indicator General associations Breed-dependent association Diet-dependent association  T V 
RFI rs109064731 rs108942504 [TMEM40] rs108942504 [TMEM40]  0.4324 0.4479 3.45% 
 rs109551772 rs110576675 rs109116282     
 rs110922588 rs29024448 [RFC5] rs109452133     
 rs111010038 rs41568366 [CD3E] rs41585447     
 rs111012032 rs41659730 rs41660789     
 rs29012628 rs42456314 [GPC5] rs42169106     
 rs41588990 [CNOT6L]  rs42540326     
 rs41654149       
RADG rs108964818 [KDELC2] rs110280556 [UNC5C] rs41627953  0.0587 0.0686 14.35% 
 rs108983714 rs41574319 rs41693645     
 rs109664122 rs41583989 [DTNA] rs42530614     
 rs109945988 rs41590616 [ABCA1] rs43474365 [SLC12A2]     
 rs109957444 [FAM135B] rs41600243      
 rs110732787 rs41854727      
 rs41565199       
 rs41664711       
 rs43557756       
RIG rs108964818 [KDELC2] rs41662450 rs29011654  0.5624 0.6796 17.24% 
 rs109449042 rs41854727 rs41612502     
 rs110007573 [FER1L5] rs42198649 [SPTBN2] rs43687983     
 rs110522962       
 rs29012628       
 rs41591189 [G3BP2]       
 rs41654149       
 rs43557756       
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Table 3.10 (cont.) 
 SNPs  RMSE Goodness-of-
fit Indicator General associations Breed-dependent association Diet-dependent association  T V 
EG rs108964818 [KDELC2] rs109880264 [GPD1] rs110237102  0.0491 0.0741 33.65% 
 rs109945988 rs41650269 rs41611799     
 rs110222344 [WDFY4] rs42250803 [SLC7A11] rs43196644     
 rs110241960 rs42973170 rs43371919 [AGAP1]     
 rs41574883 rs43209887      
 rs41589654 [CNNM2]       
 rs41625303       
 rs41664218       
 rs42457639 [GPC5]       
EI rs109064731 rs108942504 [TMEM40] rs109198879  0.3131 0.3813 17.89% 
 rs109709275 [GRAMD1B] rs110206384 [F8] rs109250591     
 rs110122189 rs110576675 rs42378531     
 rs110922588 rs41659730 rs43453950     
 rs111010038 rs41740922      
 rs41624569 rs42456314 [GPC5]      
 rs42332515       
1 
P-value < 0.0001; 
2 
Root means square error (RMSE) for the training (T) and validation (V) data sets; 
3
 Goodness-of-fit =            ⁄   . 
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Table 3.11. Enriched
1
 functional categories, Gene Ontology (GO) terms, and number of affiliated genes by SNP association 
SNP association Category GO terms Number of genes P-value 
General Molecular Function ion channel activity 18 3.00E-04 
  substrate specific channel activity 18 3.40E-04 
  channel activity 18 4.00E-04 
  passive transmembrane transporter activity 18 4.00E-04 
  nucleotide binding 60 6.40E-04 
Breed-dependent Biological Process ion transport 32 1.90E-04 
  secretion 13 2.70E-04 
  extracellular structure organization 10 3.60E-04 
 Molecular Function ion channel activity 21 5.20E-04 
  substrate specific channel activity 21 6.00E-04 
  passive transmembrane transporter activity 21 7.30E-04 
  channel activity 21 7.30E-04 
  nucleotide binding 76 7.80E-04 
Diet-dependent Biological Process protein amino acid phosphorylation 27 1.80E-04 
  phosphorus metabolic process 33 5.60E-04 
  phosphate metabolic process 33 5.60E-04 
 Molecular Function protein serine/threonine kinase activity 22 5.20E-05 
  protein kinase activity 27 1.90E-04 
  metalloendopeptidase activity 10 6.40E-04 
1 
P-value < 0.001;
 159 
 
CHAPTER 4: BIVARIATE GENOME-WIDE ASSOCIATION ANALYSIS OF THE 
GROWTH AND INTAKE COMPONENTS OF FEED EFFICIENCY 
4.1. Abstract 
A genome-wide association study for the feed efficiency components of average daily gain 
(ADG) and dry matter intake (DMI) was performed on a population of feedlot beef cattle steers. 
Univariate and bivariate analyses of these components adjusted for the maintenance 
requirements of the animals identified single nucleotide polymorphisms (SNP) associated with 
feed efficiency in a training population. The joint consideration of these traits resulted in 11 
significant associations (P-value < 0.0001), whereas eight and nine associations were uncovered 
in the univariate analyses for ADG and DMI, respectively.  Of the 28 associations in this study, 
15 were for SNPs located within gene regions. Borderline significant SNPs (P-value < 0.001) 
were further tested, and a multi-SNP model was developed (P-value < 0.0001). The number of 
selected SNPs for the multi-SNP model the bivariate, and univariate analyses of ADG and DMI, 
was seven, nine, and eight, respectively. The significant SNPs from the genome-wide and multi-
SNP analysis were tested in a validation data set in order to evaluate the replicability of these 
SNPs. Of the six SNPs validated in the genome-wide analyses five are located in three genes: 
KDELC2, PHOX2A, and TMEM40. Compared to the fit in the training set, there was a small 
drop in the model adequacy for all multi-SNP models in the validation set, amounting for 19.4, 
11.68, and 7.21% for the bivariate, and univariate ADG and DMI analyses, respectively. 
Functional analyses further improved the value of the associations. Six Gene Ontology 
categories were (P-value < 0.001) identified for the SNPs associated (P-value < 0.001) in the 
bivariate model. These were all represented by molecular functions related to ion transport 
activity. The bivariate analysis of ADG and DMI helped in the identification of SNP that have 
beneficial associations with both components of feed efficiency and can be used for genome-
enabled improvement of feed efficiency in feedlot beef cattle. 
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4.2. Introduction 
Optimization of feed efficiency in livestock demands the consideration of inputs and 
outputs. In beef cattle feedlot enterprises, feed dominates the input and weight gain dominates 
the output. The cost of feed can represent 62 to 84% of the total costs in a beef cattle production 
unit [1]. In addition, of the total energy intake 70 to 75% is used for maintenance in beef 
production [2]. Thus, the study of feed efficiency requires the consideration of three components; 
dry matter intake (DMI), average daily gain (ADG), and metabolic weight (MBW). Precise 
description of feed efficiency is particularly important in the identification and characterization 
of genomic variants (single nucleotide polymorphisms; SNPs) because most of these variants 
have a small effect on complex phenotypes like feed efficiency.  
Several studies have identified SNP associated with individual components of feed 
efficiency (e.g. ADG, DMI) and with functions of these components including residual feed 
intake (RFI), residual average daily gain (RADG), and residual intake gain (RIG) [3-5].  The 
analysis of individual phenotypes (including direct measurements such as ADG and functions 
thereof such as RFI) could potential hinder the detection and characterization of genomic 
variants associated with feed efficiency for two reasons. First, a genomic variant may have or be 
associated with a quantitative trait locus (QTL) that has pleiotropic effects on the components of 
feed efficiency and the effects may be favorable for one component and unfavorable for another 
component. In this case, the effect of the variant could cancel out when a single function of both 
components is analyzed. Second, a genomic variant may have or be associated with a QTL that 
has a pleiotropic effect on two or more components of feed efficiency and the effects may be 
favorable but low in all components. In this case, analysis of individual phenotypes may have 
limited statistical power and the low associations may not be detected in populations of limited 
size. A multivariate analysis of the components of feed efficiency can address the limitations of 
univariate analyses of feed efficiency indicators. 
Multivariate approaches have been used to detect QTLs associated with production and 
health phenotypes in livestock [6-8]. Multivariate approaches can augment the statistical 
precision to detect loci associated with multiple phenotypes through an increase in the signal 
(phenotype variation correlated by the loci) and reduction in the noise or error [6,7,9-12]. No 
study has applied multivariate models to detect SNPs associated with feed efficiency. The 
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objectives of this study were: 1) to identify and characterize SNPs associated with feed 
efficiency in a feedlot beef cattle population using multivariate and univariate analyses, 2) to 
validate individual and multi-SNP associations identified in a training data set using a validation 
data set, and 3) to interpret the associations using functional genomic and network visualization 
approaches.  An effective approach to identify SNPs that have favorable associations with both 
input (i.e. DMI) and output (i.e. ADG) feed efficiency components while adjusting for 
maintenance (i.e. MBW) is presented. These SNPs have the unique advantage to improve ADG 
while containing or reducing DMI and are well-suited for genome-enabled selection programs to 
improve feed efficiency. 
4.3. Material and Methods 
4.3.1. Ethics Statement 
All procedures were conducted following the guidelines recommended in the Guide for 
the Care and Use of Agricultural Animals in Agricultural Research and Teaching [13] with the 
approval of the University of Illinois Institutional Animal Care and Use Committee. 
4.3.2. Beef Cattle Population 
The GWAS was performed on a beef cattle population including purebred and crossbred 
steers receiving different diets. For this study, 1,321 feedlot steers from five ranches in Montana 
were harvested by groups on different years (from 2005 through 2008). The combination 
between ranches, harvest groups, and harvest years resulted in 27 levels of contemporary group 
(CG). 
The American Simmental Association Herdbook Service [14] was used to access the 
pedigree and breed information of the population. Records of 3,331 steers were used to create the 
relationship matrix and to define the breed composition of each steer. Steers were mainly 
composed by varying degrees of Angus and Simmental breeds, and steers were categorized as: 
purebred Angus (AN), 3/4 Angus (3/4AN), crossbred Angus and Simmental (ANSM), 3/4 
Simmental (3/4SM) and purebred Simmental (SM). 
Steers were fed for an average (±standard deviation) of 165 (±16) days. Each steer 
received one of the twelve diets provided [15]. The diets were further grouped into five dietary 
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treatments according to the main ingredient, total net energy, and non-degradable fiber as shown 
in Table 4.1. A comprehensive description of the diets and harvest procedures may be found 
elsewhere [15]. 
4.3.3. Phenotypes and Measurements 
Two phenotypes were analyzed: ADG and DMI. For each steer, ADG (kg) was 
calculated as the difference between adjusted final weight (FW) and initial weight (IW) in the 
trial divided by days in feed. The FW was estimated by dividing the individual hot carcass 
weight by the average dressing percentage of the harvest group. The GrowSafe automated 
feeding system (GrowSafe Systems Ltd., Airdrie, Alberta, Canada) was used for collection of 
feed intake records. Individual records were used to calculate DMI (kg/day) for each steer. 
Individual mid-test metabolic body weight (MBW; mid-test BW
0.73
) was calculated using 
the estimated body weight of the steer at the middle of the experiment. The age of the steer at 
mid-test (mA; days) was also recorded. The analyses of ADG and DMI included a linear 
adjustment for MBW to account for variation in maintenance requirements and for mA to 
account for differences in age in the population studied. The average (±standard deviation) IW, 
FW, MBW, mA, ADG, and DMI, were 310.10±40.08 kg, 597.50±48.43 kg
0.73
, 366.40±40.12 kg, 
332.58±29.32 days, 1.61±0.24 kg, and 10.48±1.42 kg/day, respectively. 
4.3.4. Genotyping and Quality Control 
Genomic variant were  identified from DNA extracted from blood samples through 
simple saltine-out method [16] using the Illumina® BovineSNP50 BeadChips v1 and v2 
platforms (Illumina Inc., San Diego, CA) that include 54,001 and 54,609 SNPs, respectively. 
Quality control was performed in two steps on the 52,340 SNPs present in both versions of the 
platform analyzed. In the first step, SNPs not assigned to chromosomes, according to the 
Bos_taurus_UMD_3.1 assembly (519 SNPs) [17], and with GenCall scores below 0.2 were 
excluded. GenCall scores below 0.2 generally indicate unreliable genotypes [18], and 16 SNPs 
were excluded based on this criterion. The software PLINK v.1.07 [19] was used to perform the 
second step of the quality control. In this step, SNPs and steers were removed when not meeting, 
in sequence, the following criteria and thresholds: steer missingness per SNP (< 20%; --geno 0.2) 
[20], Hardy-Weinberg equilibrium test (P-value > 0.00001; --hwe 0.00001) [21], SNP 
missingness per steer (< 10%; --mind 0.1) [22], and minor allele frequency (MAF > 5%; --maf 
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0.05) [22]. At the end of the second quality control step, 264 SNPs, 1,202 SNPs, 9 steers, and 
9,811 SNPs were not considered for further analysis using these thresholds, respectively. The 
final data set included 1,312 steers and 40,528 SNPs, with a total genotyping rate of 99.55%. 
4.3.5. Statistical Analyses 
Genome-wide SNP association analyses. Associations between SNP and phenotypes were 
performed through univariate and bivariate mixed models. The univariate model (Equation 4.1; 
Eq. 4.1) used to identify associations between SNPs with ADG and DMI was: 
                          (          ̅̅̅̅̅)    (            ̅̅ ̅̅ ̅̅ ̅̅ )        
        
(Eq. 4.1) 
where Yijklm is the observed ADG or DMI, µ is the overall mean, SNPi is the fixed effect of the 
SNP genotype, Bj is the fixed effect of breed (5 levels), Dk is the fixed effect of diet (5 levels), 
CGl is the random contemporary group effect (27 levels) with normal distribution (0, 
2
CG ), b1 is 
the fixed effect regression coefficient for the covariate mA, b2 is the fixed effect regression 
coefficient for the covariate MBW, aijklm is the random animal polygenic effect with normal 
distribution (0, 2aA ) where A is the additive relationship matrix, and eijklmn is the random normal 
distributed error (0, 2e ). The same explanatory variables from the univariate model were 
included in the bivariate model used to identify SNP simultaneously associated with ADG and 
DMI. The bivariate model (Eq. 4.2) used was: 
[
    
    
]  [
     
     
] [
    
    
]  [
      
      
] [
    
    
]  [
      
      
] [
    
    
]  [
    
    
] 
(Eq. 4.2) 
where YADG and YDMI are the vectors of observed ADG and DMI, respectively; XADG and XDMI are 
the incidence matrices for the fixed effects for ADG and DMI, respectively; bADG and bDMI are 
the vectors of solutions associated with XADG and XDMI, respectively; ZuADG and ZuDMI are the 
incidence matrices for the random contemporary groups for ADG and DMI, respectively; uADG 
and uDMI are the vectors of solutions associated with ZuADG and ZuDMI; respectively, ZaADG and 
ZaDMI are the incidence matrices for the random animal polygenic effects for ADG and DMI, 
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respectively; aADG and aDMI are the vectors of solutions associated with ZaADG and ZaDMI, 
respectively; and eADG and eDMI are the vectors of random errors associated with YADG and YDMI, 
respectively; assuming random effects distributed as multivariate normal having mean equal to 
zero and covariance equal to: 
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where 
ADG
2
a  and DMI
2
a  are the random animal polygenic variance for ADG and DMI, 
respectively; 
DMIADG,a
  is the random animal polygenic covariance between ADG and DMI; A is 
the additive relationship matrix; 
ADG
2
CG  and DMI
2
CG  are the random contemporary group 
variance for ADG and DMI, respectively; I is the identity matrix; 
ADG
2
e  and DMI
2
e  are the 
random error variance for ADG and DMI, respectively; 
DMIADG,e
  is the random error covariance 
between ADG and DMI. 
Associations between SNPs and phenotypes were dimmed significant at unadjusted raw 
P-value < 0.0001. For significant associations of SNPs located on autosomal chromosomes, the 
additive and dominance effects were estimated, whereas for those located on chromosome X 
only the additive effect was estimated. The additive estimates of each SNP were computed 
relative to the minor allele in the population studied. Model assumptions including independence 
of residuals, homogeneity of variance and normality were evaluated. After verification of the 
residuals, all SNP association analyses were performed using Qxpak v.5.05 [23]. 
Multi-SNP model selection. The predictability of the SNPs associated with ADG and DMI in the 
univariate and bivariate analyses was assessed by developing a multi-SNP panel. For ADG, 
DMI, and the bivariate analysis, SNPs were selected on a stepwise manner using the same 
models from the association analyses. The set of SNPs that were significantly associated at P-
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value < 0.001 in the genome-wide SNP association analyses were assessed for entering and 
staying in the multi-SNP model at P-value < 0.0001.  
Validation of the SNP association and multi-SNP analyses. The reliability of the association 
between SNPs and phenotypes in the training data set was evaluated in a validating data set. 
Training and validation data sets were generated from the records that passed the quality control 
based on sire family [24]. Steers from each sire were randomly assigned to either the training set 
(976 steers; 75%) or the validation set (336 steers; 25%), and only 23% of the grandsires were 
represented by steers in both data sets. The number and proportion of steers on each data set, by 
the levels of diet and breed, are presented in Table 4.2. The strategy is to minimize the 
relationship of the animals between data sets because of the potential confounding effect 
between SNP associations and genomic relationships [24,25]. 
The significant associations identified using the training data set were further evaluated in 
order to assess the replicability of the findings. Results were tested on the validation data set 
using the same models used for the individual SNP and multi-SNP analyses. Each significant 
associated SNP (P-value < 0.0001) was individually tested and considered validated at P-value < 
0.05 [24]. In addition, the trend (sign) of the genetic estimates was compared between the two 
independent data sets. For the multi-SNP models, the goodness-of-fit was measured as the 
change in the model adequacy (MA) using the training data set relative to the validation data set. 
For the univariate analyses of ADG and DMI, the estimated root mean square error (RMSE) 
indicates the inadequacy of the model to describe the phenotype explained by the model 
including SNPs. The MA for the univariate analyses of ADG and DMI (Eq. 4.3) was calculated, 
for each phenotype, as: 
   (
           
     
)       
(Eq. 4.3) 
where RMSEV is the RMSE from the validation data set and RSMET is the RMSE from the 
training data set. For the bivariate analysis, the failure of the model was determined by the 
average of the three root mean (co)variance terms: RMSE for ADG and for DMI, and the root 
means square covariance (RMSC) between ADG and DMI. The MA for the bivariate analysis of 
ADG and DMI (Eq. 4.4) was calculated as:  
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(Eq. 4.4) 
where MAADG is the MA calculated using the RMSE of ADG, MADMI is the MA using the RMSE 
of DMI, and MAADG,DMI is the MA using the RMSC between ADG and DMI in place of the 
RMSE. These three MAs were calculated as in Eq. 4.3, considering the details just given. 
Linkage disequilibrium. Due to the average probe spacing of 49.4 kb of the platform [26] used 
in the study and to the large number of SNPs being tested, some of the significant associations 
may be an artifact of the dependency between SNPs in high LD. Therefore, the pairwise LD was 
calculated for significant SNP pairs within 500 kb using the r
2
 statistics [27] in PLINK in order 
to identify SNPs with statistical dependencies. This distance was used due to the LD extent in 
cattle [28,29]. 
Genetic parameters. Genetic and phenotypic correlations, and heritability estimates were 
obtained using bivariate analyses. The genetic parameters of ADG and DMI were analyzed using 
the model described in Eq. 4.4. The software package WOMBAT was used to estimate the 
variance components of these phenotypes [30]. 
Functional and gene network analysis. The SNPs detected were mapped to genes when located 
within the genes or in proximal intergenic regions (within 2 kb of the 5' untranslated region or 
0.5 kb of the 3' untranslated region of a gene). The location of the SNPs was obtained from the 
National Center for Biotechnology Information SNP database [31]. 
Functional analysis of the genes corresponding to the SNPs associated (P-value < 0.01) in 
the bivariate GWAS was undertaken. The consideration of genes from the bivariate analysis only 
was due to the interest in identifying functional categories associated with genes that may have 
pleiotropic effects. In addition, genes farther upstream and downstream from the detected SNPs 
were not included in the functional analysis because the number of spurious genes added to the 
functional analysis would have overwhelmed the fewer potential true loci, thus biasing the 
results. The enrichment of Gene Ontology (GO) FAT categories and KEGG pathways among the 
genes was investigated in DAVID using Fisher’s Exact test [32]. GO FAT categories are a subset 
of the broadest GO terms, in which are filtered so that they do not overshadow the more specific 
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terms. Functional annotation charts were considered significant at P-value < 0.001 using Bos 
taurus as the genome background. 
The list of genes corresponding to enriched functional categories was used to create gene 
networks associated with feed efficiency. For visualization of the network, the Cytoscape 
software [33] and BisoGenet plug-in [34] were used, using the default options. Target genes 
identified in this study are represented by pink nodes, while intermediate genes from databases 
are represented by blue nodes. Red edges correspond to relations between target and intermediate 
genes, whereas golden edges represent those between two intermediate genes. The final pathway 
included target genes separated by at most two intermediate genes. The size of the target gene 
nodes is a function of the P-values from the association analyses. Larger nodes indicate more 
significant P-values, while the size of the intermediate gene nodes is constant. 
4.4. Results and Discussion 
4.4.1. General Results 
The GWAS identified and characterized genomic variants associated with ADG, DMI or 
both phenotypes in feedlot beef steers. Among these, the SNPs associated with either ADG or 
DMI that do not have an association with the other phenotype, or even favorably associated with 
both phenotypes (higher ADG and lower DMI), can be used in effective genome-enabled 
improvement of feed efficiency.  
The heritability estimates of ADG, DMI, and MBW, were 0.14, 0.25, and 0.44, 
respectively. The genetic correlation between ADG and DMI, ADG and MBW, and DMI and 
MBW were 0.18, 0.69, and 0.38, respectively. In addition, the phenotypic correlations between 
these traits were 0.52, 0.52, and 0.56, respectively. These results are consistent with the moderate 
to high phenotypic correlations between these traits reported by others, although the genetic 
correlations in this study showed lower results compared to the same studies [35,36]. The 
heritability estimates confirm that there is opportunity for genomic improvement of these traits 
and the genetic correlation estimate indicates that selection for higher ADG would result in 
bigger animals with higher MBW, and higher DMI, whereas selection for lower DMI would 
result in smaller animals that have lower ADG. Our results also confirm the importance of 
accounting for MBW when doing GWAS for ADG and DMI. A tri-variate GWAS of DMI, 
ADG, and MBW was not undertaken because the multicollinearity between MBW and ADG 
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could have lower the precision to detect SNPs associated with DMI and biased the findings 
towards SNPs associated with the body weight phenotypes ADG and MBW.  
A summary of the total number of unique significant SNPs and corresponding genes 
detected by the univariate and bivariate GWAS that were associated with ADG and DMI is 
presented in Table 4.3. The total number of SNP associations (P-value < 0.0001) was 28, 
including 19 and nine unique SNPs and genes not overlapping between phenotypes, respectively. 
The highest number of associations was observed in the bivariate analysis of ADG and DMI, 
which resulted in 11 SNPs significantly associations with these phenotypes, followed by the 
univariate analyses for DMI and ADG, with nine and eight associations, respectively. This result 
confirms our hypothesis that the bivariate GWAS offered increased precision to detect SNPs 
based on the genetic correlation between the phenotypes. 
The number of significant SNP associated with ADG (eight, Table 4.3) found in this 
study was similar to others previously reported in composite beef cattle populations using the 
same SNP platform and threshold (11 [37] and seven [24] associations). As for DMI, the number 
of SNP detected (nine, Table 4.3) was comparable with one study (eight associations [24]) and 
less than the other (22 associations [37]) study. 
Associations were identified on 10 chromosomes (Tables 4.4 and 4.5): BTAs 2, 4, 6, 13, 
14, 15, 17, 22, 23, and 26. The highest number (10 SNPs) was identified on BTA 15. This 
number represented approximately 36% of the associations and accounted for six SNPs located 
in four genes. The second highest number of SNPs was observed on BTAs 13 and 17, with three, 
while one association was found on BTAs 4 and 23, both with ADG. These SNP associations are 
described in the following sections. 
4.4.2. Genome-wide SNP association analysis 
Univariate analysis of ADG and DMI. The SNP significantly associated with ADG and DMI 
and corresponding genes are presented in Table 4.4. Interestingly, none of the 17 SNPs detected 
in the univariate analyses was associated with both phenotypes although the genetic correlation 
between these traits was moderate. These 17 SNPs are located within nine genes, six for ADG 
and three for DMI. 
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Previous reports indicate genomic regions associated with ADG in cattle on BTAs 2, 4-7, 
9, 11, 14-20, 22, 23, 26, and 28 [38-52]. All SNPs associated with ADG in the current study 
(Table 4.4) are located on BTAs previously reported for ADG, with the exception of rs41629972 
located on BTA 13. This SNP is located approximately 33 kb upstream the Kruppel-like factor 6 
gene (KLF6). The zinc finger protein encoded by this gene acts on several cell activities and to 
has been associated with many genes [53], as the transforming growth factor β1 (TGFβ1), a gene 
related to muscle growth and development [54]. Feedlot steers homozygous for the minor allele 
T had approximately 80g higher ADG than steers homozygous for the C allele. The other SNP 
associated with ADG not mapped within a gene was rs41565199. Located on BTA 14, this SNP 
is approximately 464 kb downstream of the zinc fingers and homeoboxes 2 gene (ZHX2), within 
a QTL region previously associated with ADG in the Japanese Black (Wagyu) cattle [47]. 
Homozygous CC steers had higher ADG than CT and TT steers. 
The remaining seven SNPs associated with ADG are located within genes. Feedlot steers 
presented higher gain when heterozygous for rs109934193 and rs110787048, on BTAs 2 and 4, 
respectively. These SNPs are located within the NCK-associated protein 5 (NCKAP5) and 
dipeptidyl-peptidase 6 (DPP6) genes, respectively. On BTA 15, three SNPs located within genes 
were associated with ADG: rs41620774 (engulfment and cell motility/CED-12 domain 
containing 1; ELMOD1), rs108964818 (Lys-Asp-Glu-Leu containing 2; KDELC2), and 
rs41768978 (paired-like homeobox 2a; PHOX2A). Both rs41620774 and rs108964818 are less 
than 1 Mb apart, and for both SNPs, feedlot steers homozygous for the minor allele (CC and TT, 
respectively) had lower ADG. In addition, rs108964818 had the most extreme additive estimate 
for ADG, with -0.40±0.09 (kg). The protein encoded by ELMOD1 has been reported to act as 
GTPase-activators of the small G proteins of the arf family [55], known for their central role in 
the organization of the secretory and endocytic pathways [56]. As for rs41768978, this SNP is 
approximately 4 Mb to QTL for ADG previously reported [45], and heterozygous feedlot steers 
(AC) had an ADG of 60 g higher than the average. This SNP is located in the intronic region of 
PHOX2A, a gene that acts on the autonomic nervous system development [57]. The last SNP 
associated with ADG in the rs42342964 (BTA 23), located within the PAK1 interacting protein 1 
gene (PAK1IP1). This gene encodes the p21-activated protein kinase-interacting protein 1, an 
enzyme with negative regulation of signal transduction [57]. 
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Previous reports indicate genomic regions associated with DMI in cattle on all BTAs, 
except 19, 27-29, and X [3,45,48,50,51,58-60]. All SNPs associated with DMI in the current 
study (Table 4.4) are located on BTAs previously identified, with the exception of rs108942504 
and rs41624569, on BTAs 22 and 26, respectively. The latter SNP is located within 500 kb of 
several genes: ATPase family, AAA domain containing 1 (ATAD1), lipase, family member J 
(LIPJ), 3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2), phosphatase and tensin 
homolog (PTEN), and renalase, FAD-dependent amine oxidase (RNLS). These genes play roles 
in mechanisms related to energy expenditure, with ATAD1 acting on ATP catabolism [57], LIPJ 
on lipid catabolism [57], and PTEN on inositol phosphate metabolism [61]. Heterozygous steers 
for this SNP (AG) had lower DMI (approximately 275 g/day) than GG steers. 
In addition to rs41624569, four other SNPs not mapped to genes were associated DMI. 
Steers homozygous for rs41663978 C>A (BTA 6) had lower DMI. This SNP is approximately 5 
Mb from a QTL previously associated with DMI [45], and is located within 500 kb of the 
ADAM metallopeptidase with thrombospondin type 1 motif, 3 (ADAMTS3), group-specific 
component vitamin D binding protein (DBP), and neuropeptide FF receptor 2 (NPFFR2) genes. 
These genes act on protein processing [57], the peroxisome pathway [61], and the neuroactive 
ligand-receptor interaction pathways [61], respectively. On BTA 13, rs41632270 is located on a 
QTL region for DMI [60] and within 500 kb of several genes: kinesin family member 16B 
(KIF16B), N-acetylneuraminic acid phosphatase (NANP), otoraplin (OTOR), 
phosphoribosylaminoimidazole carboxylase pseudogene (PAICSP), and small nuclear 
ribonucleoprotein polypeptide B (SNRPB2). NANP acts on the amino sugar and nucleotide sugar 
metabolism, and lower DMI was observed in feedlot steers heterozygous for rs41632270. 
Heterozygous steers also had lower DMI for rs111010038 (BTA 17). The highest dominance 
estimate for DMI was observed in this SNP, with AC steers having approximately 500 g/day 
lower DMI than AA steers. 
The last SNP not mapped to genes that was associated with DMI was rs42128656, on 
BTA 15. This SNP is located approximately 600 kb to the other two SNPs associated with DMI 
on this chromosome: rs43291568 and rs43291603. Although this pair of SNPs are located within 
approximately 27 kb, these two SNPs showed low LD (r
2
 = 0.052), and thus, the associations 
were considered independent from each other. These two SNPs are in the intronic region of the 
coxsackie virus and adenovirus receptor-like membrane protein gene (CLMP). This gene 
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encodes for a type I transmembrane proteins of the CTX family [62] and steers heterozygous for 
both SNPs had lower DMI. Also rs108942504 on BTA 22was associated with DMI and maps to 
a gene that encodes a structural protein, the transmembrane protein 40 gene (TMEM40). Steers 
that have the minor allele G also have higher DMI. The last association between DMI and SNP 
within gene was for rs41588990 on BTA 6. This SNP is in the intronic region of CCR4-NOT 
transcription complex, subunit 6-like (CNOT6), a gene with a role in the deadenylation of 
mRNAs in the cytoplasm [63]. For this SNP, higher DMI was observed in heterozygous steers, 
whereas homozygous AA or GG steers had similar DMI. The results of the univariate analysis of 
ADG and DMI provide SNPs that are associated with ADG or DMI controlling for the MBW of 
feedlot beef steers. 
The results from the univariate GWAS offer a first glimpse of potential SNPs that can be 
used for feed efficiency. However, these analyses do not ensure that the genotypes and alleles 
may have a favorable association with one phenotype do not have an unfavorable association 
with the other phenotype. Limited data size, limited disequilibrium between the SNP and the 
QTL or low QTL effect may have prevented the identification of the same SNP associated with 
both phenotypes. The simultaneous analysis of both phenotypes in a bivariate GWAS is expected 
to shed light on these possible scenarios. 
Bivariate analysis of ADG and DMI. The SNPs simultaneously associated with ADG and DMI 
(P-value < 0.0001) are presented in Table 4.5. Many of these SNPs that have or are associated 
with QTLs that have a pleiotropic effect were also found in either univariate analyses. The SNPs 
that showed associations in both univariate and bivariate analyses are presented in Table 4.6. Of 
the 11 associations found in the bivariate model (Table 4.5), nine were also observed in the 
univariate analyses (Table 4.6). Four SNPs were associated with univariate ADG and the 
bivariate model, whereas the remaining five were for univariate DMI and the bivariate model. 
The two new associations not previously identified in the univariate analyses were for 
rs41722387 and rs110522962, both not mapped to genes. The bivariate analyses gained precision 
to detect these SNPs, relative to the univariate analyses, through the consideration of the 
substantial (positive or negative) covariation (SNP and/or residual) between ADG and DMI. The 
detection of SNPs by the bivariate analysis that were not detected by both univariate analyses 
emphasize the need for multivariate GWAS to precisely identify and characterize SNPs 
associated with feed efficiency.  
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A SNP of potentially important value for genome-aided improvement of feed efficiency 
was uncovered by the bivariate GWAS. On BTA 14, rs41722387 is located approximately 450 
kb to rs41565199, a SNP previously associated with ADG (Table 4.4). Although physically 
close, these SNPs are in low linkage disequilibrium (r
2
 = 0.046), indicating a high evidence of 
recombination, and thus, independence from each other. This SNP is located in the pseudo 
metalloendopeptidase gene (OMA1) and approximately 400 kb upstream to the hyaluronan 
synthase 2 gene (HAS2). The bivariate analyses uncovered that this SNP has valuable association 
with the feed efficiency components. The negative additive estimate of the minor allele G, 
indicate that homozygous GG steers had lower DMI and ADG. On the other hand, the difference 
in the dominance estimates for these two phenotypes indicates that lower feed efficiency was 
observed in heterozygous steers. Although GT steers showed higher ADG (-10 g) compared to 
GG (-40 g), they showed a much higher DMI (140 g/day) than the GG (-40 g/day). Heterozygous 
steers for this SNP showed decline in feed efficiency, and thus, homozygous steers for this SNP 
are indicated for feedlot systems. 
The other SNP detected by the bivariate analysis that was not identified by the univariate 
ADG or DMI analyses was rs110522962. Located on BTA 17, this SNP is approximately 4 Mb 
to a QTL region for ADG previously reported [48]. This SNP was associated with feed 
efficiency due to the difference in the trend of the genetic estimates for ADG and DMI. While 
genotype TT was associated with higher ADG (80 g), it was also associated with and lower DMI 
(-470 g/day). Therefore, feedlot steers homozygous for rs110522962 C>T had higher feed 
efficiency than those with genotypes CT or TT. The bivariate analyses gained precision to detect 
these SNPs, relative to the univariate analyses, through the consideration of the substantial (and 
negative) covariation (SNP and/or residual) between ADG and DMI. 
Of the other nine SNPs associated with both phenotypes, three showed differences in the 
direction (trend) of the genetic estimates for ADG and DMI. These three SNPs were also 
associated with DMI in the univariate analyses, and are: rs42128656 (BTA 15), rs111010038 
(BTA 17), and rs108942504 (BTA 22). The bivariate analysis identified additional potentially 
SNPs with favorable association with both ADG and DMI. Although the additive estimates of 
rs42128656 for ADG and DMI have the same trend (or sign), the opposite trend of the 
dominance estimates indicate that feedlot steers heterozygous for this SNP have higher ADG (30 
g) and lower DMI (-190 g/day) than homozygous steers.  
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The bivariate analysis also uncovered that rs111010038 has potential value in improving 
feed efficiency. This SNP has opposite additive estimates for ADG and DMI, and the difference 
in the magnitude of the dominance estimates indicate that heterozygous steers had higher feed 
efficiency (i.e. higher ADG and lower DMI) than homozygous steers. The minor allele A was 
associated with lower ADG and higher DMI, and feedlot steers AC had higher efficiency, due to 
higher ADG (12 g) and lower DMI (-480 g/day) genetic estimates. Although the genetic 
estimates for CC steers were similar for ADG (13 g), these steers showed estimates slightly 
higher for DMI (-340 g/day). For rs108942504, located within TMEM40, AA steers had higher 
efficiency because they had slightly higher ADG (20 g) and lower DMI (-370 g/day) relative to 
the other genotypes. 
Six additional SNPs were detected by the bivariate analyses and had similar trends for 
both phenotypes. Positive associations of the same allele with both feed efficiency component 
are undesirable because an increase in ADG would be associated with an increase in DMI. The 
bivariate analyses gained precision to detect these SNPs, relative to the univariate analyses, 
through the consideration of the substantial (and positive) covariation (SNP and/or residual) 
between ADG and DMI.  
The SNP associations were carefully investigated to measure the degree in which ADG 
and DMI vary according the polymorphism. For example, the genetic estimates for ADG and 
DMI have the same trend for rs108964818 (KDELC2), although with a much higher additive 
estimate for ADG than DMI. While genotype CC was associated with higher ADG (400 g), it 
was also associated with higher DMI, at a much small degree (20 g/day). Therefore, this SNP 
showed association with feed efficiency. All significant associations identified in the univariate 
and bivariate analyses (Table 4.6) were detected at a less stringent threshold (P-value < 0.01; 
data not shown) with the univariate analyses of the other phenotype. For example, rs109934193, 
rs41629972, rs108964818, and rs41768978 were detected in the univariate ADG and bivariate 
analyses and were also associated (P-value < 0.01) with DMI in the univariate analysis. This 
scenario also observed for SNPs detected in the univariate DMI and bivariate analyses and 
associated with ADG in univariate analysis at a less significant P-value. The bivariate analysis of 
ADG and DMI supported the identification of SNPs that were borderline associated with ADG 
or DMI in the univariate analyses. 
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SNPs associated with feed efficiency components. The previous sections focused on SNPs 
detected by the bivariate analysis, some of which were also detected by either univariate 
analyses. In addition, a few SNPs were detected by either univariate analysis: rs110787048, 
rs41565199, rs41620774, and rs42342964 for ADG, and rs41663978, rs41588990, rs41632270, 
and rs43291603 for DMI. Of these, most SNPs were associated with the other phenotypes at 0.01 
< P-value < 0.05. The exceptions were 41565199 and rs42342964, associated with DMI at P-
value > 0.05. The univariate association of these SNPs could help improve feed efficiency 
because improvements in one phenotype, holding the other phenotype constant could lead to 
overall improvements in efficiency. These SNPs are worth considering provided the lack of 
significant association in the other univariate analyses is due to true to low association and not to 
limited information of the data to detect the association. 
4.4.3. Multi-SNP model 
The polygenic nature of quantitative traits as ADG and DMI can be exploited in beef 
cattle by the use of simultaneous informative SNPs significantly associated with these 
phenotypes. The development of a multi-SNP panel that can account for substantial variation in 
these phenotypes may be used to predict feed efficiency or in genome-enabled selection 
programs to improve feed efficiency. 
The multi-SNP model was developed by selecting SNPs through a stepwise method, 
including all the other explanatory variables in the model (Eq. 4.1). In order to consider SNPs 
that may have weaker associations when considered alone, and stronger associations when 
considered simultaneously with other SNPs, selection was performed using all SNPs 
significantly associated at P-value < 0.001 (data not shown). For ADG, DMI, and the bivariate 
models, the number of SNPs evaluated through the stepwise selection was 53, 58, and 84, 
respectively (Table 4.3). The final multi-SNP models for these analyses included nine, eight, and 
seven SNPs, respectively (P-value < 0.0001; Table 4.7). These associations included 21 and 10 
unique SNPs and genes, respectively. Of these, 11 associations were previously uncovered in the 
single SNP analyses, and 13 are new associations not found in our previous analyses 
representing three genes: family with sequence similarity 135, member B (FAM135B) and TatD 
DNase domain containing 1 (TATDN1) for ADG, and GRAM domain containing 1B 
(GRAMD1B) for the bivariate model. 
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The newly detected SNPs not mapped to genes are located on BTAs 2, 7, 11, 13, 20, 22, 
and 29. On BTA 2, rs108939474 was associated with ADG and is within 500 kb of the heparan 
sulfate 6-O-sulfotransferase 1 (HS6ST1), UDP-glucose glycoprotein glucosyltransferase 1 
(UGGT1), and Sin3A-associated protein, 130kDa (SAP130) genes, known for their roles on 
glycosaminoglycan biosynthesis pathway [61], protein processing in endoplasmic reticulum 
pathway [61], and histone H3 acetylation [57], respectively. Also associated with ADG, 
rs42433916 is located on BTA 7 approximately 160 kb downstream to the zinc finger protein 
608 (ZNF608), and rs109945988 is located on BTA 11 close (approximately 4 Mb) to a QTL for 
ADG previously reported [48], and within 500 kb of the genes baculoviral IAP repeat containing 
6 (BIRC6), latent transforming growth factor beta binding protein 1 (LTBP1), RAS guanyl 
releasing protein 3 (calcium and DAG-regulated, RASGRP3), and tetratricopeptide repeat 
domain 27 (TTC27). 
Of the new SNPs not mapped to genes identified in the multi-SNP model of DMI, 
rs41577108 and rs41629972 are located on BTA 13. While the latter was previously associated 
with DMI in the univariate analysis, rs41577108 is within the genes CUGBP, Elav-like family 
member 2 (CELF2), enoyl CoA hydratase domain containing 3 (ECHDC3), and USP6 N-
terminal like (USP6NL). The other two new SNPs associated with DMI were for rs41577655 and 
rs110911295. The former is located on BTA 15 less than 250 kb upstream the apoptosis inhibitor 
5 (API5) and tetratricopeptide repeat domain 17 (TTC17) genes, while the latter is located on 
BTA 20, within 500 kb upstream the PAP associated domain containing 7 (PAPD7) and steroid-
5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1; 
SRD5A1) genes, and downstream the mediator complex subunit 10 (MED10) and NOP2/Sun 
domain family, member 2 (NSUN2) genes. 
The multi-SNP model selection for the bivariate analysis of ADG and DMI resulted in 
three SNPs not mapped to genes not previously associated with the bivariate model. The variant 
rs109945988 had also been associated in the multi-SNP ADG model, and rs41600811 and 
rs42459305 represent new associations. Located on BTA 22, rs41600811 is 100 kb downstream 
the cell adhesion molecule with homology to L1CAM (close homolog of L1; CHL1) gene, 
whereas rs42459305 is located on a highly dense region of BTA 29 with several predicted loci 
and located less than 3 kb downstream the olfactory receptor, family 8, subfamily G, member 5 
(OR8G5) gene. 
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4.4.4. Validation of the SNP association and multi-SNP analyses 
The SNP associations identified in the univariate and bivariate analyses of ADG and 
DMI on the training data set were evaluated in the validation data set. Individual SNP 
associations were confirmed when significant at P-value < 0.05 in the validation data set. A less 
stringent threshold (P-value < 0.05) was used because of the two phase approach (SNPs have 
already been detected once in the training data set at a P-value < 0.0001 threshold) and the 
limited number of SNPs being validated. Since a more stringent threshold (P-value < 0.0001) 
was used in the training data set, a lower false positive rate is expected when using the validation 
data set. For the multi-SNP models, validation was assessed by the indicator of model adequacy 
of the selected SNPs on the validation data set relative to the training data set. 
A total of six SNP associations were validated for the single SNP univariate (Table 4.4) 
and bivariate (Table 4.5) analyses of ADG and DMI. These associations represent five SNPs and 
three genes. Three significant associations (P-value < 0.05) were identified in the bivariate 
model, and the number of associations validated in the univariate analyses of ADG and DMI 
were two and one, respectively. 
From the univariate analysis of DMI, rs108942504, located in the intronic region of 
TMEM40 was validated. This SNP was also borderline significant (P-value = 0.0932) in the 
validation bivariate analysis. The favorable polymorphism G>A was associated with lower 
genetic estimate for DMI (-310 g/day). The univariate analysis of ADG validated rs41629972 
and rs108964818. The former SNP is not assigned to genes and higher ADG genetic estimates 
were associated in feedlot steers with the TT genotype. From the bivariate analyses, 
rs108964818 was validated. This SNP is located in the intronic region of KDELC2 and had the 
same trend for ADG and DMI (Table 4.5). Steers that CC for rs108964818 had higher ADG and 
slightly higher DMI compared to TT steers. From the bivariate analysis, rs41768978 located in 
the intronic region of PHOX2A was validated. The similar trend of the SNP estimates for ADG 
and DMI, combined to the high estimates for DMI, indicate that consideration of this SNP and 
associated QTL may not lead to effective improvement of feed efficiency. Also, from the 
bivariate analyses, rs41768978 located in the intronic region of PHOX2A was validated. With 
higher ADG (80 g) and lower DMI (-470 g/day) genetic estimates, feedlot steers homozygous for 
rs41768978 C>T indicate that this SNP may be associated with feed efficiency. The validation of 
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these SNPs associated with both phenotypes indicates that the join consideration of feed intake 
components in SNP association analysis provides valuable information regarding the genomic 
architecture of feed efficiency in beef cattle. 
The indicators used to assess model adequacy (MA) in the validation data set relative to 
the training data set were RMSE (univariate and bivariate analyses) and RMSC (bivariate 
analysis). The low differences between the indicators of both models indicated comparable 
multi-SNP model adequacy across data sets. The relative adequacy of the univariate and 
bivariate multi-SNP models are presented in Table 4.7. 
Overall, the MA in the small validation data set was comparable to that in the larger 
training data set used to detect the SNPs. This result confirms that the SNPs detected have a high 
likelihood to be replicable in additional populations.  For example, the validation data set only 
had a relative increase of 11.67% in the RMSE compared to the training data set in the multi-
SNP univariate ADG analysis. Likewise, there was limited loss in MA for DMI, amounting to 
7.21%. For the bivariate analysis, the MA in the validation data set decreased only 19.40%. The 
higher loss in MA for the bivariate multi-SNP analysis may be due the higher parameterization 
of the model and lower precision of each estimate relative to univariate models. 
4.4.5. Functional and gene network analyses 
The 236 genes from SNPs simultaneously associated (P-value < 0.01; Table 4.3) with 
ADG and DMI in the bivariate model were used for functional analysis. A less significant P-
value threshold was used to select the SNPs and identify the genes for functional analysis 
because the comparison of univariate and bivariate results demonstrated that several borderline 
SNPs (0.0001 < P-value < 0.01) in the former analysis were also significant at a lower level in 
the latter analyses. The results are presented in Table 4.8. The seven molecular functions 
enriched (P-value < 0.001) are listed in Table 4.8. No biological processes or pathways were 
enriched. 
A total of 10 genes were represented across the molecular functions enriched. The most 
significant GO terms, cation channel activity (GO:0005261; P-value = 6.0E-5; FDR-adjusted P-
value = 7.6E-2) and metal ion transmembrane transporter activity (GO:0046873) encompassed 
these 10 genes. Present only in these two GO terms is the transient receptor potential channel 2 
gene (TRPC2). This gene was represented by rs41603221 (BTA 15) in the results, and this SNP 
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was significantly associated (P-value = 0.0006) in the bivariate analysis of ADG and DMI. This 
SNP is located approximately 4 Mb to a QTL for ADG previously reported [45], and the TRPC2 
gene is associated with several behavioral responses and channel activities in the cell [57]. 
Therefore, this gene may have important role in the cellular ion transport mechanisms. 
Three other genes were not present in all seven functional categories, and these are: 
calcium channel, voltage-dependent, beta 2 subunit (CACNB2) on BTA 13 (rs41628259), 
potassium channel, subfamily K, member 9 (NCNK9) on BTA 14 (rs111005924), and basic 
fibroblast growth factor 2 (FGF2) on BTA 17 (rs41609100). In addition to the two previous GO 
terms, CACNB2 and FGF2 were also associated with the molecular functions of voltage-gated 
ion channel activity (GO:0005244) and voltage-gated channel activity (GO:0022832), whereas 
NCNK9 was also with potassium channel activity (GO:0005267), voltage-gated cation channel 
activity (GO:0022843), and potassium ion transport (GO:0006813). Encoding for a protein of the 
fibroblast growth factor family, FGF2 acts on several biological processes related to cell 
differentiation and growth [57], and on signaling pathways including the MAPK and PI3K-Akt 
[61]. This gene is located on BTA 17 within two QTL regions for ADG previously reported 
[45,48]. In addition to CACNB2 and NCNK9, the other six genes with enriched molecular 
functions have general ion channel activity. These genes were present in all seven molecular 
functions enriched, and are the Kv channel interacting protein 4 (KCNIP4), potassium large 
conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1), potassium 
voltage-gated channel, KQT-like subfamily, member 3 (KCNQ3), and potassium voltage-gated 
channel, subfamily H (eag-related), members 1 (KCNH1), 7 (KCNH7), and 8 (KCNH8). 
A comprehensive network of the genes in the enriched molecular functions is depicted in 
Figure 4.1. The target gene identified in this study with the greatest number of edges was FGF2, 
whereas ubiquitin C (UBC) was the intermediate gene showing more connections. Thus, FGF2 
could have driver or hub role in ADG, DMI, or feed efficiency in general. This gene encodes for 
a regulatory protein known for distinct roles, such as activation of protein kinases and in 
signalling [64], and this may also explain the high number of edges associated with this 
intermediate gene. The only two genes interconnected by first order intermediates were KCNH1 
and KCNQ3. These target genes identified in this study were interconnected by three 
intermediate calmodulin genes (CALM1, CALM2, and CALM3) known for mediating the control 
of a large number of enzymes, ion channels and other proteins by Ca
2+
 [65]. The functional and 
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network analyses aided in the understanding of the pathways and molecular functions that may 
play critical roles in feed efficiency. 
4.5. Conclusions 
Associations between SNPs with ADG and DMI in independent and simultaneously 
manners were identified in feedlot beef steers using univariate and bivariate analyses. The 
bivariate analysis resulted in 11 SNPs associated with the feed efficiency components ADG and 
DMI, more SNPs than for the univariate analyses of ADG and DMI. The bivariate analyses 
gained precision to detect these SNPs through the consideration of the substantial covariation 
between ADG and DMI. In addition, three of the six validated SNPs in this study were obtained 
from the bivariate analysis, supporting even more the joint consideration of ADG and DMI in 
GWAS. 
Genomic variants that had favorable associations with ADG and DMI simultaneously or 
favorable associations with either trait individually without detriment to the other trait, while 
accounting for the body maintenance requirements, were identified. Four of the six validated 
associations were directly associated with feed efficiency: rs41629972 for ADG, rs108942504 
for DMI, and rs108964818 and rs41768978 for the bivariate analysis. The validation of models 
and SNPs suggest that the findings are replicable. The molecular functions enriched among the 
genes associated with the detected SNPs and network visualization showed that general ion 
channel activities are associated with ADG and DMI. The bivariate analysis of ADG and DMI 
helped in the identification of SNP that have beneficial associations with both components of 
feed efficiency and can be used for genome-enabled improvement of feed efficiency in feedlot 
beef cattle. 
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4.7. Figures 
 
Figure 4.1. Network of all genes with enriched molecular functions on feed efficiency 
Interaction between the genes from the network and functional analysis of bivariate ADG and 
DMI (P-value < 0.001). Genes harboring SNPs significantly associated with feed efficiency 
(target genes; P-value < 0.01) are represented by pink nodes, whereas those in blue represent 
intermediate genes. Red edges represent in direct interaction with target genes with any other 
gene, while golden edges represent interactions between intermediate genes. The size of the 
network nodes from the target genes is a function of the P-values from the association analyses, 
in which larger nodes indicate more significant P-values.   
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4.8. Tables 
Table 4.1. Description of the diets 
 Diets 
Item A B C D E 
TNE, Mcal/lb 1.40 1.15 1.15 1.15 1.09 
NDF, %  18.5 39.2 41.5 40.1 45.1 
DM, % 66.7 63 65 54 49 
CP, % 13.9 18.8 14.4 17.7 21.4 
ADF, % 7.8 21.9 23.6 22.8 25.6 
TDN, % 75.7 67.5 68 68 66 
Main 
ingredients 
Dry-rolled 
corn and 
stored wet 
distiller grain 
Distiller 
grains with 
solubles and 
fresh wet 
corn gluten 
feed 
Dry-rolled 
corn and corn 
gluten feed 
Fresh wet 
distiller 
grains and 
wet corn 
gluten feed 
Stored wet 
distiller 
grains and 
hay 
TNE, Total net energy; NDF, Non-degradable fiber; DM, Dry matter; CP, Crude protein; ADF, 
Acid detergent fiber; TDN, Total digestible nutrient. 
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Table 4.2. Number (proportion) of steers by breed and diet within data sets 
Training (n = 976)  Validation (n = 336) 
Breed Diet  Breed Diet 
AN 102 (0.10) A 232 (0.24)  AN 35 (0.10) A 83 (0.25) 
3/4AN 115 (0.12) B 300 (0.31)  3/4AN 67 (0.20) B 88 (0.26) 
ANSM 640 (0.66) C 111 (0.11)  ANSM 190 (0.57) C 48 (0.14) 
3/4SM 39 (0.04) D 257 (0.26)  3/4SM 19 (0.06) D 105 (0.31) 
SM 80 (0.08) E 76 (0.08)  SM 25 (0.07) E 25 (0.07) 
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Table 4.3. Number of SNPs with significant associations and genes harboring SNPs by P-
value 
 P-value < 0.0001  P-value < 0.001  P-value < 0.01 
Phenotype SNPs Genes  SNPs Genes  SNPs Genes 
ADG 8 6  53 21  413 153 
DMI 9 3  58 18  560 206 
Bivariate 11 5  84 34  587 236 
Total
1
 19 9  146 51  1126 419 
1 
Unique SNPs and genes. 
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Table 4.4. Additive
1
 and dominance estimates of SNPs associated
2
 with ADG and DMI 
    Gene 
Symbol 
    P-value
4
 
Trait SNP BTA Allele Gene Name Additive
3
 Dominance
3
  T V 
ADG rs109934193 2 C*/T NCKAP5 NCK-associated protein 5 0.03±0.01 0.03±0.01  1.91E-05 9.04E-01 
 rs110787048 4 A*/G DPP6 Dipeptidyl-peptidase 6 0.03±0.01 0.06±0.01  5.40E-05 8.31E-01 
 rs41629972 13 C/T*    0.04±0.01 0.01±0.01  7.22E-05 3.20E-02 
 rs41565199 14 C*/T    0.03±0.01 -0.04±0.01  5.16E-05 9.42E-01 
 rs41620774 15 A/C* ELMOD1 ELMO/CED-12 domain 
containing 1 
-0.15±0.04 -0.18±0.04  2.99E-05 3.01E-01 
 rs108964818 15 C/T* KDELC2 KDEL (Lys-Asp-Glu-Leu) 
containing 2 
-0.40±0.09 -0.39±0.09  6.52E-06 3.60E-02 
 rs41768978 15 A*/C PHOX2A Paired-like homeobox 2a 0.01±0.01 0.06±0.01  1.18E-05 1.03E-01 
 rs42342964 23 G*/T PAK1IP1 PAK1 interacting protein 1 0.01±0.01 0.06±0.01  9.04E-05 4.63E-01 
DMI rs41663978 6 A*/C    -0.22±0.05 -0.01±0.06  6.33E-05 8.71E-02 
 rs41588990 6 A*/G CNOT6L CCR4-NOT transcription 
complex, subunit 6-like 
0.01±0.06 0.29±0.07  3.55E-05 1.37E-01 
 rs41632270 13 G/T*    -0.13±0.09 -0.40±0.10  9.00E-05 9.41E-01 
 rs42128656 15 A*/G    -0.19±0.05 -0.10±0.06  2.20E-05 9.52E-01 
 rs43291568 15 A*/G CLMP CXADR-like membrane protein -0.25±0.05 -0.04±0.06  3.42E-06 8.44E-01 
 rs43291603 15 C/T* CLMP CXADR-like membrane protein -0.29±0.09 0.14±0.10  4.18E-05 7.44E-01 
 rs111010038 17 A*/C    0.35±0.18 -0.50±0.19  2.41E-05 8.95E-01 
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.31±0.09 -0.02±0.11  2.26E-05 1.69E-02 
 rs41624569 26 A*/G    -0.04±0.05 -0.27±0.06  1.94E-05 7.41E-01 
1 
Additive estimate relative to the minor allele; 
2 
P-value < 0.0001; 
3 
Estimate±standard error; 
4 
T, training data set; V, validation data set; 
* 
Minor allele. 
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Table 4.5. Additive
1
 and dominance estimates of SNPs simultaneously associated
2
 with ADG and DMI 
   Gene 
Symbol 
 ADG  DMI  P-value
4
 
SNP BTA Allele Gene Name Additive
3
 Dominance
3
  Additive
3
 Dominance
3
  T V 
rs109934193 2 C*/T NCKAP5 NCK-associated 
protein 5 
0.04±0.01 0.03±0.01  0.06±0.05 0.15±0.06  6.84E-05 9.60E-01 
rs41629972 13 C/T*    0.04±0.01 0.01±0.01  0.20±0.05 0.02±0.06  6.82E-05 1.07E-01 
rs41722387 14 G*/T    -0.04±0.01 -0.01±0.01  -0.04±0.05 0.14±0.06  9.27E-05 1.69E-01 
rs108964818 15 C/T* KDELC2 KDEL (Lys-Asp-Glu-
Leu) containing 2 
-0.40±0.09 -0.39±0.09  -0.02±0.01 -0.05±0.48  3.71E-07 4.05E-02 
rs42128656 15 A*/G    -0.03±0.01 0.03±0.01  -0.19±0.05 -0.10±0.05  2.07E-05 2.85E-01 
rs43291568 15 A*/G CLMP CXADR-like 
membrane protein 
-0.02±0.01 -0.01±0.01  -0.25±0.05 -0.05±0.06  5.85E-05 5.62E-01 
rs41768978 15 A*/C PHOX2A Paired-like homeobox 
2a 
0.01±0.01 0.06±0.01  0.13±0.07 0.11±0.08  1.90E-05 8.35E-03 
rs111010038 17 A*/C    -0.13±0.04 0.12±0.05  0.34±0.16 -0.48±0.17  6.64E-06 3.66E-01 
rs110522962 17 C/T*    0.08±0.03 -0.05±0.03  -0.47±0.18 0.30±0.20  5.89E-05 3.81E-02 
rs108942504 22 A/G* TMEM40 Transmembrane 
protein 40 
-0.02±0.01 -0.04±0.02  0.37±0.10 -0.04±0.12  7.92E-05 9.32E-02 
rs41624569 26 A*/G    -0.01±0.01 -0.01±0.01  -0.03±0.05 -0.24±0.06  5.88E-05 1.80E-01 
1 
Additive estimate relative to the minor allele; 
2 
P-value < 0.0001; 
3 
Estimate±standard error; 
4 
T, training data set; V, validation data set; 
* 
Minor allele. 
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Table 4.6. SNPs associated
1
 with ADG and DMI in multiple analyses 
SNP BTA Gene Symbol Phenotype 
rs109934193 2 NCKAP5 ADG, Bivariate 
rs41629972 13 - ADG, Bivariate 
rs108964818 15 KDELC2 ADG, Bivariate 
rs42128656 15 - DMI,  Bivariate 
rs43291568 15 CLMP DMI,  Bivariate 
rs41768978 15 PHOX2A ADG, Bivariate 
rs111010038 17 - DMI,  Bivariate 
rs108942504 22 TMEM40 DMI,  Bivariate 
rs41624569 26 - DMI,  Bivariate 
1 
P-value < 0.0001; 
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Table 4.7. SNPs selected
1
 for the multi-SNP models and model adequacy 
   Gene 
Symbol 
RMSE
2
   
Phenotype SNP BTA T V  MA
4
 
ADG rs108939474 2 - 0.1049 0.1187  11.68% 
 rs109934193 2 NCKAP5     
 rs110787048 4 DPP6     
 rs42433916 7 -     
 rs109945988 11 -     
 rs109957444 14 FAM135B     
 rs42230512 14 TATDN1     
 rs108964818 15 KDELC2     
 rs41768978 15 PHOX2A     
DMI rs41588990 6 CNOT6L 0.5242 0.5650  7.21% 
 rs41577108 13 -     
 rs41629972 13 -     
 rs41632270 13 -     
 rs41577655 15 -     
 rs43291568 15 CLMP     
 rs110911295 20 -     
 rs41624569 26 -     
    RMSE
2
      
    ADG  DMI  RMSC
3
   
    T V  T V  T V  MA
4
 
Bivariate rs108964818 15 KDELC2 0.0802 0.0985  0.3700 0.4672  0.0949 0.1166  19.40% 
 rs110522962 17 -               
 rs41624569 26 -               
 rs41600811 22 -               
 rs109709275 15 GRAMD1B               
 rs42459305 29 -               
 rs109945988 11 -               
1 
P-value < 0.0001; 
2
 Root mean square errors (RMSE) for the models using the training (T) and validation (V) data sets; 
3
 Root means square covariance (RMSC) for the bivariate model using the training (T) and validation (V) data sets; 
4
 MA, Model adequancy as defined in Eqs. 4.3 and 4.4, for the univariate and bivariate analyses, respectively; 
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Table 4.8. Gene Ontology (GO) terms of enriched molecular functions for the bivariate model 
GO term Genes P-value 
cation channel activity CACNB2, FGF2, KCNH1, KCNH7, KCNH8, KCNIP4, KCNK9, KCNMA1, 
KCNQ3, and TRPC2 
6.0E-5 
metal ion transmembrane transporter 
activity 
CACNB2, FGF2, KCNH1, KCNH7, KCNH8, KCNIP4, KCNK9, KCNMA1, 
KCNQ3, and TRPC2 
2.1E-4 
voltage-gated ion channel activity CACNB2, FGF2, KCNH1, KCNH7, KCNH8, KCNIP4, KCNMA1, and KCNQ3 2.6E-4 
voltage-gated channel activity CACNB2, FGF2, KCNH1, KCNH7, KCNH8, KCNIP4, KCNMA1, and KCNQ3 2.6E-4 
potassium channel activity KCNH1, KCNH7, KCNH8, KCNIP4, KCNK9, KCNMA1, and KCNQ3 4.2E-4 
voltage-gated cation channel activity KCNH1, KCNH7, KCNH8, KCNIP4, KCNK9, KCNMA1, and KCNQ3 4.9E-4 
potassium ion transport KCNH1, KCNH7, KCNH8, KCNIP4, KCNK9, KCNMA1, and KCNQ3 7.1E-4 
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APPENDIX: ADDITIONAL TABLES 
Appendix A. Single nucleotide polymorphisms and haplotypes associated with feed efficiency in beef cattle 
Table A.1. Additive
1
 and dominance estimates of SNPs that have general association
2
 with feed efficiency 
Trait SNP BTA Allele Gene Symbol Gene Name Additive
3
 Dominance
3
 P-Value Final
4
 
RFI rs41654149 4 C/T*   0.03±0.04 -0.23±0.05 1.09E-05  
 rs41663978 6 A*/C   0.18±0.04 0.03±0.05 7.14E-05  
 rs109500421 8 C/T* CNTFR Ciliary neurotrophic factor receptor -0.01±0.05 0.24±0.06 4.54E-05  
 rs110922588 8 G/T*   0.01±0.04 -0.24±0.05 8.77E-06  
 rs41634631 16 C*/T   1.03±0.23 -1.09±0.23 1.57E-05  
 rs111010038 17 A*/C   -0.74±0.20 1.03±0.21 8.16E-07  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.36±0.10 -0.09±0.11 9.04E-06 yes 
RADG rs42433916 7 G/T*   0.02±0.01 -0.02±0.01 7.40E-05  
 rs109945988 11 G/T*   -0.10±0.03 0.12±0.03 2.71E-05  
 rs41664711 11 A*/G   0.01±0.01 -0.04±0.01 2.95E-05  
 rs110732787 13 A*/G   -0.04±0.02 -0.08±0.02 3.69E-05  
 rs41565199 14 C*/T   -0.02±0.01 0.02±0.01 2.63E-05  
 rs41627953 14 C*/T   -0.04±0.01 -0.01±0.01 8.20E-05  
 rs108964818 15 C/T* KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 1-like 0.35±0.06 0.34±0.06 3.44E-08 yes 
 rs41620774 15 A/C* ELMOD1 ELMO/CED-12 domain containing 1 0.12±0.03 0.13±0.03 5.58E-05  
 rs42342964 23 G*/T PAK1IP1 PAK1 interacting protein 1 0.01±0.01 0.05±0.01 9.16E-06  
RIG rs41963899 1 A*/G   -0.14±0.10 -0.45±0.11 2.02E-05  
 rs41654149 4 C/T*   0.01±0.06 0.32±0.08 9.80E-05  
 rs110922588 8 G/T*   -0.01±0.06 0.34±0.08 1.86E-05  
 rs41722387 14 G*/T   -0.15±0.06 -0.27±0.07 3.83E-05  
 rs108964818 15 C/T* KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 1-like 2.96±0.56 2.83±0.57 7.43E-07  
 rs110522962 17 C/T*   1.10±0.26 -0.82±0.27 8.18E-06  
 rs111010038 17 A*/C   1.21±0.28 -1.54±0.30 1.03E-06  
 rs109449042 25 C/T*   1.36±0.32 -1.25±0.33 9.75E-05  
EI rs41654149 4 C/T*   0.02±0.04 -0.22±0.05 2.34E-05  
 rs41663978 6 A*/C   0.17±0.04 0.02±0.05 7.31E-05  
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Table A.1 (cont.) 
Trait SNP BTA Allele Gene Symbol Gene Name Additive
3
 Dominance
3
 P-Value Final
4
 
EI rs109500421 8 C/T* CNTFR Ciliary neurotrophic factor receptor -0.02±0.05 0.23±0.06 5.03E-05  
 rs110922588 8 G/T*   0.02±0.04 -0.23±0.05 1.19E-05  
 rs109709275 15 A/G* GRAMD1B GRAM domain containing 1B 0.05±0.05 -0.18±0.05 6.29E-05  
 rs42128656 15 A*/G   -0.13±0.04 -0.12±0.06 3.08E-05  
 rs41634631 16 C*/T   0.99±0.22 -1.05±0.22 1.77E-05  
 rs111010038 17 A*/C   -0.71±0.19 1.02±0.20 2.87E-07  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.32±0.10 -0.05±0.11 2.29E-05 yes 
 rs109064731 24 A/G*   0.15±0.05 0.25±0.06 7.23E-05  
EG rs110340232 1 G*/T RAB6B RAB6B, member RAS oncogene family 0.01±0.01 0.04±0.01 5.07E-05  
 rs110787048 4 A*/G DPP6 Dipeptidyl-peptidase 6 -0.03±0.01 -0.04±0.01 9.32E-05  
 rs41574883 4 A*/G   0.07±0.01 0.06±0.02 5.47E-06  
 rs43191790 4 G/T*   0.06±0.01 -0.05±0.02 1.44E-05  
 rs110051312 8 A*/C PTPN3 Protein tyrosine phosphatase, non-receptor type 3 0.04±0.03 0.09±0.03 5.46E-05  
 rs110196238 8 C*/T PTPN3 Protein tyrosine phosphatase, non-receptor type 3 0.04±0.03 0.09±0.03 5.09E-05  
 rs109945988 11 G/T*   -0.13±0.03 0.14±0.03 2.59E-05  
 rs41611457 12 A/G* ENOX1 Ecto-NOX disulfide-thiol exchanger 1 -0.04±0.01 0.03±0.01 6.70E-05  
 rs110732787 13 A*/G   -0.03±0.02 -0.07±0.02 4.29E-05  
 rs108964818 15 C/T* KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 1-like 0.37±0.07 0.37±0.07 4.42E-07  
 rs41620774 15 A/C* ELMOD1 ELMO/CED-12 domain containing 1 0.12±0.03 0.15±0.03 2.94E-05  
 rs110522962 17 C/T*   0.13±0.03 -0.10±0.03 2.24E-05 yes 
 rs109889052 19 C/T* PIK3R6 Phosphoinositide-3-kinase, regulatory subunit 6 -0.27±0.07 0.29±0.07 7.79E-05  
1 
Additive estimate relative to the minor allele; 
2 
P-value < 0.0001; 
3 
Estimate±standard error; 
4 
SNPs significantly associated (P-value < 0.05) in the validation data set; 
* 
Minor allele. 
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Table A.2. Additive
1
 estimates of SNPs that have breed-dependent association
2
 with feed efficiency 
Trait SNP BTA Allele 
Gene 
Symbol Gene Name 
Breed
3
 
P-Value Final
4
 AN 3/4 AN AN/SM 3/4 SM 
RFI rs109158476 5 C*/T   -0.06±0.07 0.04±0.07 0.10±0.06 -0.40±0.09 7.08E-06  
 rs110425294 5 A/G* AVIL Advillin -0.09±0.06 0.09±0.06 0.13±0.05 -0.23±0.08 5.71E-05  
 rs29026607 5 C/T*   -0.12±0.07 -0.02±0.07 0.04±0.06 -0.51±0.10 8.10E-05  
 rs110708529 12 G/T*   -0.23±0.07 -0.40±0.07 -0.21±0.06 -0.47±0.09 8.84E-05  
 rs42456314 12 A/G* GPC5 Glypican 5 -0.08±0.07 -0.27±0.07 -0.20±0.06 -0.57±0.08 2.69E-05  
 rs29024448 17 G/T* RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
0.14±0.06 0.31±0.06 0.05±0.05 0.20±0.07 8.32E-06  
 rs41854727 17 C/T*   0.01±0.08 0.17±0.07 -0.04±0.06 0.36±0.10 2.73E-05  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.05±0.13 0.15±0.12 0.17±0.10 0.53±0.13 3.07E-06 yes 
 rs109863480 24 C*/T   0.06±0.07 -0.04±0.07 0.06±0.06 -0.57±0.10 1.26E-05  
 rs29018901 24 A*/G   0.18±0.07 0.09±0.07 0.13±0.06 -0.46±0.10 3.75E-05  
RADG rs109808044 3 A*/G SNED1 Sushi, nidogen and EGF-like 
domains 1 
-0.04±0.01 -0.08±0.01 -0.01±0.01 -0.03±0.01 2.44E-05  
 rs110742206 3 C/T* CSMD2 CUB and Sushi multiple domains 2 0.11±0.03 0.11±0.03 0.08±0.02 0.23±0.04 1.98E-05  
 rs109320755 4 C/T*   -0.04±0.01 -0.05±0.01 -0.02±0.01 -0.02±0.01 7.15E-05  
 rs110690110 5 C*/G ERC1 ELKS/RAB6-interacting/CAST 
family member 1 
-0.03±0.01 -0.05±0.01 -0.02±0.01 -0.07±0.01 2.49E-05  
 rs110280556 6 A*/G UNC5C Unc-5 homolog C (C. elegans) -0.02±0.01 -0.03±0.01 0.00±0.01 0.05±0.01 6.65E-06  
 rs110244477 8 A*/T   0.08±0.02 0.12±0.02 0.05±0.01 0.09±0.02 9.09E-05  
 rs41854727 17 C/T*   -0.02±0.01 -0.03±0.01 0.01±0.01 -0.04±0.02 2.96E-05  
 rs41583989 24 C*/T DTNA Dystrobrevin, alpha -0.07±0.02 0.04±0.02 -0.02±0.01 -0.04±0.02 9.20E-05  
 rs41600243 28 A/G*   0.05±0.01 0.00±0.01 0.02±0.01 0.00±0.01 6.52E-05  
RIG rs110131536 2 A*/G IGFBP5 Insulin-like growth factor binding 
protein 5 
0.33±0.14 0.40±0.13 0.47±0.12 -0.69±0.20 2.30E-05  
 rs109195623 3 A*/C   -0.15±0.12 -0.28±0.12 -0.37±0.11 0.82±0.21 7.00E-05 yes 
 rs110280556 6 A*/G UNC5C Unc-5 homolog C (C. elegans) -0.13±0.08 -0.11±0.08 0.06±0.06 0.62±0.11 3.88E-05  
 rs41613098 6 C/T*   0.14±0.12 0.08±0.13 0.29±0.10 -1.02±0.20 2.66E-06  
 rs109533642 7 C*/T   0.45±0.14 -0.07±0.12 -0.07±0.10 -0.81±0.17 5.63E-05  
 rs41662450 9 C/T*   0.18±0.09 0.01±0.09 0.03±0.07 -0.59±0.11 3.97E-05 yes 
 rs109137042 10 A*/G   0.11±0.17 0.14±0.18 0.16±0.14 -1.61±0.31 5.37E-05 yes 
 rs110745951 10 A/G*   0.09±0.10 0.07±0.10 -0.08±0.08 0.28±0.11 8.71E-05  
 rs109885711 12 C/T*   0.20±0.09 -0.01±0.09 0.21±0.07 0.79±0.12 1.35E-05  
 rs41624425 12 C/T*   -0.20±0.15 -0.23±0.15 -0.19±0.13 -1.40±0.23 4.75E-05  
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Table A.2 (cont.) 
Trait SNP BTA Allele 
Gene 
Symbol Gene Name 
Breed
3
 
P-Value Final
4
 AN 3/4 AN AN/SM 3/4 SM 
RIG rs41625438 12 C/T* DACH1 Dachshund homolog 1 
(Drosophila) 
0.06±0.15 0.03±0.15 0.05±0.13 1.08±0.21 8.82E-05  
 rs41626923 12 C*/T   0.09±0.09 0.03±0.09 0.10±0.07 0.81±0.12 4.05E-05  
 rs42456314 12 A/G* GPC5 Glypican 5 0.22±0.10 0.41±0.10 0.36±0.08 0.90±0.12 2.35E-06  
 rs43693414 12 C/T*   0.10±0.13 0.20±0.13 0.18±0.12 0.99±0.18 4.66E-05  
 rs42206139 15 A*/G   -0.31±0.11 -0.54±0.1 -0.21±0.08 0.14±0.12 6.66E-05  
 rs41623603 16 A*/C CNST Consortin, connexin sorting protein 0.08±0.10 0.10±0.11 0.19±0.09 -0.36±0.13 5.13E-05  
 rs29024448 17 G*/T RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
-0.15±0.09 -0.48±0.09 -0.09±0.07 -0.32±0.11 1.71E-05  
 rs41854727 17 C/T*   -0.13±0.11 -0.34±0.11 0.06±0.09 -0.56±0.14 2.14E-07  
 rs109863480 24 C*/T   -0.07±0.10 -0.05±0.10 -0.10±0.08 0.84±0.14 6.30E-06  
 rs42666807 24 C*/T   0.17±0.10 -0.18±0.09 -0.04±0.08 0.66±0.13 4.41E-05  
EI rs41659730 4 A*/G   -0.27±0.07 0.27±0.07 0.10±0.05 -0.07±0.07 2.87E-05  
 rs109053103 5 A*/G BIN2 Bridging integrator 2-like 0.28±0.08 0.28±0.08 -0.01±0.06 0.36±0.10 8.57E-05 yes 
 rs109158476 5 C*/T   -0.06±0.07 0.06±0.07 0.11±0.06 -0.35±0.09 1.52E-05  
 rs42456314 12 A/G* GPC5 Glypican 5 -0.10±0.07 -0.26±0.07 -0.21±0.06 -0.55±0.08 3.13E-05  
 rs29024448 17 G*/T RFC5 Replication factor C (activator 1) 5, 
36.5kDa 
0.11±0.06 0.30±0.06 0.07±0.05 0.19±0.07 3.23E-05  
 rs41567063 17 C/T*   0.49±0.08 0.22±0.07 0.21±0.05 0.12±0.08 2.91E-05  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.05±0.12 0.09±0.11 0.16±0.10 0.48±0.13 8.72E-06 yes 
 rs110206384 X A/G* F8 Coagulation factor VIII, 
procoagulant component 
0.17±0.05 -0.07±0.05 -0.02±0.04 0.01±0.07 5.48E-05  
EG rs110742206 3 C/T* CSMD2 CUB and Sushi multiple domains 2 0.54±0.13 0.46±0.12 0.35±0.11 1.08±0.17 7.31E-05  
 rs41613367 8 A*/G   -0.09±0.04 -0.08±0.04 0.05±0.04 -0.13±0.05 9.24E-05  
 rs41620815 8 A*/C   -0.31±0.06 -0.25±0.05 -0.19±0.05 -0.45±0.07 3.49E-05  
 rs42250803 17 A*/G SLC7A11 Solute carrier family 7 (anionic 
amino acid transporter light chain, 
xc- system), member 11 
0.06±0.06 -0.06±0.05 0.02±0.04 -0.31±0.06 2.23E-05  
1
 Contrast of the additive estimate between each level of breed and breed SM, relative to the minor allele;  
2 
P-value < 0.0001; 
3 
Estimate±standard error;  
4 
SNPs significantly associated (P-value < 0.05) in the validation data set; 
* 
Minor allele.  
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Table A.3. Additive
1
 estimates of SNPs that have diet-dependent association
2
 with feed efficiency 
Trait SNP BTA Allele 
Gene 
Symbol Gene Name 
Diet
3
 
P-Value Final
4
 A B C D 
RFI rs42320097 2 A*/G   -0.06±0.07 -0.20±0.07 -0.61±0.10 -0.04±0.07 8.48E-05  
 rs109452133 6 A/G*   -0.12±0.07 -0.02±0.06 0.26±0.07 0.07±0.06 1.07E-06 yes 
 rs41663978 6 A*/C   0.07±0.05 0.10±0.05 0.19±0.06 0.08±0.05 9.54E-05  
 rs43453950 6 A*/G   -0.05±0.05 0.00±0.05 0.31±0.07 0.01±0.06 3.25E-05  
 rs42378531 9 C/T*   -0.07±0.05 0.13±0.05 0.14±0.06 0.09±0.05 5.31E-05  
 rs41256074 11 C*/T   -0.09±0.10 0.07±0.09 0.50±0.13 -0.22±0.10 5.24E-05  
 rs109198879 13 A/G*   0.05±0.05 0.20±0.05 0.13±0.06 0.03±0.05 8.88E-05  
 rs41660789 15 A*/G   -0.14±0.06 -0.09±0.06 0.12±0.06 -0.21±0.06 2.02E-05  
 rs110479395 17 C*/T   -0.01±0.08 0.07±0.08 0.53±0.11 -0.07±0.08 2.88E-05  
 rs41856111 18 C/T*   -0.06±0.07 -0.02±0.07 -0.24±0.07 0.13±0.07 2.94E-05 yes 
 rs43238631 20 A/G*   0.05±0.06 0.01±0.05 -0.35±0.08 0.11±0.05 7.60E-05  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.27±0.08 0.28±0.08 0.29±0.09 0.22±0.08 1.66E-05  
RADG rs43474365 7 A/G* SLC12A2 Solute carrier family 12 
(sodium/potassium/chloride 
transporters), member 2 
0.00±0.01 -0.03±0.01 0.01±0.01 -0.03±0.01 4.11E-05  
RIG rs41609661 1 G*/T   -0.38±0.07 -0.45±0.07 -0.41±0.08 -0.21±0.07 6.72E-05  
 rs42530614 1 C*/T   0.39±0.08 0.45±0.07 0.49±0.09 0.22±0.07 3.25E-05 yes 
 rs42320097 2 A*/G   0.26±0.10 0.45±0.10 0.98±0.14 0.28±0.10 4.29E-05  
 rs29011654 3 A/G*   -0.40±0.07 -0.36±0.07 -0.47±0.08 -0.25±0.07 9.64E-05  
 rs41856111 18 C/T*   0.14±0.10 0.06±0.09 0.37±0.10 -0.14±0.10 4.81E-05 yes 
 rs43687983 20 A*/G   0.46±0.08 0.28±0.08 0.13±0.10 0.33±0.08 2.99E-05  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 -0.51±0.12 -0.40±0.11 -0.46±0.14 -0.32±0.12 5.80E-05  
 rs41612502 28 A/G*   -0.23±0.11 -0.04±0.11 -0.12±0.13 0.11±0.11 8.98E-05  
 rs41619246 29 A*/G   0.00±0.13 0.30±0.12 1.84±0.41 -0.31±0.14 4.26E-05  
EI rs42320097 2 A*/G   -0.05±0.07 -0.18±0.07 -0.63±0.10 -0.05±0.07 4.17E-05  
 rs41593945 4 A*/C CNPY1 Canopy 1 homolog -0.04±0.07 -0.16±0.07 0.22±0.07 -0.02±0.07 4.80E-05  
 rs109452133 6 A/G*   -0.11±0.06 -0.01±0.06 0.26±0.07 0.07±0.06 1.06E-06 yes 
 rs109976880 6 A*/G   0.09±0.06 -0.03±0.06 -0.19±0.06 -0.01±0.06 8.42E-05  
 rs41663978 6 A*/C   0.03±0.05 0.10±0.05 0.17±0.05 0.06±0.05 7.42E-05  
 rs43453950 6 A*/G   -0.02±0.05 0.02±0.05 0.36±0.06 0.02±0.05 6.46E-07  
 rs110707592 9 C/T*   -0.22±0.05 -0.03±0.05 0.01±0.06 -0.21±0.05 1.95E-05  
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Table A.3 (cont.) 
Trait SNP BTA Allele 
Gene 
Symbol Gene Name 
Diet
3
 
P-Value Final
4
 A B C D 
EI rs42378531 9 C/T*   -0.09±0.05 0.12±0.05 0.16±0.06 0.08±0.05 2.30E-06  
 rs42952059 9 A/G*   -0.23±0.05 -0.12±0.05 0.04±0.06 -0.24±0.05 3.16E-05  
 rs41256074 11 C*/T   -0.10±0.10 0.07±0.09 0.54±0.12 -0.23±0.10 5.38E-06  
 rs41660789 15 A*/G   -0.11±0.06 -0.06±0.05 0.17±0.06 -0.16±0.06 7.14E-06  
 rs110479395 17 C*/T   -0.01±0.08 0.07±0.08 0.51±0.11 -0.08±0.08 1.21E-05  
 rs43238631 20 A/G*   0.06±0.06 -0.01±0.05 -0.37±0.08 0.10±0.05 1.22E-05  
 rs108942504 22 A/G* TMEM40 Transmembrane protein 40 0.21±0.08 0.23±0.07 0.24±0.09 0.18±0.08 8.28E-05 yes 
 rs42072585 25 A/G* CLN3 Ceroid-lipofuscinosis, neuronal 3 0.18±0.06 0.21±0.06 0.36±0.06 0.27±0.06 7.02E-05 yes 
 rs41619246 29 A*/G   -0.01±0.09 -0.18±0.08 -1.41±0.27 0.18±0.09 6.83E-05  
EG rs109291606 12 G/T* ENOX1 Ecto-NOX disulfide-thiol 
exchanger 1 
0.04±0.01 0.04±0.01 0.04±0.01 0.02±0.01 8.93E-05  
1
 Contrast of the additive estimate between each level of diet and diet E, relative to the minor allele;  
2 
P-value < 0.0001; 
3 
Estimate±standard error;  
4 
SNPs significantly associated (P-value < 0.05) in the validation data set; 
* 
Minor allele. 
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Table A.4. Description of the haplotype blocks significantly associated
1
 with feed efficiency 
Haplotype BTA SNP Allele Gene  ̅  Traits (association
2
) 
H01 1 rs41623606 C/T  0.15 RFI (b), EI (b), and RIG (b) 
  rs43211556 A/C    
  rs43210901 A/G    
  rs41630314 G/T GRIK1   
H02 1 rs41635180 C/T  0.43 RFI (g)
V
 
  rs109187996 C/T    
  rs41578805 A/C PARL   
  rs109562914 C/T MAP6D1   
  rs41603780 A/G YEATS2   
H03 2 rs43324587 C/T FBXO42 0.66 RFI (d), EI (d), and RIG (d) 
  rs43326092 C/T FBXO42   
H04 5 rs43426639 C/T PPP1R12A 0.43 RIG (b)
V
 
  rs43426641 G/T PPP1R12A   
  rs41592931 A/G PPP1R12A   
  rs41653612 C/T PPP1R12A   
  rs41653616 C/T PPP1R12A   
  rs41566962 C/T PPP1R12A   
  rs110140052 C/T    
H05 6 rs110767541 C/T  0.37 RADG (b) 
  rs29025601 A/G FAM13A   
  rs41627896 A/G FAM13A   
  rs109998457 A/T    
H06 7 rs110957342 A/C  0.21 RADG (g)
V
 
  rs41596177 A/G    
  rs41669611 C/T    
  rs42315549 C/T    
H07 10 rs109668946 A/T MYO9A 0.21 RFI (b)
V
 and EI (b)
V
 
  rs110829769 A/T MYO9A   
  rs41626107 C/G MYO9A   
  rs41626110 C/T    
H08 10 rs108977212 C/T CHP 0.22 RIG (b) 
  rs109827805 C/T NDUFAF1   
  rs41584997 A/G    
  rs109430556 C/T RTF1   
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Table A.4 (cont.) 
Haplotype BTA SNP Allele Gene  ̅  Traits (association
2
) 
H09 10 rs43626304 A/G NID2 0.62 RADG (b) and RIG (b)
V
 
  rs43625528 A/C NID2   
  rs43625453 A/C NID2   
  rs41588508 A/G NID2   
  rs41588507 C/T    
  rs43627130 G/T    
  rs43710946 A/G PIF1   
H10 11 rs29003479 C/T RAB1A 0.27 RIG (d) 
  rs41668653 C/T    
  rs29018917 C/T    
  rs41599919 C/T    
  rs29015166 A/G ACTR2   
H11 11 rs110935406 A/G SPRED2 0.45 RFI (d), EI (d), and RIG (d) 
  rs109658327 A/G    
  rs110624650 C/G    
  rs110351243 C/T    
  rs110249674 C/T    
H12 12 rs41571241 C/T  0.62 RADG (d) and EG (d) 
  rs43688242 C/T    
  rs43081920 A/C    
H13 12 rs110364209 A/T  0.55 RADG (b) 
  rs109845266 C/T TNFSF11   
  rs110425177 A/G TNFSF11   
  rs110699038 C/T    
  rs41630106 G/T    
H14 12 rs109675697 C/T  0.19 RIG (b) 
  rs110448596 C/T    
H15 15 rs41568366 A/G CD3E 0.22 RFI (g) and RIG (g) 
  rs41568365 G/T CD3E   
H16 15 rs43291568 A/G  0.29 RFI (g) and EI (g) 
  rs43291603 C/T    
  rs29014510 C/T    
  rs110441482 G/T    
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Table A.4 (cont.) 
Haplotype BTA SNP Allele Gene  ̅  Traits (association
2
) 
H17 16 rs41806515 A/G  0.94 EI (d) 
  rs41805926 A/G    
  rs109248300 A/G    
  rs41579702 G/T    
H18 17 rs41842607 A/G  0.61 RADG (b) and RIG (b) 
  rs41842594 C/T SUDS3   
  rs41842624 C/T    
  rs41843338 C/T TAOK3   
H19 20 rs42680543 A/G  0.30 RFI (g) and EI (g) 
  rs41946124 C/T RXFP3   
  rs41601589 A/G RXFP3   
  rs110201922 G/T ADAMTS12   
H20 25 rs110665834 A/G  0.26 RIG (d)
V
 
  rs41664150 C/T    
1 
P-value < 0.001; 
2 
g, general haplotype association; b, breed-by- haplotype association; d, diet-by- haplotype association;  
V 
Haplotypes significantly associated (P-value < 0.05) in the validation data set. 
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Table A.5. Enriched functional categories, Gene Ontology (GO) terms, and genes by SNP effect 
SNP 
association Category GO Term 
Number of  
genes P-value Genes 
Main Molecular 
Function 
ion channel activity 18 3.00E-04 ACCN1, CACNB2, CACNB4, FGF2, GABRA3, 
GABRR3, GRIA2, GRIA4, GRID2, GRIN2B, KCNH8, 
KCNIP4, KCNK2, KCNK9, NALCN, RYR3, TRPC2, 
and TTYH1 
  substrate specific channel 
activity 
18 3.40E-04 ACCN1, CACNB2, CACNB4, FGF2, GABRA3, 
GABRR3, GRIA2, GRIA4, GRID2, GRIN2B, KCNH8, 
KCNIP4, KCNK2, KCNK9, NALCN, RYR3, TRPC2, 
and TTYH1 
  channel activity 18 4.00E-04 ACCN1, CACNB2, CACNB4, FGF2, GABRA3, 
GABRR3, GRIA2, GRIA4, GRID2, GRIN2B, KCNH8, 
KCNIP4, KCNK2, KCNK9, NALCN, RYR3, TRPC2, 
and TTYH1 
  passive transmembrane 
transporter activity 
18 4.00E-04 ACCN1, CACNB2, CACNB4, FGF2, GABRA3, 
GABRR3, GRIA2, GRIA4, GRID2, GRIN2B, KCNH8, 
KCNIP4, KCNK2, KCNK9, NALCN, RYR3, TRPC2, 
and TTYH1 
  nucleotide binding 60 6.40E-04 ABCA6, ABCB5, ABCD3, ACACB, ACOX1, ACSS1, 
AGAP1, ALPK2, BLM, CLPB, DACH1, DDX47, 
DHX32, DHX57, DNAH2, DNAJC27, EEFSEC, EHD1, 
ENOX1, EPHA6, EWSR1, G3BP2, GTF2H4, GTPBP4, 
GUCY2F, HRNBP3, HSPA1L, IGF1R, KALRN, MAK, 
MAP2K2, MAP3K4, MAPKAPK3, MSH5, MYH9, 
NAV2, PDE2A, PDPK1, PFKFB1, PFKFB3, PFKL, 
PRKCA, RAB11A, RAB6B, RABL2B, RAD51L1, 
RAD54B, RALYL, RASL10A, RAVER2, RIPK1, 
RPS6KA1, SAR1B, SMARCA2, SNRNP35, STK3, 
TDRD10, TGFBR1, WRN, and XPA 
Breed Biological 
Process 
ion transport 32 1.90E-04 ACCN1, ACCN2, ATP13A5, ATP5S, ATP6V1B1, 
CACNA1E, CACNA1H, CHRNA7, CNGB3, GABRA2, 
GABRG3, GABRR3, GRIA2, GRIK1, GRIK4, KCNC2, 
KCNH8, KCNIP4, KCNMA1, KCNN2, KCTD8, 
NFATC1, NNT, PLCZ1, PRKCB, SCN7A, SLC12A2, 
SLC26A10, SLC39A11, SLCO3A1, TPCN1, and TRPM7 
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Table A.5 (cont.) 
SNP 
association Category GO Term 
Number of  
genes P-value Genes 
Breed Biological 
Process 
secretion 13 2.70E-04 ABCA1, ABCG5, ATP6V1B1, BDNF, EXOC6B, 
KCNMA1, LEP, MC4R, MYH10, NLGN1, PTGES2, SYN3, 
and TRAF3IP2 
  extracellular structure 
organization 
10 3.60E-04 ABI3BP, ADAMTS2, APP, COL11A1, COL1A1, ECM2, 
GFOD2, NEPN, NLGN1, and TGFBR1 
 Molecular 
Function 
ion channel activity 21 5.20E-04 ACCN1, ACCN2, CACNA1E, CACNA1H, CHRNA7, 
CNGB3, GABRA2, GABRG3, GABRR3, GRIA2, GRIK1, 
GRIK4, KCNC2, KCNH8, KCNIP4, KCNMA1, KCNN2, 
KCTD8, SCN7A, TPCN1, and TRPM7 
  substrate specific channel 
activity 
21 6.00E-04 ACCN1, ACCN2, CACNA1E, CACNA1H, CHRNA7, 
CNGB3, GABRA2, GABRG3, GABRR3, GRIA2, GRIK1, 
GRIK4, KCNC2, KCNH8, KCNIP4, KCNMA1, KCNN2, 
KCTD8, SCN7A, TPCN1, and TRPM7 
  passive transmembrane 
transporter activity 
21 7.30E-04 ACCN1, ACCN2, CACNA1E, CACNA1H, CHRNA7, 
CNGB3, GABRA2, GABRG3, GABRR3, GRIA2, GRIK1, 
GRIK4, KCNC2, KCNH8, KCNIP4, KCNMA1, KCNN2, 
KCTD8, SCN7A, TPCN1, and TRPM7 
  channel activity 21 7.30E-04 ACCN1, ACCN2, CACNA1E, CACNA1H, CHRNA7, 
CNGB3, GABRA2, GABRG3, GABRR3, GRIA2, GRIK1, 
GRIK4, KCNC2, KCNH8, KCNIP4, KCNMA1, KCNN2, 
KCTD8, SCN7A, TPCN1, and TRPM7 
  nucleotide binding 76 7.80E-04 ABCA1, ABCA6, ABCG5, ACACB, ACSS3, ADCY1, 
AGAP1, ATP10D, ATP13A5, CCT2, CLPB, CLPX, 
COQ6, CSNK1G1, DACH1, DNM2, EGFR, ENOX1, 
EWSR1, FLT1, FOX1, FYN, GNAO1, GPD1, GRK4, 
GRK5, GTPBP4, GUCY2F, HRNBP3, ICK, INO80, 
KIF16B, KIF1A, KIF27, MAPK10, MAPKAPK3, MELK, 
MSI2, MYH10, MYH11, NCBP2, NNT, NTRK2, NUBP2, 
PCCA, PCCB, PHGDH, PRKCB, PRKCE, PRKD1, 
PRKG1, RAB11A, RALYL, RASL10A, RAVER2, RBM17, 
RBM19, RBMS3, RFC2, RFC5, RIMKLA, RIPK1, 
RPS6KA2, SART3, SCYL1, SFRS15, SPEG, STK3, 
STK38L, SYN3, TDRD9, TESK2, TGFBR1, TOR3A, 
TPK1, and TRPM7 
 205 
 
Table A.5 (cont.) 
SNP 
association Category GO Term 
Number of  
genes P-value Genes 
Diet Biological 
Process 
protein amino acid 
phosphorylation 
27 1.80E-04 AAK1, CDK13, CDK18, CIT, DYRK3, FLT1, GAK, 
GSK3B, HGF, KALRN, KSR2, MAP3K4, MAPK10, 
MAPKAPK2, MELK, MUSK, MYLK, NEK11, PRKCI, 
PRPF4B, PSEN1, RIPK1, RPS6KA2, STK3, STK40, 
TRPM7, and ULK4 
  phosphorus metabolic 
process 
33 5.60E-04 AAK1, CDK13, CDK18, CIT, DYRK3, FLT1, GAK, 
GSK3B, HGF, KALRN, KSR2, MAP3K4, MAPK10, 
MAPKAPK2, MELK, MUSK, MYLK, NEK11, PPM1E, 
PRKCI, PRPF4B, PSEN1, PTPRD, PTPRF, PTPRN2, 
PTPRR, PTPRT, RIPK1, RPS6KA2, STK3, STK40, 
TRPM7, and ULK4 
  phosphate metabolic 
process 
33 5.60E-04 AAK1, CDK13, CDK18, CIT, DYRK3, FLT1, GAK, 
GSK3B, HGF, KALRN, KSR2, MAP3K4, MAPK10, 
MAPKAPK2, MELK, MUSK, MYLK, NEK11, PPM1E, 
PRKCI, PRPF4B, PSEN1, PTPRD, PTPRF, PTPRN2, 
PTPRR, PTPRT, RIPK1, RPS6KA2, STK3, STK40, 
TRPM7, and ULK4 
 Molecular 
Function 
protein serine/threonine 
kinase activity 
22 5.20E-05 AAK1, CDK13, CDK18, CIT, DYRK3, ERCC3, GAK, 
GSK3B, KALRN, KSR2, MAP3K4, MAPK10, 
MAPKAPK2, MELK, MYLK, NEK11, PRPF4B, RIPK1, 
RPS6KA2, STK3, STK40, and TRPM7 
  protein kinase activity 27 1.90E-04 AAK1, NEK11, CDK18, PRPF4B, CDK13, CIT, GAK, 
ERCC3, FLT1, GSK3B, KSR2, MELK, MAPK10, 
MAP3K4, MAPKAPK2, MUSK, MYLK, KCNH1, 
PRKCI, RIPK1, RPS6KA2, STK3, STK40, KALRN, 
TRPM7, DYRK3, and ULK4 
  metalloendopeptidase 
activity 
10 6.40E-04 ADAM12, ADAMTS12, ADAMTS19, ADAMTS2, ECE1, 
MIPEP, MMP16, MMP20, NLN, and THSD4 
 
